ciprofloxacin has been researched along with Infections, Pseudomonas in 667 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous year and predefined sputum bacteria." | 9.27 | RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. ( Aksamit, T; Bandel, TJ; Criollo, M; De Soyza, A; Elborn, JS; Operschall, E; Polverino, E; Roth, K; Wilson, R; Winthrop, KL, 2018) |
| "Phase II, 24-week Australian/New Zealand multicentre, randomised, double-blind, placebo-controlled trial in 42 adult bronchiectasis subjects with ≥2 pulmonary exacerbations in the prior 12 months and ciprofloxacin-sensitive P aeruginosa at screening." | 9.17 | Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. ( Bilton, D; Bruinenberg, P; Cipolla, D; De Soyza, A; Gonda, I; Greville, HW; Kolbe, J; Serisier, DJ; Thompson, PJ, 2013) |
| "This study tested the effect of adding inhaled tobramycin solution to oral ciprofloxacin (Cip) for the treatment of acute exacerbations of non-CF bronchiectasis in patients with P aeruginosa infection." | 9.12 | Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. ( Bilton, D; Gotfried, M; Henig, N; Morrissey, B, 2006) |
| "This report focuses on the role of Pseudomonas aeruginosa in complicated urinary tract infections in a prospective, open-label, multicenter study designed to evaluate the safety and efficacy of extended-release ciprofloxacin (ciprofloxacin XR) 1000 mg once daily for 7-14 days for the treatment of complicated urinary tract infections." | 9.12 | Complicated urinary tract infections treated with extended-release ciprofloxacin with emphasis on Pseudomonas aeruginosa. ( Benson, A; Haverstock, D; Herrington, J; Perroncel, R; Pertel, P; Saltzstein, D; Wachs, B, 2007) |
| "/oral ciprofloxacin monotherapy offers a safe and efficacious alternative to standard parenteral therapy for acute pulmonary exacerbations in pediatric cystic fibrosis patients." | 9.08 | Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. ( Church, DA; Echols, RM; Haverstock, DC; Kanga, JF; Kuhn, RJ; Painter, BG; Perroncel, RY; Rubio, TT; Spohn, WA; Stevens, JC; Thurberg, BE, 1997) |
| "The efficacy and safety of oral ciprofloxacin as a maintenance antipseudomonal therapy were evaluated in 44 patients with cystic fibrosis who had completed a 14-day regimen of intensive hospital therapy with intravenous ceftazidime and amikacin, supplemented by amikacin inhalation therapy." | 9.08 | Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. ( Hampel, B; Kraemer, R; Ruedeberg, A; Schaad, UB; Wedgwood, J, 1997) |
| " This study examined the disposition of sequentially administered intravenous and oral ciprofloxacin, as well as provided dosing recommendations, for the treatment of acute pulmonary exacerbations in pediatric cystic fibrosis patients." | 9.08 | Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ( Church, DA; Echols, RM; Kuhn, RJ; Lettieri, JT; Miles, MV; Rubio, TT, 1997) |
| "More data on the efficacy and safety of ciprofloxacin in pediatric cystic fibrosis patients are needed." | 9.08 | Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. ( Hampel, BJ; Nousia-Arvanitakis, S; Richard, DA; Schaad, UB; Sollich, V; Sommerauer, B, 1997) |
| "To evaluate the efficacy of ciprofloxacin compared with tobramycin and placebo ear drops in the treatment of chronic suppurative otitis media without cholesteatoma." | 9.08 | Chronic otitis media treated topically with ciprofloxacin or tobramycin. ( Ben-David, J; Brodsky, A; Fradis, M; Larboni, J; Podoshin, L; Srugo, I, 1997) |
| "Ciprofloxacin is effective for treating pulmonary infection in adult cystic fibrosis patients, and demonstrates excellent efficacy against Pseudomonas aeruginosa, but its use in paediatric cystic fibrosis patients has been limited because quinolone-induced cartilage toxicity has been observed in juvenile animals and has been considered a potential risk for children." | 9.08 | Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning. ( Daggett, S; Kubin, R; MacFarland, M; Mitchell, M; Redmond, A; Sweeney, L, 1998) |
| "The efficacy and safety of long-term ciprofloxacin therapy in the management of severe bronchiectasis were retrospectively assessed in patients who had taken oral ciprofloxacin continuously for at least 90 days." | 9.07 | Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. ( Cole, PJ; Rayner, CF; Tillotson, G; Wilson, R, 1994) |
| "Intravenously administered ciprofloxacin was compared with imipenem for the treatment of severe pneumonia." | 9.07 | Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. ( Caldwell, JW; Fink, MP; Heard, SO; Johnson, RH; Leeper, KV; Niederman, MS; Schentag, JJ; Siami, GA; Snydman, DR; Wunderink, RG, 1994) |
| "In 31 adult patients with cystic fibrosis (CF) who were chronically infected with Pseudomonas aeruginosa we examined the effect of giving regular three monthly oral ciprofloxacin." | 9.07 | Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. ( Assoufi, BK; Hodson, ME; Sheldon, CD, 1993) |
| "The clinical efficacy and tolerability of ciprofloxacin orally administered at the dosage of 250 mg twice a day was evaluated in 25 patients affected by acute bacterial pharyngotonsillitis." | 9.06 | Oral ciprofloxacin for treatment of acute bacterial pharyngotonsillitis. ( D'Errico, G; Esposito, S; Montanaro, C, 1990) |
| "The clinical and bacteriological efficacy of ciprofloxacin was studied in three groups composed of 20 patients each, all of whom were affected by chronic otitis media in the acute stage." | 9.06 | Topical and oral treatment of chronic otitis media with ciprofloxacin. A preliminary study. ( D'Errico, G; Esposito, S; Montanaro, C, 1990) |
| "In order to determine the optimal antipseudomonal therapy in patients with cystic fibrosis aztreonam plus amikacin was compared to ceftazidime plus amikacin, and these two-week hospital regimens were followed by oral ciprofloxacin given for four weeks." | 9.06 | Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. ( Buehlmann, U; Guenin, K; Kraemer, R; Schaad, UB; Wedgwood-Krucko, J, 1989) |
| "In order to evaluate the clinical efficacy and safety of oral ciprofloxacin in the treatment of acute pulmonary exacerbations of cystic fibrosis and trace the possible development of resistance over time, three trials were conducted." | 9.06 | Use of ciprofloxacin in cystic fibrosis patients. ( Bosso, JA, 1989) |
| "The steady state pharmacokinetic properties of ciprofloxacin and ofloxacin were compared in cystic fibrosis patients." | 9.06 | Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. ( Hvidberg, EF; Jensen, T; Pedersen, SS, 1987) |
| "The clinical efficacy and safety of ciprofloxacin and ofloxacin were compared in a prospective, randomized double blind, placebo combined cross-over study in 26 adult cystic fibrosis patients with chronic broncho-pulmonary Pseudomonas aeruginosa infection." | 9.06 | The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. ( Høiby, N; Jensen, T; Koch, C; Nielsen, CH; Pedersen, SS, 1987) |
| "Ciprofloxacin has potent in vitro activity against Pseudomonas aeruginosa and Pseudomonas cepacia strains isolated from cystic fibrosis patients." | 9.06 | Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ( Blumer, JL; Goldfarb, J; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, 1987) |
| "Twenty-nine adult patients with cystic fibrosis who had chronic bronchopulmonary infection were randomly assigned to receive 750 or 1,000 mg of oral ciprofloxacin every 12 hours for two weeks." | 9.06 | Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. ( Chartrand, SA; Hilman, BC; Marks, MI; Shalit, I; Stutman, HR, 1987) |
| "Twenty adult patients with chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli were enrolled in an open, prospective cooperative study to determine the effect of oral ciprofloxacin therapy in a dosage of 750 mg every 12 hours." | 9.06 | Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli. ( Craven, PC; Gilbert, DN; Marsh, PK; Preheim, LC; Tice, AD, 1987) |
| "2 years), with urinary tract infections caused by Pseudomonas species or other organisms resistant to trimethoprim-sulfamethoxazole were treated with 500 mg of orally administered ciprofloxacin every 12 hours." | 9.06 | Oral ciprofloxacin in resistant urinary tract infections. ( Andriole, VT; Berenson, CS; Greco, TP; Mangi, RJ; Ryan, JL; Sims, M; Thornton, GF, 1987) |
| "Literature searches were made in Medline and Pubmed using the search terms [Pseudomonas] or [Staphylococcus] and [fluoroquinolone] or [cephalosporin] or [gentamicin] and [keratitis] or [cornea]." | 8.87 | Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins. ( Willcox, MD, 2011) |
| "The clinical and bacteriological efficacy and safety of ciprofloxacin given as oral doses of 500 to 1,500 mg (normally 750 mg) twice daily for treatment of Gram-negative bacillary osteomyelitis are reviewed." | 8.77 | Ciprofloxacin in the treatment of acute and chronic osteomyelitis: a review. ( Norrby, SR, 1989) |
| "Fluoroquinolone antibiotics, namely ciprofloxacin and levofloxacin, play an important role in treating infection in cystic fibrosis (CF) and ciprofloxacin remains the last widely used and orally available antipseudomonal agent." | 8.02 | Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis. ( McCaughan, J; Millar, BC; Moore, JE; Rendall, JC, 2021) |
| " aeruginosa isolated from cystic fibrosis and wound patients, and one laboratory strain was treated singly and with combinations of anti-Pseudomonas phage PEV20 and ciprofloxacin." | 7.91 | Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients. ( Chan, HK; Chang, RYK; Das, T; Kutter, E; Manos, J; Morales, S, 2019) |
| " DoE was employed for optimization of ciprofloxacin loaded PLGA NPs for pulmonary delivery against Pseudomonas aeruginosa infections in cystic fibrosis (CF) lungs." | 7.83 | Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: Design of experiments approach. ( Günday Türeli, N; Schneider, M; Türeli, AE, 2016) |
| " Recognizing the thick and tenacious airway mucus seen in the cystic fibrosis (CF) patients as a critical barrier to effective drug delivery, both into the mucus layer itself as well as across that layer to the underlying airway epithelium, we hypothesize that mannitol or NaCl can form inhalable drug carriers, improve drug penetration into the mucus, and ultimately enhance the drug's therapeutic effect." | 7.77 | Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model. ( Lin, Q; Shin, S; Tsifansky, MD; Yang, Y; Yeo, Y, 2011) |
| "To assess the probability of achieving ciprofloxacin pharmacodynamic targets with currently recommended dosages in order to investigate the risk of ciprofloxacin underexposure in children with cystic fibrosis." | 7.76 | Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. ( Chhun, S; Ferroni, A; Guillot, E; Jullien, V; Pons, G; Sermet, I; Zahar, JR, 2010) |
| "For fifteen years oral ciprofloxacin has been the standard treatment for malignant otitis externa, a sometimes fatal osteomyelitis of the skull base usually caused by Pseudomonas aeruginosa." | 7.74 | Resistance of Pseudomonas to ciprofloxacin: implications for the treatment of malignant otitis externa. ( Bernstein, JM; Holland, NJ; Maw, AR; Porter, GC, 2007) |
| "We report two cases of prolonged blood clotting times as demonstrated by a raised international normalised ratio and elevated activated partial thromboplastin time in patients with cystic fibrosis taking ciprofloxacin." | 7.74 | Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin. ( Jones, AM; Moore, GC; Redfern, J; Shiach, CR; Webb, K, 2007) |
| " aureus keratitis, following the treatments, the median number of CFU of recoverable bacteria for chlorhexidine (n = 10), ciprofloxacin (n = 12), tobramycin/cefazolin (n = 12), and controls (n = 10) was 1." | 7.74 | A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Bouchard, CS; Bu, P; Carey, R; Riske, PS; Zaya, NE, 2007) |
| "A biodegradable system of poly-D,L-dilactide releasing ciprofloxacin was assessed in a Pseudomonas aeruginosa osteomyelitis model after inoculation of the test pathogen into the left tibia of 76 New Zealand White rabbits; 31 were controls (group A), and 45 were implanted with the polymer at the infection site (group B)." | 7.74 | Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin. ( Andreopoulos, A; Dontas, I; Dounis, E; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kanellakopoulou, K; Karagiannakos, P; Kolia, M; Nakopoulou, L; Thivaios, GC, 2008) |
| "3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin." | 7.73 | Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. ( Carrier, M; Jensen, H; Short, B; Zerouala, C, 2005) |
| "Both moxifloxacin and ciprofloxacin performed significantly better than control in the treatment of Pseudomonas aeruginosa keratitis (P=0." | 7.73 | Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits. ( Aliprandis, E; Ciralsky, J; Herling, I; Katz, HR; Lai, H, 2005) |
| "To determine whether there has been an increase in ciprofloxacin-resistant pseudomonas malignant otitis externa, and if this has increased the morbidity of the disease." | 7.71 | Evolving resistant pseudomonas to ciprofloxacin in malignant otitis externa. ( Berenholz, L; Harell, M; Katzenell, U, 2002) |
| "Controlled clinical trials have shown efficacy of high-dose ciprofloxacin for hospital-acquired (HAP) or nosocomial pneumonia." | 7.71 | [Ciprofloxacin in the treatment of hospital-acquired pneumonia: a surveillance study in 676 patients]. ( Kljucar, S; Landen, H; Rost, KL, 2002) |
| " We report an 18-year-old young woman with cystic fibrosis who experienced a pronounced decline in renal function after oral treatment with ciprofloxacin for 3 weeks." | 7.71 | Ciprofloxacin-induced acute renal failure in a patient with cystic fibrosis. ( Bald, M; Nikolaizik, W; Ratjen, F; Wingen, AM, 2001) |
| "A deep-seated Pseudomonas aeruginosa mouse kidney abscess model was used to compare the therapeutic efficacy of clinafloxacin, a fluoroquinolone in clinical trials, with that of clinically relevant standard drugs." | 7.70 | Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model. ( Desaty, TM; Griffin, TJ; Heifetz, CL; Sesnie, JC; Shapiro, MA, 1998) |
| "To determine ciprofloxacin resistance of corneal isolates of Pseudomonas and to review the clinical response to topical therapy in cases of ciprofloxacin-resistant Pseudomonas keratitis, where medical therapy was begun with 0." | 7.70 | Ciprofloxacin-resistant Pseudomonas keratitis. ( Garg, P; Rao, GN; Sharma, S, 1999) |
| "To determine injection time and effective dose of ciprofloxacin in endophthalmitis and to evaluate the effectiveness of dexamethasone." | 7.69 | Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis. ( Chung, KH; Kim, IT; Koo, BS, 1996) |
| "36% tobramycin in two experimental models of keratitis, using a methicillin-sensitive strain of Staphylococcus aureus and an aminoglycoside-sensitive strain of Pseudomonas aeruginosa, respectively." | 7.68 | Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Cohen, KL; Lauffenburger, MD, 1993) |
| "To compare the efficacy of ciprofloxacin hydrochloride ointment with that of ciprofloxacin drops for treatment of experimental Pseudomonas keratitis, rabbit eyes were infected by intrastromal injection of 10(3) colony-forming units (CFU) log-phase P." | 7.68 | Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental Pseudomonas keratitis. ( Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ, 1993) |
| "The mechanisms of persistence to ciprofloxacin in nine sets of Pseudomonas aeruginosa strains isolated during ciprofloxacin therapy of chronic lung infections in cystic fibrosis patients were studied." | 7.68 | Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. ( Bryan, LE; Diver, JM; Rabin, HR; Schollaardt, T; Thorson, C, 1991) |
| "The in vitro activities of two-drug combinations of aztreonam, ciprofloxacin, and ceftazidime were studied in 96 clinical isolates of Pseudomonas aeruginosa and in 20 clinical isolates of Pseudomonas cepacia from cystic fibrosis patients." | 7.68 | In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. ( Bosso, JA; Matsen, JM; Saxon, BA, 1990) |
| "Studies using ciprofloxacin for the therapy of experimental aminoglycoside-resistant keratitis caused by Pseudomonas aeruginosa were conducted using transcorneal iontophoresis as the drug-delivery system." | 7.68 | Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis. ( Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ; Reidy, JJ, 1990) |
| "Twenty-two adult patients with osteomyelitis due to Pseudomonas aeruginosa were enrolled in an open, prospective cooperative study to determine the efficacy of oral ciprofloxacin therapy in a dosage of 750 mg twice a day." | 7.68 | Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis. ( Dan, M; Pitlik, S; Raz, R; Siegman-Igra, Y, 1990) |
| "The therapeutic efficacy of ciprofloxacin, an investigational quinoline derivative, was compared with those of ticarcillin and tobramycin in guinea pigs with experimental Pseudomonas aeruginosa pneumonia." | 7.67 | Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. ( Pennington, JE; Schiff, JB; Small, GJ, 1984) |
| "Fifty patients with gram-negative lower respiratory tract infections were treated with intravenous ciprofloxacin to evaluate efficacy and safety." | 7.67 | Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. ( Cumbo, TJ; Nix, DE; Peloquin, CA; Sands, MF; Schentag, JJ, 1989) |
| "Twelve cystic fibrosis patients, aged over 18, who had developed an acute respiratory exacerbation and who had Pseudomonas species isolated from their sputum, were entered into a clinical trial involving ciprofloxacin." | 7.67 | Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients. ( Black, AE; Collier, PS; Redmond, AO; Scott, EM; Steen, HJ; Stevenson, MI, 1989) |
| "Twenty patients (17-27 yr) with cystic fibrosis were given ciprofloxacin at 30 pulmonary infectious exacerbations." | 7.67 | Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. ( Hjelte, L; Lindblad, A; Ljungberg, B; Malmborg, AS; Nilsson-Ehle, I; Strandvik, B, 1989) |
| "In an open study, a group of 11 patients with asymptomatic urinary tract infections, caused by resistant Pseudomonas strains, were given 200 mg of ciprofloxacin per day for 1 week." | 7.67 | Oral treatment of Pseudomonas-induced urinary tract infections with ciprofloxacin. ( Chysky, V; Dammekens, H; Van Poppel, H; Wegge, M, 1986) |
| "The therapeutic activity of ciprofloxacin, enoxacin, and ofloxacin was evaluated in guinea pigs with acute and chronic experimental Pseudomonas aeruginosa pneumonia." | 7.67 | Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia. ( Kemmerich, B; Pennington, JE; Small, GJ, 1986) |
| "Eighty hospital patients with acute purulent exacerbations of chronic bronchitis associated with Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis or Pseudomonas aeruginosa were treated with ciprofloxacin." | 7.67 | Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. ( Baur, C; Davies, BI; Maesen, FP, 1986) |
| "Ten patients with cystic fibrosis received 19 therapeutic courses of ciprofloxacin at a dose of 750 mg orally twice daily." | 7.67 | Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients. ( Rubio, TT; Shapiro, C, 1986) |
| "The potential of ciprofloxacin for the therapy of Pseudomonas aeruginosa meningitis was evaluated in an animal model by determining the penetration of the drug into CSF, its concentration-dependent killing characteristics in vivo, and its relative efficacy compared with ceftazidime and tobramycin." | 7.67 | Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits. ( Chambers, HF; Hackbarth, CJ; Sande, MA; Shibl, AM; Stella, F, 1986) |
| "Single intravitreal doses of ciprofloxacin, gentamicin, or imipenem were administered to rabbits with pseudomonas endophthalmitis for determination of the maximally effective dose." | 7.67 | Dose response of experimental Pseudomonas endophthalmitis to ciprofloxacin, gentamicin, and imipenem: evidence for resistance to "late" treatment of infections. ( Barza, M; Davey, PG; Stuart, M, 1987) |
| "Ciprofloxacin, a new carboxyquinoline antimicrobial agent, was compared with tobramycin in the treatment of chronic osteomyelitis due to Pseudomonas aeruginosa in rabbits." | 7.67 | Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa. ( Norden, CW; Shinners, E, 1985) |
| "The use of ciprofloxacin for the treatment of pulmonary infection in cystic fibrosis patients was investigated." | 7.67 | The use of ciprofloxacin in the treatment of patients with cystic fibrosis. ( Bakker, W; Mattie, H; van den Broek, PJ; van Gulpen, C, 1987) |
| "Thirty courses of ciprofloxacin were given to 28 patients with complicated urinary tract infections mainly caused by Pseudomonas aeruginosa." | 7.67 | Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria. ( Emmanuel, FX; Leigh, DA; Petch, VJ, 1986) |
| "Levels of ciprofloxacin in serum and sputum were studied for eight patients with cystic fibrosis who were infected with Pseudomonas aeruginosa." | 7.67 | Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. ( Batten, JC; Bowyer, H; Hodson, ME; Smith, MJ; White, LO; Willis, J, 1986) |
| "5 mg or 65 mg was well tolerated with similar incidences of adverse events across all groups." | 6.80 | Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. ( Delesen, H; Nagelschmitz, J; Staab, D; Stass, H, 2015) |
| "Ciprofloxacin DPI was absorbed rapidly after inhalation." | 6.78 | Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. ( Nagelschmitz, J; Rolinck-Werninghaus, C; Staab, D; Stass, H; Weimann, B, 2013) |
| " The recommended dosage regimen for administration of CPF, i." | 6.69 | Clinical pharmacokinetics of ciprofloxacin in patients with major burns. ( Bourget, P; Goudin, C; Latarjet, J; Lesne-Hulin, A; Ravat, F, 1999) |
| "Ciprofloxacin was clinically more effective than the standard therapy in reducing the size of the ulcer (p less than 0." | 6.66 | A comparative study of ciprofloxacin and conventional therapy in the treatment of patients with chronic lower leg ulcers infected with Pseudomonas aeruginosa or other gram-negative rods. ( Kariniemi, AL; Karppinen, L; Valtonen, V, 1989) |
| "Oral ciprofloxacin is a useful short-term treatment for patients with CF who are infected with Ps aeruginosa." | 6.66 | Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. ( Batten, JC; Butland, RJ; Hodson, ME; Roberts, CM; Smith, MJ, 1987) |
| "Ciprofloxacin is a major advance in the treatment of bronchopulmonary infection in patients with cystic fibrosis." | 6.66 | Ciprofloxacin therapy in cystic fibrosis. ( Davidson, S; Nakatomi, M; Neu, HC; Ores, C; Scully, BE, 1987) |
| "Ciprofloxacin displays excellent in vitro activity against gram-negative bacilli and offers the potential for outpatient therapy." | 6.66 | Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis. ( Francis, JB; Freer, C; Lesse, AJ; Salata, RA; Scheld, WM, 1987) |
| "Ciprofloxacin is a potent fluoroquinolone antibiotic with in vitro activity against many significant gram-positive and gram-negative ocular pathogens." | 6.38 | Insights from experimental data on ciprofloxacin in the treatment of bacterial keratitis and ocular infections. ( Cokingtin, CD; Hyndiuk, RA, 1991) |
| "Nebulized gentamicin solution combined with systemic antibiotics appears to be safe and has comparable efficacy to other strategies in eradicating early Pa infections in children with CF." | 5.51 | Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis. ( Morrow, BM; Van Stormbroek, B; Zampoli, M, 2019) |
| "Skull base osteomyelitis is an uncommon disease that usually complicates a malignant external otitis with temporal bone involvement." | 5.46 | Severe skull base osteomyelitis caused by Pseudomonas aeruginosa with successful outcome after prolonged outpatient therapy with continuous infusion of ceftazidime and oral ciprofloxacin: a case report. ( Conde-Díaz, C; Gutiérrez, F; Llenas-García, J; Masiá, M; Parra Grande, M; Terol Esclapez, G, 2017) |
| " Methods An open-label, prospective pharmacokinetic study was performed." | 5.46 | Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients. ( Buchard, A; Dalbøge, CS; Dalhoff, K; Duno, M; Høiby, N; Johansen, HK; Nielsen, XC; Pressler, T; Schultz, AN; Wang, H, 2017) |
| "Ciprofloxacin treatment is effective in life-threatening multi-drug-resistant P." | 5.32 | Ciprofloxacin treatment in newborns with multi-drug-resistant nosocomial Pseudomonas infections. ( Belet, N; Haciömeroğlu, P; Küçüködük, S, 2004) |
| "Oral ciprofloxacin therapy was continued for 10 days and the patient remained free of symptoms with formed stools thereafter." | 5.29 | Pseudomonas aeruginosa as a cause of infectious diarrhea successfully treated with oral ciprofloxacin. ( Porco, FV; Visconte, EB, 1995) |
| "Ciprofloxacin is a fluoroquinolone antibiotic with broad spectrum bactericidal activity." | 5.29 | The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. ( Callegan, MC; Engel, LS; Folkens, AT; Hill, JM; O'Callaghan, RJ; Shimomura, Y, 1996) |
| "Ciprofloxacin was administered orally (15 mg/kg of body weight) or intravenously (6 mg/kg) twice a day for at least 10 days during separate treatment periods." | 5.28 | Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. ( Christensson, BA; Hjelte, L; Lindblad, A; Ljungberg, B; Malmborg, AS; Nilsson-Ehle, I; Strandvik, B, 1992) |
| "We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous year and predefined sputum bacteria." | 5.27 | RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. ( Aksamit, T; Bandel, TJ; Criollo, M; De Soyza, A; Elborn, JS; Operschall, E; Polverino, E; Roth, K; Wilson, R; Winthrop, KL, 2018) |
| "Ciprofloxacin is a new quinolone antibiotic that is highly active in vitro against Pseudomonas aeruginosa." | 5.27 | Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits. ( Dick, JD; Gottsch, JD; O'Brien, TP; Sawusch, MR, 1988) |
| "The osteomyelitis was secondary to trauma in 12 patients, joint replacement in six, previous acute hematogenous infection in two and osteotomy in one." | 5.27 | Treatment of chronic osteomyelitis with ciprofloxacin. ( Mulier, JC; Stuyck, J; Verbist, L, 1987) |
| "Ciprofloxacin has been studied extensively in discriminative animal models of infection, and its efficacy in the treatment of these infections has been compared with that of standard therapy." | 5.27 | Efficacy of ciprofloxacin in animal models of infection: endocarditis, meningitis, and pneumonia. ( Brooks-Fournier, RA; Gerberding, JL; Sande, MA, 1987) |
| "Phase II, 24-week Australian/New Zealand multicentre, randomised, double-blind, placebo-controlled trial in 42 adult bronchiectasis subjects with ≥2 pulmonary exacerbations in the prior 12 months and ciprofloxacin-sensitive P aeruginosa at screening." | 5.17 | Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. ( Bilton, D; Bruinenberg, P; Cipolla, D; De Soyza, A; Gonda, I; Greville, HW; Kolbe, J; Serisier, DJ; Thompson, PJ, 2013) |
| "This study tested the effect of adding inhaled tobramycin solution to oral ciprofloxacin (Cip) for the treatment of acute exacerbations of non-CF bronchiectasis in patients with P aeruginosa infection." | 5.12 | Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. ( Bilton, D; Gotfried, M; Henig, N; Morrissey, B, 2006) |
| "This report focuses on the role of Pseudomonas aeruginosa in complicated urinary tract infections in a prospective, open-label, multicenter study designed to evaluate the safety and efficacy of extended-release ciprofloxacin (ciprofloxacin XR) 1000 mg once daily for 7-14 days for the treatment of complicated urinary tract infections." | 5.12 | Complicated urinary tract infections treated with extended-release ciprofloxacin with emphasis on Pseudomonas aeruginosa. ( Benson, A; Haverstock, D; Herrington, J; Perroncel, R; Pertel, P; Saltzstein, D; Wachs, B, 2007) |
| "/oral ciprofloxacin monotherapy offers a safe and efficacious alternative to standard parenteral therapy for acute pulmonary exacerbations in pediatric cystic fibrosis patients." | 5.08 | Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. ( Church, DA; Echols, RM; Haverstock, DC; Kanga, JF; Kuhn, RJ; Painter, BG; Perroncel, RY; Rubio, TT; Spohn, WA; Stevens, JC; Thurberg, BE, 1997) |
| "The efficacy and safety of oral ciprofloxacin as a maintenance antipseudomonal therapy were evaluated in 44 patients with cystic fibrosis who had completed a 14-day regimen of intensive hospital therapy with intravenous ceftazidime and amikacin, supplemented by amikacin inhalation therapy." | 5.08 | Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. ( Hampel, B; Kraemer, R; Ruedeberg, A; Schaad, UB; Wedgwood, J, 1997) |
| " This study examined the disposition of sequentially administered intravenous and oral ciprofloxacin, as well as provided dosing recommendations, for the treatment of acute pulmonary exacerbations in pediatric cystic fibrosis patients." | 5.08 | Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. ( Church, DA; Echols, RM; Kuhn, RJ; Lettieri, JT; Miles, MV; Rubio, TT, 1997) |
| "More data on the efficacy and safety of ciprofloxacin in pediatric cystic fibrosis patients are needed." | 5.08 | Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. ( Hampel, BJ; Nousia-Arvanitakis, S; Richard, DA; Schaad, UB; Sollich, V; Sommerauer, B, 1997) |
| "To evaluate the efficacy of ciprofloxacin compared with tobramycin and placebo ear drops in the treatment of chronic suppurative otitis media without cholesteatoma." | 5.08 | Chronic otitis media treated topically with ciprofloxacin or tobramycin. ( Ben-David, J; Brodsky, A; Fradis, M; Larboni, J; Podoshin, L; Srugo, I, 1997) |
| "Ciprofloxacin is effective for treating pulmonary infection in adult cystic fibrosis patients, and demonstrates excellent efficacy against Pseudomonas aeruginosa, but its use in paediatric cystic fibrosis patients has been limited because quinolone-induced cartilage toxicity has been observed in juvenile animals and has been considered a potential risk for children." | 5.08 | Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning. ( Daggett, S; Kubin, R; MacFarland, M; Mitchell, M; Redmond, A; Sweeney, L, 1998) |
| "The efficacy and safety of long-term ciprofloxacin therapy in the management of severe bronchiectasis were retrospectively assessed in patients who had taken oral ciprofloxacin continuously for at least 90 days." | 5.07 | Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. ( Cole, PJ; Rayner, CF; Tillotson, G; Wilson, R, 1994) |
| "Intravenously administered ciprofloxacin was compared with imipenem for the treatment of severe pneumonia." | 5.07 | Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. ( Caldwell, JW; Fink, MP; Heard, SO; Johnson, RH; Leeper, KV; Niederman, MS; Schentag, JJ; Siami, GA; Snydman, DR; Wunderink, RG, 1994) |
| "In 31 adult patients with cystic fibrosis (CF) who were chronically infected with Pseudomonas aeruginosa we examined the effect of giving regular three monthly oral ciprofloxacin." | 5.07 | Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. ( Assoufi, BK; Hodson, ME; Sheldon, CD, 1993) |
| "To assess whether chronic pulmonary colonisation with Pseudomonas aeruginosa in cystic fibrosis is preventable, 26 patients who had never received anti-pseudomonas chemotherapy were randomly allocated to groups receiving either no anti-pseudomonas chemotherapy or oral ciprofloxacin and aerosol inhalations of colistin twice daily for 3 weeks, whenever Ps aeruginosa was isolated from routine sputum cultures." | 5.07 | Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. ( Høiby, N; Koch, C; Valerius, NH, 1991) |
| "The clinical efficacy and tolerability of ciprofloxacin orally administered at the dosage of 250 mg twice a day was evaluated in 25 patients affected by acute bacterial pharyngotonsillitis." | 5.06 | Oral ciprofloxacin for treatment of acute bacterial pharyngotonsillitis. ( D'Errico, G; Esposito, S; Montanaro, C, 1990) |
| "The clinical and bacteriological efficacy of ciprofloxacin was studied in three groups composed of 20 patients each, all of whom were affected by chronic otitis media in the acute stage." | 5.06 | Topical and oral treatment of chronic otitis media with ciprofloxacin. A preliminary study. ( D'Errico, G; Esposito, S; Montanaro, C, 1990) |
| "In order to determine the optimal antipseudomonal therapy in patients with cystic fibrosis aztreonam plus amikacin was compared to ceftazidime plus amikacin, and these two-week hospital regimens were followed by oral ciprofloxacin given for four weeks." | 5.06 | Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. ( Buehlmann, U; Guenin, K; Kraemer, R; Schaad, UB; Wedgwood-Krucko, J, 1989) |
| "In order to evaluate the clinical efficacy and safety of oral ciprofloxacin in the treatment of acute pulmonary exacerbations of cystic fibrosis and trace the possible development of resistance over time, three trials were conducted." | 5.06 | Use of ciprofloxacin in cystic fibrosis patients. ( Bosso, JA, 1989) |
| "Thirty one patients were treated with oral ciprofloxacin for bronchitis with Pseudomonas aeruginosa." | 5.06 | Ciprofloxacin for respiratory tract infection with Pseudomonas aeruginosa. ( Haverkorn, MJ, 1987) |
| "The steady state pharmacokinetic properties of ciprofloxacin and ofloxacin were compared in cystic fibrosis patients." | 5.06 | Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. ( Hvidberg, EF; Jensen, T; Pedersen, SS, 1987) |
| "The clinical efficacy and safety of ciprofloxacin and ofloxacin were compared in a prospective, randomized double blind, placebo combined cross-over study in 26 adult cystic fibrosis patients with chronic broncho-pulmonary Pseudomonas aeruginosa infection." | 5.06 | The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. ( Høiby, N; Jensen, T; Koch, C; Nielsen, CH; Pedersen, SS, 1987) |
| "Ciprofloxacin has potent in vitro activity against Pseudomonas aeruginosa and Pseudomonas cepacia strains isolated from cystic fibrosis patients." | 5.06 | Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. ( Blumer, JL; Goldfarb, J; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, 1987) |
| "Twenty-nine adult patients with cystic fibrosis who had chronic bronchopulmonary infection were randomly assigned to receive 750 or 1,000 mg of oral ciprofloxacin every 12 hours for two weeks." | 5.06 | Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. ( Chartrand, SA; Hilman, BC; Marks, MI; Shalit, I; Stutman, HR, 1987) |
| "Twenty adult patients with chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli were enrolled in an open, prospective cooperative study to determine the effect of oral ciprofloxacin therapy in a dosage of 750 mg every 12 hours." | 5.06 | Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli. ( Craven, PC; Gilbert, DN; Marsh, PK; Preheim, LC; Tice, AD, 1987) |
| "2 years), with urinary tract infections caused by Pseudomonas species or other organisms resistant to trimethoprim-sulfamethoxazole were treated with 500 mg of orally administered ciprofloxacin every 12 hours." | 5.06 | Oral ciprofloxacin in resistant urinary tract infections. ( Andriole, VT; Berenson, CS; Greco, TP; Mangi, RJ; Ryan, JL; Sims, M; Thornton, GF, 1987) |
| "Literature searches were made in Medline and Pubmed using the search terms [Pseudomonas] or [Staphylococcus] and [fluoroquinolone] or [cephalosporin] or [gentamicin] and [keratitis] or [cornea]." | 4.87 | Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins. ( Willcox, MD, 2011) |
| "The clinical and bacteriological efficacy and safety of ciprofloxacin given as oral doses of 500 to 1,500 mg (normally 750 mg) twice daily for treatment of Gram-negative bacillary osteomyelitis are reviewed." | 4.77 | Ciprofloxacin in the treatment of acute and chronic osteomyelitis: a review. ( Norrby, SR, 1989) |
| " This paper explores the tolerance to 8 different antibiotics of 61 microbial keratitis isolates of Pseudomonas aeruginosa from Australia and India using the MBC/MIC ratio, with tolerance defined by a ratio ≥ 32, and tolerance to ciprofloxacin by an agar diffusion assay." | 4.31 | Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates. ( Khan, M; Ma, K; Wan, I; Willcox, MD, 2023) |
| " aeruginosa strains were isolated from cystic fibrosis patients and minimum inhibitory concentration of amikacin, tobramycin, and ciprofloxacin was determined against all the strains." | 4.31 | Determining effects of nitrate, arginine, and ferrous on antibiotic recalcitrance of clinical strains of Pseudomonas aeruginosa in biofilm-inspired alginate encapsulates. ( Beigverdi, R; Emaneini, M; Halimi, S; Jabalameli, F; Siroosi, M, 2023) |
| " Concomitantly, high entrapment or encapsulation efficiencies (%EE) were achieved, as illustrated in this work for β-carotene and vitamins derivatives (>85%) for cosmetic application, and for antibiotics currently used in chemotherapy, like rifampicin (69-85%) and pyrazinamide (14-29%) against Mycobacterium tuberculosis (TB), and ciprofloxacin (>65%) and tobramycin (~100%) in Cystic Fibrosis (CF) respiratory infections therapy." | 4.12 | LipNanoCar Technology - A Versatile and Scalable Technology for the Production of Lipid Nanoparticles. ( de Barros, DPC; Dos Santos, ACA; Esgueira, VLR; Fonseca, LP; Leitão, JH; Lopes, CPA; Pinto, F; Sousa, SA, 2022) |
| "Fluoroquinolone antibiotics, namely ciprofloxacin and levofloxacin, play an important role in treating infection in cystic fibrosis (CF) and ciprofloxacin remains the last widely used and orally available antipseudomonal agent." | 4.02 | Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis. ( McCaughan, J; Millar, BC; Moore, JE; Rendall, JC, 2021) |
| " aeruginosa isolated from cystic fibrosis and wound patients, and one laboratory strain was treated singly and with combinations of anti-Pseudomonas phage PEV20 and ciprofloxacin." | 3.91 | Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients. ( Chan, HK; Chang, RYK; Das, T; Kutter, E; Manos, J; Morales, S, 2019) |
| "Ciprofloxacin (CFX) is a fluoroquinolone antibiotic used as a first line treatment against infections caused by Pseudomonas aeruginosa and Streptococcus pneumonia that are commonly acquired by cystic fibrosis (CF) patients." | 3.88 | Fabrication of inhaled hybrid silver/ciprofloxacin nanoparticles with synergetic effect against Pseudomonas aeruginosa. ( Al-Obaidi, H; Kalgudi, R; Zariwala, MG, 2018) |
| "Bacteremia due to Pseudomonas aeruginosa resistant to carbapenems is a public health problem due to the limitations it places on therapeutic options, as well as the increased time patients must spend in hospital, costs and the risk of mortality." | 3.83 | Risk factors for hospital-acquired bacteremia due to carbapenem-resistant Pseudomonas aeruginosa in a Colombian hospital. ( Álvarez, C; Ardila, N; Ariza, B; Caro, MA; Gil, F; González, PF; Valderrama, SL, 2016) |
| " DoE was employed for optimization of ciprofloxacin loaded PLGA NPs for pulmonary delivery against Pseudomonas aeruginosa infections in cystic fibrosis (CF) lungs." | 3.83 | Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: Design of experiments approach. ( Günday Türeli, N; Schneider, M; Türeli, AE, 2016) |
| "The purpose of this study was to evaluate ciprofloxacin-releasing silicone hydrogel contact lens materials in vitro and in vivo for the treatment of microbial keratitis." | 3.80 | In vitro and in vivo evaluation of novel ciprofloxacin-releasing silicone hydrogel contact lenses. ( Hui, A; Jones, L; Willcox, M, 2014) |
| " She presented to clinic with nausea and anorexia within a few days of addition of ciprofloxacin to her current regimen of medications, which included digoxin." | 3.79 | Possible digoxin toxicity associated with concomitant ciprofloxacin therapy. ( Kim, JJ; Moffett, BS; Valdes, SO, 2013) |
| "First, compromised immunity caused by delayed healing of burn wounds in patients with large-area burns and long-term administration of carbapenems may be the important factors in the initiation and progression of PDRPA infection." | 3.77 | Large-area burns with pandrug-resistant Pseudomonas aeruginosa infection and respiratory failure. ( Bian, J; Ning, FG; Zhang, GA; Zhao, XZ, 2011) |
| " Recognizing the thick and tenacious airway mucus seen in the cystic fibrosis (CF) patients as a critical barrier to effective drug delivery, both into the mucus layer itself as well as across that layer to the underlying airway epithelium, we hypothesize that mannitol or NaCl can form inhalable drug carriers, improve drug penetration into the mucus, and ultimately enhance the drug's therapeutic effect." | 3.77 | Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model. ( Lin, Q; Shin, S; Tsifansky, MD; Yang, Y; Yeo, Y, 2011) |
| " Altered pharmacokinetics of fluoroquinolones have been described in cystic fibrosis patients as for other drugs, and a higher dosage than usual is recommended." | 3.77 | Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal. ( LeBel, M, 1991) |
| "In the light of current concerns regarding ciprofloxacin resistance and the changing face of malignant otitis externa, we reviewed cases of malignant otitis externa treated in our centre, in order both to evaluate the current epidemiology of the condition and to assess the status of drug resistance in our patient population." | 3.76 | Malignant otitis externa: case series. ( Ali, T; Anari, S; ElBadawey, MR; Meade, K; Zammit-Maempel, I, 2010) |
| "To assess the probability of achieving ciprofloxacin pharmacodynamic targets with currently recommended dosages in order to investigate the risk of ciprofloxacin underexposure in children with cystic fibrosis." | 3.76 | Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. ( Chhun, S; Ferroni, A; Guillot, E; Jullien, V; Pons, G; Sermet, I; Zahar, JR, 2010) |
| "Retrospective analysis of 189 nonredundant strains of Pseudomonas aeruginosa sequentially recovered from the sputum samples of 46 cystic fibrosis (CF) patients over a 10-year period (1998 to 2007) revealed that 53 out of 189 (28%) samples were hypersusceptible to the beta-lactam antibiotic ticarcillin (MIC < or = 4 microg/ml) (phenotype dubbed Tic(hs))." | 3.75 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. ( Attrée, I; Ducruix, A; El Garch, F; Llanes, C; Muller, C; Phan, G; Plésiat, P; Vettoretti, L, 2009) |
| "To compare the therapeutic effectiveness of a single intrastromal dose of gentamycin, tobramycin, ciprofloxacin and ofloxacin for the treatment of corneal ulcers due to Pseudomonas aeruginosa." | 3.75 | [Bacterial corneal ulcer treated with intrastromal antibiotic. Experimental model in vivo]. ( Naranjo-Tackman, R; Stangogiannis-Druya, C; Stangogiannis-Druya, E; Vanzzini, V; Villar-Kurí, J, 2009) |
| "P aeruginosa bacteremic isolates from patients who have been exposed to ciprofloxacin during the 30 days prior to the development of bacteremia have an increased risk of being resistant to ceftazidime, imipenem, meropenem, piperacillin-tazobactam, or ciprofloxacin and to have multidrug resistance." | 3.75 | Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. ( Almela, M; López, J; López-Dupla, M; Marco, F; Martínez, JA; Mensa, J; Olona, M; Soriano, A; Vidal, F, 2009) |
| "For fifteen years oral ciprofloxacin has been the standard treatment for malignant otitis externa, a sometimes fatal osteomyelitis of the skull base usually caused by Pseudomonas aeruginosa." | 3.74 | Resistance of Pseudomonas to ciprofloxacin: implications for the treatment of malignant otitis externa. ( Bernstein, JM; Holland, NJ; Maw, AR; Porter, GC, 2007) |
| "We report two cases of prolonged blood clotting times as demonstrated by a raised international normalised ratio and elevated activated partial thromboplastin time in patients with cystic fibrosis taking ciprofloxacin." | 3.74 | Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin. ( Jones, AM; Moore, GC; Redfern, J; Shiach, CR; Webb, K, 2007) |
| " aureus keratitis, following the treatments, the median number of CFU of recoverable bacteria for chlorhexidine (n = 10), ciprofloxacin (n = 12), tobramycin/cefazolin (n = 12), and controls (n = 10) was 1." | 3.74 | A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Bouchard, CS; Bu, P; Carey, R; Riske, PS; Zaya, NE, 2007) |
| "A biodegradable system of poly-D,L-dilactide releasing ciprofloxacin was assessed in a Pseudomonas aeruginosa osteomyelitis model after inoculation of the test pathogen into the left tibia of 76 New Zealand White rabbits; 31 were controls (group A), and 45 were implanted with the polymer at the infection site (group B)." | 3.74 | Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin. ( Andreopoulos, A; Dontas, I; Dounis, E; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kanellakopoulou, K; Karagiannakos, P; Kolia, M; Nakopoulou, L; Thivaios, GC, 2008) |
| "3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin." | 3.73 | Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. ( Carrier, M; Jensen, H; Short, B; Zerouala, C, 2005) |
| "Both moxifloxacin and ciprofloxacin performed significantly better than control in the treatment of Pseudomonas aeruginosa keratitis (P=0." | 3.73 | Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits. ( Aliprandis, E; Ciralsky, J; Herling, I; Katz, HR; Lai, H, 2005) |
| " Twelve days later, she was diagnosed with posterior scleritis and treated with oral ciprofloxacin." | 3.73 | Posterior scleritis secondary to Pseudomonas aeruginosa keratitis. ( Dastjerdi, M; Fahim, K; Houghton, O; Mian, SI, 2005) |
| "The aim of the present study was to characterize the population pharmacokinetics of ciprofloxacin in patients with and without cystic fibrosis ranging in age from 1 day to 24 years and to propose a limited sampling strategy to estimate individual pharmacokinetic parameters." | 3.72 | Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. ( Aigrain, Y; Aujard, Y; Bressolle, F; Jacqz-Aigrain, E; Munck, A; Payen, S; Serreau, R, 2003) |
| "We evaluated the virulence of Pseudomonas aeruginosa carrying bla(IMP), a metallo-beta-lactamase gene, and the efficacy of ceftazidime, imipenem-cilastatin, and ciprofloxacin in the endogenous bacteremia model." | 3.72 | Virulence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in vitro and in vivo. ( Aoki, S; Gotoh, N; Hirakata, Y; Kamihira, S; Kohno, S; Kondoh, A; Miyazaki, Y; Tomono, K; Yamada, Y; Yanagihara, K, 2004) |
| "Overall, moxifloxacin was the most effective of the four fluoroquinolones in reducing CFU/cornea in the rabbit model of gram-negative keratitis." | 3.72 | Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis. ( Caballero, AR; Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA, 2004) |
| "24 preterm neonates with age < 28 days, who received intravenous ciprofloxacin 10 mg/kg/dose 12 hourly for clinical and/or culture proven sepsis, were enrolled." | 3.72 | Multiple dose pharmacokinetics of ciprofloxacin in preterm babies. ( Aggarwal, P; Dutta, S; Garg, SK; Narang, A, 2004) |
| "In a previous study in experimental Klebsiella pneumoniae pneumonia, the therapeutic potential of ciprofloxacin was significantly improved by encapsulation in polyethylene glycol-coated ("pegylated") long-circulating (STEALTH) liposomes." | 3.71 | Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. ( Bakker-Woudenberg, IA; Guo, L; Mouton, JW; ten Kate, MT; Working, P, 2002) |
| "To determine whether there has been an increase in ciprofloxacin-resistant pseudomonas malignant otitis externa, and if this has increased the morbidity of the disease." | 3.71 | Evolving resistant pseudomonas to ciprofloxacin in malignant otitis externa. ( Berenholz, L; Harell, M; Katzenell, U, 2002) |
| "Controlled clinical trials have shown efficacy of high-dose ciprofloxacin for hospital-acquired (HAP) or nosocomial pneumonia." | 3.71 | [Ciprofloxacin in the treatment of hospital-acquired pneumonia: a surveillance study in 676 patients]. ( Kljucar, S; Landen, H; Rost, KL, 2002) |
| " We report an 18-year-old young woman with cystic fibrosis who experienced a pronounced decline in renal function after oral treatment with ciprofloxacin for 3 weeks." | 3.71 | Ciprofloxacin-induced acute renal failure in a patient with cystic fibrosis. ( Bald, M; Nikolaizik, W; Ratjen, F; Wingen, AM, 2001) |
| "To report a clinical case of a 21-year old male with a severe corneal abscess due to Pseudomonas aeruginosa refractory to intensive treatment with topical Ciprofloxacin." | 3.71 | [Pseudomonas aeruginosa corneal abscess refractory to fluoroquinolones]. ( Alós Cortés, JI; Arteaga Sánchez, A; Díaz Valle, D; Díaz-Valle, T; Poza Morales, Y; Toledano Fernández, N, 2002) |
| "A deep-seated Pseudomonas aeruginosa mouse kidney abscess model was used to compare the therapeutic efficacy of clinafloxacin, a fluoroquinolone in clinical trials, with that of clinically relevant standard drugs." | 3.70 | Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model. ( Desaty, TM; Griffin, TJ; Heifetz, CL; Sesnie, JC; Shapiro, MA, 1998) |
| "To determine ciprofloxacin resistance of corneal isolates of Pseudomonas and to review the clinical response to topical therapy in cases of ciprofloxacin-resistant Pseudomonas keratitis, where medical therapy was begun with 0." | 3.70 | Ciprofloxacin-resistant Pseudomonas keratitis. ( Garg, P; Rao, GN; Sharma, S, 1999) |
| "Ciprofloxacin, a quinolone antibiotic, is used to treat a wide variety of infections including Pseudomonas aeruginosa in patients with cystic fibrosis (CF)." | 3.70 | If you can't stand the rash, get out of the kitchen: an unusual adverse reaction to ciprofloxacin. ( Bush, A; Jaffé, A, 1999) |
| "Ciprofloxacin and prednisolone, but not an aminoglycoside and dexamethasone, were previously found to be effective in killing bacteria and reducing inflammation for the treatment of Pseudomonas keratitis." | 3.69 | Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. ( Callegan, MC; Engel, LS; Hill, JM; Hobden, JA; O'Callaghan, RJ; Reidy, JJ, 1995) |
| "To determine injection time and effective dose of ciprofloxacin in endophthalmitis and to evaluate the effectiveness of dexamethasone." | 3.69 | Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis. ( Chung, KH; Kim, IT; Koo, BS, 1996) |
| "36% tobramycin in two experimental models of keratitis, using a methicillin-sensitive strain of Staphylococcus aureus and an aminoglycoside-sensitive strain of Pseudomonas aeruginosa, respectively." | 3.68 | Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. ( Cohen, KL; Lauffenburger, MD, 1993) |
| "To compare the efficacy of ciprofloxacin hydrochloride ointment with that of ciprofloxacin drops for treatment of experimental Pseudomonas keratitis, rabbit eyes were infected by intrastromal injection of 10(3) colony-forming units (CFU) log-phase P." | 3.68 | Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental Pseudomonas keratitis. ( Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ, 1993) |
| "The mechanisms of persistence to ciprofloxacin in nine sets of Pseudomonas aeruginosa strains isolated during ciprofloxacin therapy of chronic lung infections in cystic fibrosis patients were studied." | 3.68 | Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. ( Bryan, LE; Diver, JM; Rabin, HR; Schollaardt, T; Thorson, C, 1991) |
| "The in vitro activities of two-drug combinations of aztreonam, ciprofloxacin, and ceftazidime were studied in 96 clinical isolates of Pseudomonas aeruginosa and in 20 clinical isolates of Pseudomonas cepacia from cystic fibrosis patients." | 3.68 | In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. ( Bosso, JA; Matsen, JM; Saxon, BA, 1990) |
| "Studies using ciprofloxacin for the therapy of experimental aminoglycoside-resistant keratitis caused by Pseudomonas aeruginosa were conducted using transcorneal iontophoresis as the drug-delivery system." | 3.68 | Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis. ( Hill, JM; Hobden, JA; Insler, MS; O'Callaghan, RJ; Reidy, JJ, 1990) |
| "The Cystic Fibrosis Clinic at the Royal Belfast Hospital for Sick Children has treated 31 children with ciprofloxacin, for serious pseudomonas infection in cystic fibrosis, and carefully monitored the safety and acceptability of the drug." | 3.68 | Tolerance and safety of ciprofloxacin in paediatric patients. ( Black, A; Oborska, IT; Redmond, AO; Steen, HJ, 1990) |
| "Twenty-two adult patients with osteomyelitis due to Pseudomonas aeruginosa were enrolled in an open, prospective cooperative study to determine the efficacy of oral ciprofloxacin therapy in a dosage of 750 mg twice a day." | 3.68 | Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis. ( Dan, M; Pitlik, S; Raz, R; Siegman-Igra, Y, 1990) |
| "The therapeutic efficacy of ciprofloxacin, an investigational quinoline derivative, was compared with those of ticarcillin and tobramycin in guinea pigs with experimental Pseudomonas aeruginosa pneumonia." | 3.67 | Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. ( Pennington, JE; Schiff, JB; Small, GJ, 1984) |
| "Fifty patients with gram-negative lower respiratory tract infections were treated with intravenous ciprofloxacin to evaluate efficacy and safety." | 3.67 | Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. ( Cumbo, TJ; Nix, DE; Peloquin, CA; Sands, MF; Schentag, JJ, 1989) |
| "Twelve cystic fibrosis patients, aged over 18, who had developed an acute respiratory exacerbation and who had Pseudomonas species isolated from their sputum, were entered into a clinical trial involving ciprofloxacin." | 3.67 | Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients. ( Black, AE; Collier, PS; Redmond, AO; Scott, EM; Steen, HJ; Stevenson, MI, 1989) |
| "Twenty patients (17-27 yr) with cystic fibrosis were given ciprofloxacin at 30 pulmonary infectious exacerbations." | 3.67 | Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. ( Hjelte, L; Lindblad, A; Ljungberg, B; Malmborg, AS; Nilsson-Ehle, I; Strandvik, B, 1989) |
| "In an open study, a group of 11 patients with asymptomatic urinary tract infections, caused by resistant Pseudomonas strains, were given 200 mg of ciprofloxacin per day for 1 week." | 3.67 | Oral treatment of Pseudomonas-induced urinary tract infections with ciprofloxacin. ( Chysky, V; Dammekens, H; Van Poppel, H; Wegge, M, 1986) |
| "The therapeutic activity of ciprofloxacin, enoxacin, and ofloxacin was evaluated in guinea pigs with acute and chronic experimental Pseudomonas aeruginosa pneumonia." | 3.67 | Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia. ( Kemmerich, B; Pennington, JE; Small, GJ, 1986) |
| "Eighty hospital patients with acute purulent exacerbations of chronic bronchitis associated with Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis or Pseudomonas aeruginosa were treated with ciprofloxacin." | 3.67 | Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. ( Baur, C; Davies, BI; Maesen, FP, 1986) |
| "The efficacy and safety of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections was evaluated in 72 patients suffering from upper urinary tract infection (19 patients), deep soft tissue infection (16), chronic osteomyelitis (12), abscess (7), chronic otitis media (6), otitis externa (3) and bronchopneumonia (9)." | 3.67 | Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. ( Daikos, GK; Daphnis, E; Dendrinos, C; Galanakis, N; Giamarellou, H; Stefanou, J, 1986) |
| "Ten patients with cystic fibrosis received 19 therapeutic courses of ciprofloxacin at a dose of 750 mg orally twice daily." | 3.67 | Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients. ( Rubio, TT; Shapiro, C, 1986) |
| "The potential of ciprofloxacin for the therapy of Pseudomonas aeruginosa meningitis was evaluated in an animal model by determining the penetration of the drug into CSF, its concentration-dependent killing characteristics in vivo, and its relative efficacy compared with ceftazidime and tobramycin." | 3.67 | Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits. ( Chambers, HF; Hackbarth, CJ; Sande, MA; Shibl, AM; Stella, F, 1986) |
| "Single intravitreal doses of ciprofloxacin, gentamicin, or imipenem were administered to rabbits with pseudomonas endophthalmitis for determination of the maximally effective dose." | 3.67 | Dose response of experimental Pseudomonas endophthalmitis to ciprofloxacin, gentamicin, and imipenem: evidence for resistance to "late" treatment of infections. ( Barza, M; Davey, PG; Stuart, M, 1987) |
| "Ciprofloxacin, a new carboxyquinoline antimicrobial agent, was compared with tobramycin in the treatment of chronic osteomyelitis due to Pseudomonas aeruginosa in rabbits." | 3.67 | Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa. ( Norden, CW; Shinners, E, 1985) |
| "The use of ciprofloxacin for the treatment of pulmonary infection in cystic fibrosis patients was investigated." | 3.67 | The use of ciprofloxacin in the treatment of patients with cystic fibrosis. ( Bakker, W; Mattie, H; van den Broek, PJ; van Gulpen, C, 1987) |
| "Thirty courses of ciprofloxacin were given to 28 patients with complicated urinary tract infections mainly caused by Pseudomonas aeruginosa." | 3.67 | Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria. ( Emmanuel, FX; Leigh, DA; Petch, VJ, 1986) |
| "Levels of ciprofloxacin in serum and sputum were studied for eight patients with cystic fibrosis who were infected with Pseudomonas aeruginosa." | 3.67 | Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. ( Batten, JC; Bowyer, H; Hodson, ME; Smith, MJ; White, LO; Willis, J, 1986) |
| "5 mg or 65 mg was well tolerated with similar incidences of adverse events across all groups." | 2.80 | Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. ( Delesen, H; Nagelschmitz, J; Staab, D; Stass, H, 2015) |
| "Ciprofloxacin DPI was absorbed rapidly after inhalation." | 2.78 | Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. ( Nagelschmitz, J; Rolinck-Werninghaus, C; Staab, D; Stass, H; Weimann, B, 2013) |
| " Adverse events were similar across groups." | 2.76 | Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. ( Burns, JL; Chatfield, BA; Froh, DK; Gibson, RL; Hiatt, P; Khan, U; Kronmal, R; Kulich, M; Mayer-Hamblett, N; Orenstein, D; Ramsey, BW; Retsch-Bogart, G; Rosenfeld, M; Spencer, T; Treggiari, MM; Williams, J, 2011) |
| "Treatment with ciprofloxacin eardrops seemed to be at least as efficient as treatment with tobramycin." | 2.69 | [Local treatment of purulent chronic otitis media with ciprofloxacin]. ( Ben-David, J; Brodzki, A; Fradis, M; Larboni, J; Podoshin, L; Srugo, I, 1998) |
| " The recommended dosage regimen for administration of CPF, i." | 2.69 | Clinical pharmacokinetics of ciprofloxacin in patients with major burns. ( Bourget, P; Goudin, C; Latarjet, J; Lesne-Hulin, A; Ravat, F, 1999) |
| " Despite the antipseudomonal advantage noted for ciprofloxacin monotherapy, it is unknown whether this advantage is maintained when the fluoroquinolones are used in combination with antipseudomonal beta-lactams such as ceftazidime and piperacillin." | 2.68 | Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa. ( Klepser, ME; Nicolau, DP; Nightingale, CH; Patel, KB; Quintiliani, R, 1995) |
| "Ciprofloxacin appears to be an effective treatment of chronic otitis media, and superior to amoxycillin/clavulanic acid." | 2.67 | Controlled prospective study of oral ciprofloxacin versus amoxycillin/clavulanic acid in chronic suppurative otitis media in adults. ( Beauvillain, C; Berche, P; Bordure, P; Legent, F, 1994) |
| " Eight adverse effects were observed in five patients and treatment had to be discontinued in one case." | 2.67 | Study of the efficacy and safety of ciprofloxacin in the treatment of chronic otitis. ( Barrault, S; Dobler, S; Ebbo, D; Fombeur, JP; Koubbi, G; Laurier, JN; Lecomte, F; Sorrel, N, 1994) |
| "Ciprofloxacin was given as an initial 100 mg twice daily as intravenous infusion, and this was switched to an oral form of 500 mg b." | 2.67 | Ciprofloxacin in severe infections. ( Aswapokee, N; Aswapokee, P; Pruksachatvuthi, S, 1990) |
| "Necrotising otitis externa is a progressive infection of the external auditory canal which extends to affect the temporal bone and adjacent structures." | 2.66 | A retrospective review and multi-specialty, evidence-based guideline for the management of necrotising otitis externa. ( Baring, D; Bennett, A; Henderson, N; Hopkins, ME; MacSween, KF; Sutherland, R, 2020) |
| "Ciprofloxacin was clinically more effective than the standard therapy in reducing the size of the ulcer (p less than 0." | 2.66 | A comparative study of ciprofloxacin and conventional therapy in the treatment of patients with chronic lower leg ulcers infected with Pseudomonas aeruginosa or other gram-negative rods. ( Kariniemi, AL; Karppinen, L; Valtonen, V, 1989) |
| "Ciprofloxacin has been shown to be effective against a wide range of gram-negative and gram-positive organisms." | 2.66 | Ciprofloxacin for the treatment of chronic ear disease. ( Parnes, SM; Piccirillo, JF, 1989) |
| "Oral ciprofloxacin is a useful short-term treatment for patients with CF who are infected with Ps aeruginosa." | 2.66 | Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. ( Batten, JC; Butland, RJ; Hodson, ME; Roberts, CM; Smith, MJ, 1987) |
| "Ciprofloxacin is a major advance in the treatment of bronchopulmonary infection in patients with cystic fibrosis." | 2.66 | Ciprofloxacin therapy in cystic fibrosis. ( Davidson, S; Nakatomi, M; Neu, HC; Ores, C; Scully, BE, 1987) |
| "Ciprofloxacin displays excellent in vitro activity against gram-negative bacilli and offers the potential for outpatient therapy." | 2.66 | Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis. ( Francis, JB; Freer, C; Lesse, AJ; Salata, RA; Scheld, WM, 1987) |
| " The drug dosage was 300 mg every 12 hours in 19 patients and 200 mg intravenously every 12 hours in nine patients." | 2.66 | Treatment of serious infections with intravenous ciprofloxacin. ( Neu, HC; Scully, BE, 1987) |
| "Bronchiectasis is a chronic respiratory disease with heterogeneous etiology, characterized by a cycle of bacterial infection and inflammation, resulting in increasing airway damage." | 2.58 | Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug-device combination. ( Durbha, P; Elborn, JS; Haynes, A; McShane, PJ; Miller, DP; Mundry, T; Operschall, E; Tarara, TE; Weers, JG, 2018) |
| "Bronchiectasis is a chronic respiratory disease characterised by abnormal and irreversible dilatation of the smaller airways and associated with a mortality rate greater than twice that of the general population." | 2.58 | Dual antibiotics for bronchiectasis. ( Armstrong, R; Felix, LM; Grundy, S; Harrison, H; Lynes, D; Milan, SJ; Spencer, S, 2018) |
| "To determine whether antibiotic treatment of early Pseudomonas aeruginosa infection in children and adults with cystic fibrosis eradicates the organism, delays the onset of chronic infection, and results in clinical improvement." | 2.55 | Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. ( Langton Hewer, SC; Smyth, AR, 2017) |
| "To determine whether antibiotic treatment of early Pseudomonas aeruginosa infection in children and adults with cystic fibrosis eradicates the organism, delays the onset of chronic infection, and results in clinical improvement." | 2.50 | Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. ( Langton Hewer, SC; Smyth, AR, 2014) |
| " Older literature supports an oral dosing regimen of 40 mg/kg/day divided every 12 hr, up to 2 g/day, and intravenous (IV) ciprofloxacin 30 mg/kg/day divided every 8 hr, maximum 1." | 2.49 | Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. ( Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT, 2013) |
| "To determine whether antibiotic treatment of early Pseudomonas aeruginosa infection in children and adults with CF eradicates the organism, improves clinical and microbiological outcome and is superior to or more cost-effective than other strategies." | 2.45 | Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. ( Langton Hewer, SC; Smyth, AR, 2009) |
| "For levofloxacin-treated CAP patients with P." | 2.43 | Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. ( Davis, NB; Kahn, J; Tennenberg, AM; Wu, SC, 2006) |
| "Ciprofloxacin thus seems to be a particularly useful antibiotic for the treatment of malignant external otitis, both because of its clinical and bacteriological efficacy and because it is well tolerated." | 2.39 | Ciprofloxacin in the treatment of malignant external otitis. ( Gehanno, P, 1994) |
| "Ciprofloxacin is a potent fluoroquinolone antibiotic with in vitro activity against many significant gram-positive and gram-negative ocular pathogens." | 2.38 | Insights from experimental data on ciprofloxacin in the treatment of bacterial keratitis and ocular infections. ( Cokingtin, CD; Hyndiuk, RA, 1991) |
| " Care in selection of patients, attention to optimal duration of therapy and adequate dosage may help to prevent emergence of resistance but combination therapy has not proven effective." | 2.38 | Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. ( Ball, P, 1990) |
| "Necrotizing otitis externa is an invasive infection, affecting older patients, with significant associated morbidity." | 1.91 | Management and Clinical Outcomes of 37 Patients with Necrotizing Otitis Externa: Retrospective Review of a Standardized 6-Week Treatment Pathway. ( Beale, T; David, K; Dhariwal, A; Khetarpal, P; Logan, S; Manjaly, JG; Mehta, N; Morris-Jones, S; Patel, B, 2023) |
| " Non-steroid anti-inflammatory drugs have shown the antimicrobial potential to be used in combination with antibiotics against bacterial pathogens." | 1.72 | Evaluation of the effect of ibuprofen in combination with ciprofloxacin on the virulence-associated traits, and efflux pump genes of Pseudomonas aeruginosa. ( Ghanbari, F; Khodaparast, S; Zamani, H, 2022) |
| "One reason for CSOM recurrence might be surgery failure." | 1.56 | Chronic Suppurative Otitis Media: A Case Report. ( Eslami, G; Ghalavand, Z; Kodori, M; Tabriz, MS; Taheri, M; Yazdi, AK; Yazdi, MMK, 2020) |
| " Previously, we demonstrated that the complexation of CIP with copper (CIP-Cu) reduces its apparent epithelial permeability and pulmonary absorption rate without affecting antimicrobial activity against Pseudomonas aeruginosa grown planktonically or as biofilms." | 1.56 | In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa. ( Bahamondez-Canas, TF; Moraga-Espinoza, D; Smyth, HDC; Tewes, F; Watts, AB, 2020) |
| " To investigate the physical and chemical changes of drugs due to the combination, the tested drugs, both alone and in combination with TDN, were subjected to differential scanning calorimetry (DSC), infrared (IR) spectroscopy, and X-ray diffraction studies." | 1.56 | Comparative Study of Antibacterial Effects of Titanium Dioxide Nanoparticles Alone and in Combination with Antibiotics on MDR ( Abd El-Baky, RM; Ahmed, FY; Farghaly Aly, U; Waly, NGFM, 2020) |
| "Ciprofloxacin (CIP) is an antibiotic commonly used to treat P." | 1.56 | Transcriptomic determinants of the response of ST-111 Pseudomonas aeruginosa AG1 to ciprofloxacin identified by a top-down systems biology approach. ( Campos-Sánchez, R; Chavarría-Azofeifa, M; Chinchilla-Montero, D; García, F; Molina-Mora, JA; Mora-Rodríguez, R; Shi, L; Ulloa-Morales, AJ, 2020) |
| " There was no drug-drug interaction observed during the transport of ciprofloxacin and colistin across the cell monolayer, when they were dosed together in the solution form." | 1.51 | Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model. ( Chai, G; Li, J; Park, H; Xu, Q; Yu, S; Zhou, F; Zhou, QT, 2019) |
| "Nebulized gentamicin solution combined with systemic antibiotics appears to be safe and has comparable efficacy to other strategies in eradicating early Pa infections in children with CF." | 1.51 | Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis. ( Morrow, BM; Van Stormbroek, B; Zampoli, M, 2019) |
| "Patients with cystic fibrosis are more susceptible than members of the general population to lung infections." | 1.51 | No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis. ( Claude, F; Hafen, GM; Rochat, I, 2019) |
| "Otitis externa is a common presentation to secondary care otolaryngology clinics." | 1.48 | Microbiology and antimicrobial susceptibility of otitis externa: a changing pattern of antimicrobial resistance. ( Cullen, M; Heward, E; Hobson, J, 2018) |
| " aeruginosa eradication since a biofilm minimal inhibitory dosage would be applied." | 1.48 | Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance. ( Monteiro, R; Pereira, MO; Sousa, AM, 2018) |
| "2-Hydroxyethyl methacrylate (HEMA) was used as a solvent and backbone monomer, ethylene glycol dimethacrylate (EGDMA) as a cross-linker, methacrylic acid (MAA) as a functional monomer and CFX as the template molecule." | 1.46 | Ciprofloxacin-imprinted hydrogels for drug sustained release in aqueous media. ( Heidari, S; Khameneh, B; Kioomars, S; Malaekeh-Nikouei, B; Mohajeri, SA; Shayani Rad, M, 2017) |
| "Skull base osteomyelitis is an uncommon disease that usually complicates a malignant external otitis with temporal bone involvement." | 1.46 | Severe skull base osteomyelitis caused by Pseudomonas aeruginosa with successful outcome after prolonged outpatient therapy with continuous infusion of ceftazidime and oral ciprofloxacin: a case report. ( Conde-Díaz, C; Gutiérrez, F; Llenas-García, J; Masiá, M; Parra Grande, M; Terol Esclapez, G, 2017) |
| " Methods An open-label, prospective pharmacokinetic study was performed." | 1.46 | Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients. ( Buchard, A; Dalbøge, CS; Dalhoff, K; Duno, M; Høiby, N; Johansen, HK; Nielsen, XC; Pressler, T; Schultz, AN; Wang, H, 2017) |
| " Population pharmacokinetic analysis and Monte Carlo simulation was undertaken using Pmetrics." | 1.43 | Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. ( Lefrant, JY; Lipman, J; Louart, B; Muller, L; Roberts, JA; Roger, C; Wallis, SC, 2016) |
| " aeruginosa, fosfomycin in combination with polymyxin B or tobramycin (FOF(S) isolates) or ciprofloxacin (FOF(R) isolates) increased bacterial killing, but did not suppress emergence of fosfomycin resistance." | 1.43 | Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. ( Bergen, PJ; Hirsch, EB; Kirkpatrick, CM; Landersdorfer, CB; McIntosh, MP; Peleg, AY; Walsh, CC, 2016) |
| "aeruginosa murine burn wound infection." | 1.42 | Efficacy of purified lactonase and ciprofloxacin in preventing systemic spread of Pseudomonas aeruginosa in murine burn wound model. ( Chhibber, S; Gupta, P; Harjai, K, 2015) |
| " One equivalent generic was selected for analysis by high-pressure liquid chromatography-tandem mass spectrometry (LC-MS/MS), to confirm chemical identity, and resistance selection experiments in a hollow-fiber (HF) system simulating two clinical dosing regimens." | 1.42 | Impact on resistance of the use of therapeutically equivalent generics: the case of ciprofloxacin. ( Agudelo, M; Rodriguez, CA; Vesga, O; Zuluaga, AF, 2015) |
| "The aim of this work was to define the optimal dosage (OD) of ciprofloxacin in order to prevent the emergence of bacterial resistance of Pseudomonas aeruginosa in a geriatric population with a bloodstream infection." | 1.42 | Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study. ( Bourguignon, L; Cazaubon, Y; Ducher, M; Goutelle, S; Maire, P; Martin, O, 2015) |
| "Treatment with ciprofloxacin decreased the viability of PAO1 and ΔkatA biofilms but not of gyrA biofilms." | 1.40 | Formation of hydroxyl radicals contributes to the bactericidal activity of ciprofloxacin against Pseudomonas aeruginosa biofilms. ( Bjarnsholt, T; Briales, A; Brochmann, RP; Ciofu, O; Hempel, C; Høiby, N; Jensen, PØ; Kolpen, M; Kragh, KN; Wang, H, 2014) |
| "Increased awareness of septic sacroiliitis as a potential disease process in the differential diagnosis of troops presenting with a combination of fever, low-back pain, and weight-bearing difficulty is important." | 1.39 | Novel Pseudomonas fluorescens septic sacroiliitis in a healthy soldier. ( Akers, KS; Alderete, JF; Lindholm, DA; Murray, CK; O'Brien, SD; Vento, TJ, 2013) |
| "Pseudomonas folliculitis is a bacterial infection of the hair follicles." | 1.39 | Pseudomonas folliculitis in Arabian baths. ( Molina-Leyva, A; Ruiz-Ruigomez, M, 2013) |
| "Twenty patients were identified." | 1.39 | Skull base osteomyelitis: current microbiology and management. ( Neeff, M; Spielmann, PM; Yu, R, 2013) |
| "To compare the antipseudomonal efficacy of doripenem and imipenem as well as their abilities to restrict the enrichment of resistant Pseudomonas aeruginosa, multiple-dosing regimens of each drug were simulated at comparable values of the cumulative percentages of a 24-h period that the drug concentration exceeds the MIC under steady-state pharmacokinetic conditions (T(>MIC)) and ratios of the 24-hour area under the curve (AUC(24)) to the MIC." | 1.38 | Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model. ( Firsov, AA; Gilbert, D; Greer, K; Portnoy, YA; Zinner, SH, 2012) |
| "Necrotizing otitis externa is an uncommon but potentially life-threatening infection disease of the external auditory canal and temporal bone." | 1.37 | Differential diagnosis and treatments of necrotizing otitis externa: a report of 19 cases. ( Chan, KC; Chen, CK; Chen, YA; Wu, CM, 2011) |
| " The rabbits received ciprofloxacin 10 times a day at a 2-hour dosing interval." | 1.37 | [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. ( Li, Y; Liu, MT; Sheng, MY; Zhang, Y, 2011) |
| "Free cefepime exposures were estimated by using a validated population pharmacokinetic model." | 1.36 | Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. ( Bulik, CC; Crandon, JL; Kuti, JL; Nicolau, DP, 2010) |
| "aeruginosa nosocomial infections, particularly those caused by multidrug-resistant isolates that emerge during antipseudomonal treatments." | 1.36 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. ( Ge, Y; Juan, C; Moya, B; Oliver, A; Pérez, JL; Zamorano, L, 2010) |
| " However, additional experiments are required to validate the robustness of this model after longer exposure periods and multiple dosing regimens, as well as in vivo." | 1.36 | Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa. ( Comets, E; Couet, W; Grégoire, N; Grignon, C; Marliat, M; Ploy, MC; Raherison, S, 2010) |
| "Levofloxacin use was associated with increased resistance of P." | 1.36 | Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use. ( Chun, CL; Hsueh, PR; Lee, YJ; Lin, YC; Liu, HY; Sun, KL, 2010) |
| "Levofloxacin 1." | 1.36 | Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models. ( Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Shanks, RM, 2010) |
| "Doripenem is a new carbapenem antimicrobial with activity against a range of gram-negative organisms, including Pseudomonas aeruginosa." | 1.35 | In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. ( Bulik, CC; Crandon, JL; Nicolau, DP, 2009) |
| "Osteomyelitis is a relatively frequent bacterial infection of the jaw bones." | 1.35 | Mandibular osteomyelitis due to Pseudomonas aeruginosa. Case report. ( Brutto, D; Cappello, V; Carlino, V; Consolo, G; Marescalco, M; Mauro, M; Pappalardo, S; Tanteri, L, 2008) |
| "Ciprofloxacin-resistance was found in 4% of isolates." | 1.35 | Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. ( Hansen, CR; Høiby, N; Pressler, T, 2008) |
| "Aztreonam and amikacin were intravenously administered at doses of 2 g/day and 800 mg/day, respectively." | 1.35 | [Infection treatment caused by multiple-drug-resistant Pseudomonas aeruginosa in a patient undergoing allogeneic hematopoietic stem cell transplantation]. ( Fukuoka, N; Houchi, H; Inoue, T; Ishida, T; Kaji, M; Kawazoe, H; Ninomiya, M; Ohnishi, H; Takiguchi, Y; Tanaka, H; Tsuji, S; Yamaguchi, K, 2008) |
| "aeruginosa respiratory tract infections and to develop a tool to estimate the probability of MDR among such high-risk patients." | 1.34 | Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. ( Furuno, JP; Graffunder, E; Graves, J; Lodise, TP; Lomaestro, B; McGregor, JC; McNutt, LA; Miller, CD, 2007) |
| "Bacterial wound infection is a major problem, which hinders the normal healing process." | 1.34 | Collagen bilayer dressing with ciprofloxacin, an effective system for infected wound healing. ( Ahmed, MR; Kumar, MS; Sehgal, PK; Sripriya, R, 2007) |
| "Ciprofloxacin therapy was initiated and renal function was restored within 2 days." | 1.33 | Pseudomonas aeruginosa infection: an uncommon cause of post-renal obstruction following induction therapy for acute lymphoblastic leukemia. ( Burghardt, KM; Feber, J; Filler, G; Halton, J; Leonard, M, 2006) |
| " The goal of this study was to predict the relative efficacies of three ciprofloxacin dosing regimens for P." | 1.33 | Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations. ( Ariano, R; Forrest, A; Harding, G; Zelenitsky, S, 2005) |
| "Levofloxacin use was more frequent in the QR P." | 1.33 | Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. ( Carmeli, Y; Dodds, AE; Engemann, JJ; Kanafani, ZA; Kaye, KS; Weber, SG, 2006) |
| "Owing to increasing resistance rates in Europe, pharmacodynamic analyses were proposed to determine optimal empirical antibiotic therapy against Pseudomonas aeruginosa isolated in Hungary." | 1.33 | Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals. ( Konkoly-Thege, M; Kuti, JL; Ludwig, E; Nicolau, DP, 2006) |
| "Ciprofloxacin treatment is effective in life-threatening multi-drug-resistant P." | 1.32 | Ciprofloxacin treatment in newborns with multi-drug-resistant nosocomial Pseudomonas infections. ( Belet, N; Haciömeroğlu, P; Küçüködük, S, 2004) |
| " Ceftazidime plus ciprofloxacin and ceftazidime plus tobramycin were dosed every 12 h for 48 h using simultaneous or staggered administration." | 1.32 | Effect of antibiotic sequence on combination regimens against Pseudomonas aeruginosa in a multiple-dose, in vitro infection model. ( Ariano, RE; Harding, GK; Iacovides, H; Zelenitsky, SA, 2004) |
| "To achieve this, a burn wound infection model was established in mice by using a highly pathogenic burn wound clinical isolate of P." | 1.32 | Therapeutic efficacy of "nubiotics" against burn wound infection by Pseudomonas aeruginosa. ( Dale, RM; Schnell, G; Wong, JP, 2004) |
| "Treatment with ciprofloxacin and gamma-globulin dramatically improved the patient's clinical features." | 1.32 | [Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient]. ( Komatsu, N; Mori, M; Nagai, T; Obara, Y; Ohmine, K; Ozawa, K; Toshima, M, 2004) |
| " Factors considered included length of stay prior to initial P aeruginosa culture, isolation site, initial minimum inhibitory concentration (MIC), antibiotic area under the 24-hour concentration curve (AUC24), total area under the 24-hour inhibitory concentration curve ([AUIC24] AUC24/MIC summed for all active drugs), antibiotic(s) used as dichotomous variables (yes/no), and use of monotherapy or combination therapy." | 1.31 | Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa. ( Hyatt, JM; Schentag, JJ, 2000) |
| " We compared the activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, or trovafloxacin at different concentrations against P." | 1.31 | Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill. ( Burgess, DS; Hastings, RW, 2000) |
| "Ciprofloxacin has potential in treating this condition when used in high doses." | 1.31 | Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis. ( Allworth, A; Lipman, J; Wallis, SC, 2000) |
| "No cases of MOE in selective IgA deficiency have been reported in literature." | 1.31 | Malignant otitis externa in an infant with selective IgA deficiency: a case report. ( Balraj, A; Job, A; Justus, A; Kirubakaran, CP; Paul, AC, 2001) |
| "Bacterial infections were seen in 37% of patients with acute pancreatitis." | 1.31 | Incidence, spectrum and antibiotic sensitivity pattern of bacterial infections among patients with acute pancreatitis. ( Bohidar, NP; Garg, PK; Kapil, A; Khanna, S; Tandon, RK, 2001) |
| "Clinafloxacin was more active than ciprofloxacin, norfloxacin and pefloxacin, independent to the sensitivity pattern or the resistance to ceptazidime and imipenem." | 1.31 | [The activity of four fluoroquinolones against strains of Pseudomonas aeruginosa with a different sensitivity pattern to ceftazidime and imipenem]. ( Chaves, J; del Carmen Conejo, M; Hernández, G; Joyanes, P; Martínez-Martínez, L; Pascual A, A; Perea, EJ, 2001) |
| "Ciprofloxacin resistance has increased, while Ceftazidime susceptibility is unchanged (> 90 %)." | 1.31 | [Current therapeutical management, new antibiotics and treatment of Pseudomonas aeruginosa in bacterial ENT-infections]. ( Elies, W, 2002) |
| "Twelve patients had no recurrence at 3 to 15 months after the study." | 1.30 | Efficacy of ototopical ciprofloxacin in pediatric patients with otorrhea. ( Hart, MC; Nahata, MC; Wintermeyer, SM, 1997) |
| "We report a case of Candida purulent constrictive pericarditis in an immunocompromised heart transplant patient who was treated successfully with antifungal agents, surgical drainage, and pericardiectomy." | 1.30 | Fungal purulent constrictive pericarditis in a heart transplant patient. ( Canver, CC; Kosolcharoen, P; Patel, AK; Voytovich, MC, 1998) |
| "Ciprofloxacin MICs were 0." | 1.30 | In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients. ( Hamilton, VE; Richards, RM; Thomas, MR, 1998) |
| "Ciprofloxacin was released over seven days with an average release rate of 1." | 1.30 | A liposomal hydrogel for the prevention of bacterial adhesion to catheters. ( Bruce, AW; DiCosmo, F; DiTizio, V; Ferguson, GW; Khoury, AE; Mittelman, MW, 1998) |
| "IOSP following inguinal hernia repair is extremely rare." | 1.30 | Pseudomonas osteomyelitis of the symphysis pubis after inguinal hernia repair. ( Mader, R; Yeromenco, E, 1999) |
| "The in vivo efficacy of ciprofloxacin or pefloxacin alone or in combination with fosfomycin was evaluated in experimental aortic valve endocarditis induced in 133 rabbits by a multidrug-susceptible or multidrug-resistant strain of Pseudomonas aeruginosa." | 1.29 | Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa. ( Baron, D; Bugnon, D; Caillon, J; Drugeon, H; Jehl, F; Le Conte, P; Potel, G; Stephant, G; Xiong, YQ, 1995) |
| "stutszeri (1), and unidentified (1)." | 1.29 | Treatment and prevention of relapses of CAPD Pseudomonas peritonitis. ( Eftimimiadou, A; Kaliengidou, M; Kartali, S; Panagoutsos, S; Papazoglou, D; Pasadakis, P; Thodis, E; Vargemezis, V, 1993) |
| "Episodes of septic arthritis caused by Pseudomonas aeruginosa occurred in a patient with an infected vascular graft." | 1.29 | Recurrent pseudomonas septic arthritis. ( Price, T; Vickers, MH, 1993) |
| " These results suggest that either salt of prednisolone, when combined with ciprofloxacin, reduces ocular inflammation without affecting the antimicrobial efficacy of the antibiotic." | 1.29 | Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis. ( Callegan, MC; Engel, LS; Hill, JM; Hobden, JA; O'Callaghan, RJ, 1993) |
| " Rats were also treated with E5 or B55 in combination with a suboptimal dose of ciprofloxacin at fever onset and again 24 h later." | 1.29 | Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis. ( Opal, SM; Palardy, JE; Romulo, RL, 1993) |
| "Oral ciprofloxacin therapy was continued for 10 days and the patient remained free of symptoms with formed stools thereafter." | 1.29 | Pseudomonas aeruginosa as a cause of infectious diarrhea successfully treated with oral ciprofloxacin. ( Porco, FV; Visconte, EB, 1995) |
| "Ciprofloxacin is a fluoroquinolone antibiotic with broad spectrum bactericidal activity." | 1.29 | The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. ( Callegan, MC; Engel, LS; Folkens, AT; Hill, JM; O'Callaghan, RJ; Shimomura, Y, 1996) |
| " Test fluoroquinolones were administered orally at 1 h (single dose) or at 1 and 3 h (divided dose) postinfection, with 10 infected mice used for each of six concentrations of each fluoroquinolone tested (1 to 40 mg/kg of body weight) in each dosing regimen." | 1.29 | In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia. ( Amaratunga, DJ; Barrett, JF; Frosco, MB; Yagel, SK, 1996) |
| "Ciprofloxacin was administered orally in order to suppress bacteremia for 36 months." | 1.28 | Long-term oral ciprofloxacin in the treatment of prosthetic valve endocarditis due to Pseudomonas aeruginosa. ( Akalin, HE; Demircin, M; Ugurlu, B; Unal, S; Uzun, O; Yorgancioglu, AC, 1992) |
| "Ciprofloxacin was administered orally (15 mg/kg of body weight) or intravenously (6 mg/kg) twice a day for at least 10 days during separate treatment periods." | 1.28 | Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. ( Christensson, BA; Hjelte, L; Lindblad, A; Ljungberg, B; Malmborg, AS; Nilsson-Ehle, I; Strandvik, B, 1992) |
| "Ofloxacin and enoxacin were administered per os and pefloxacin and ciprofloxacin were injected subcutaneously." | 1.28 | [Activity of fluoroquinolones studied on a model of suppurative meningoencephalitis caused by Pseudomonas aeruginosa in mice]. ( Mnatsakanian, VE; Padeĭskaia, EN, 1991) |
| "Oral ciprofloxacin is an effective, convenient, nontoxic, economically justified alternative to the combination intravenous therapy previously advocated." | 1.28 | Successful treatment of malignant external otitis with oral ciprofloxacin: report of experience with 23 patients. ( Goshen, S; Kitzes-Cohen, R; Lang, R; Sadé, J, 1990) |
| " Therapy has traditionally consisted of the long-term administration of combination parenteral antibiotics, but morbidity and mortality remain substantial despite this therapy." | 1.28 | Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis. ( Kamerer, DB; Matador, A; Muder, RR; Rubin, J; Stoehr, G; Yu, VL, 1989) |
| "The treatment with ciprofloxacin was well tolerated with no significant side effects, whereas serious side effects were noted in 45." | 1.28 | Ciprofloxacin treatment of malignant external otitis. ( Goshen, S; Kitzes-Cohen, R; Lang, R; Sadé, J, 1989) |
| " The dose, dosing interval, and duration of therapy were varied, and the resulting antibiotic levels in serum and vegetations were correlated with bacterial clearance from vegetations." | 1.27 | The importance of pharmacodynamics in determining the dosing interval in therapy for experimental pseudomonas endocarditis in the rat. ( Ingerman, MJ; Levison, ME; Pitsakis, PG; Rosenberg, AF, 1986) |
| "Ciprofloxacin was administered orally to 48 patients with 24 Pseudomonas aeruginosa infections and 13 other infections caused by cephalothin-resistant gram-negative bacilli." | 1.27 | Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria. ( Eron, LJ; Harvey, L; Hixon, DL; Poretz, DM, 1985) |
| "Ciprofloxacin was given in doses of 500 mg orally or 200-300 mg i." | 1.27 | Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. ( Bindschedler, M; Follath, F; Frei, R; Reber, H; Stalder, H; Wenk, M, 1986) |
| "Ciprofloxacin was rapidly absorbed, and effective levels persisted for 1-4 hr relative to the dose administered." | 1.27 | Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis. ( Andriole, VT; Johnson, M; Miniter, P, 1987) |
| "Ciprofloxacin was more effective than norfloxacin or pefloxacin and comparable in efficacy to ofloxacin." | 1.27 | Efficacy of ciprofloxacin in stationary-phase bacteria in vivo. ( Voigt, WH; Zeiler, HJ, 1987) |
| " This risk may depend on the dosing schedule and may be reduced by combined therapy." | 1.27 | Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. ( Auckenthaler, R; Michéa-Hamzehpour, M; Pechère, JC; Regamey, P, 1987) |
| "Ciprofloxacin was studied in vitro and in an experimental thigh infection model in mice to evaluate its efficacy against Pseudomonas aeruginosa in comparison with that of tobramycin." | 1.27 | The activity of ciprofloxacin against Pseudomonas aeruginosa in normal and granulocytopenic mice. ( Hoogeterp, JJ; Mattie, H; Terporten, P, 1987) |
| "Ciprofloxacin was studied in vitro and in an experimental thigh infection model in mice to evaluate its efficacy against Pseudomonas aeruginosa in comparison with that of tobramycin." | 1.27 | The relative efficacies of tobramycin and ciprofloxacin against Pseudomonas aeruginosa in vitro and in normal and granulocytopenic mice. ( Hoogeterp, JJ; Mattie, H; Terporten, P, 1988) |
| "Ciprofloxacin is a new quinolone antibiotic that is highly active in vitro against Pseudomonas aeruginosa." | 1.27 | Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits. ( Dick, JD; Gottsch, JD; O'Brien, TP; Sawusch, MR, 1988) |
| "Ciprofloxacin was 1 to 3 twofold dilutions more active than A-61827 against these gram-negative bacteria." | 1.27 | A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. ( Bower, RR; Chu, DT; Fernandes, PB; Hanson, CW; Hardy, DJ; Ramer, NR; Stamm, JM; Swanson, RN, 1988) |
| "The osteomyelitis was secondary to trauma in 12 patients, joint replacement in six, previous acute hematogenous infection in two and osteotomy in one." | 1.27 | Treatment of chronic osteomyelitis with ciprofloxacin. ( Mulier, JC; Stuyck, J; Verbist, L, 1987) |
| "Norfloxacin was ineffective at 200 mg/kg per day against E." | 1.27 | In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. ( Bower, RR; Chu, DT; Fernandes, PB; Jarvis, KP; Ramer, NR; Shipkowitz, N, 1986) |
| "No ciprofloxacin resistance was detected among Pseudomonas isolates from cardiac vegetations." | 1.27 | Efficacy of ciprofloxacin in experimental aortic valve endocarditis caused by a multiply beta-lactam-resistant variant of Pseudomonas aeruginosa stably derepressed for beta-lactamase production. ( Bayer, AS; Blomquist, IK; Hirano, L; Lee, D; Lindsay, P; Yih, J, 1986) |
| " The terminal serum elimination half-life averaged 4." | 1.27 | Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model. ( Dudley, MN; Ericson, J; Gilbert, D; Mandler, HD; Mayer, KH; Zinner, SH, 1987) |
| "Ciprofloxacin has been studied extensively in discriminative animal models of infection, and its efficacy in the treatment of these infections has been compared with that of standard therapy." | 1.27 | Efficacy of ciprofloxacin in animal models of infection: endocarditis, meningitis, and pneumonia. ( Brooks-Fournier, RA; Gerberding, JL; Sande, MA, 1987) |
| " Depending on renal function the dosage varied from 100 mg once daily to 250 mg twice daily." | 1.27 | The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection. ( Brown, EM; Morris, R; Stephenson, TP, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 111 (16.64) | 18.7374 |
| 1990's | 140 (20.99) | 18.2507 |
| 2000's | 156 (23.39) | 29.6817 |
| 2010's | 190 (28.49) | 24.3611 |
| 2020's | 70 (10.49) | 2.80 |
| Authors | Studies |
|---|---|
| Segawa, J | 1 |
| Kitano, M | 1 |
| Kazuno, K | 1 |
| Matsuoka, M | 1 |
| Shirahase, I | 1 |
| Ozaki, M | 1 |
| Matsuda, M | 1 |
| Tomii, Y | 1 |
| Kise, M | 1 |
| Miyamoto, T | 1 |
| Matsumoto, J | 1 |
| Chiba, K | 1 |
| Egawa, H | 1 |
| Shibamori, K | 1 |
| Minamida, A | 1 |
| Nishimura, Y | 1 |
| Okada, H | 1 |
| Kataoka, M | 1 |
| Fujita, M | 1 |
| Frigola, J | 1 |
| Vañó, D | 1 |
| Torrens, A | 1 |
| Gómez-Gomar, A | 1 |
| Ortega, E | 1 |
| García-Granda, S | 1 |
| Takeda, S | 1 |
| Nakai, T | 1 |
| Wakai, Y | 1 |
| Ikeda, F | 1 |
| Hatano, K | 1 |
| Lodise, TP | 1 |
| Miller, CD | 1 |
| Graves, J | 1 |
| Furuno, JP | 1 |
| McGregor, JC | 1 |
| Lomaestro, B | 1 |
| Graffunder, E | 1 |
| McNutt, LA | 1 |
| Doi, Y | 1 |
| de Oliveira Garcia, D | 1 |
| Adams, J | 1 |
| Paterson, DL | 1 |
| Reinhardt, A | 1 |
| Köhler, T | 3 |
| Wood, P | 1 |
| Rohner, P | 1 |
| Dumas, JL | 1 |
| Ricou, B | 1 |
| van Delden, C | 3 |
| Peña, C | 1 |
| Guzmán, A | 1 |
| Suarez, C | 1 |
| Dominguez, MA | 1 |
| Tubau, F | 2 |
| Pujol, M | 1 |
| Gudiol, F | 1 |
| Ariza, J | 2 |
| Plasencia, V | 1 |
| Borrell, N | 2 |
| Maciá, MD | 2 |
| Moya, B | 2 |
| Pérez, JL | 6 |
| Oliver, A | 8 |
| Hocquet, D | 3 |
| Berthelot, P | 1 |
| Roussel-Delvallez, M | 2 |
| Favre, R | 1 |
| Jeannot, K | 3 |
| Bajolet, O | 1 |
| Marty, N | 1 |
| Grattard, F | 1 |
| Mariani-Kurkdjian, P | 2 |
| Bingen, E | 4 |
| Husson, MO | 1 |
| Couetdic, G | 2 |
| Plésiat, P | 8 |
| Muller, A | 1 |
| Blanc, K | 1 |
| Talon, D | 2 |
| Monnet, DL | 1 |
| Bertrand, X | 2 |
| Khalil, H | 1 |
| Chen, T | 1 |
| Riffon, R | 1 |
| Wang, R | 1 |
| Wang, Z | 1 |
| Elsen, S | 1 |
| Attree, I | 2 |
| Garza-Ramos, U | 1 |
| Morfin-Otero, R | 1 |
| Sader, HS | 1 |
| Jones, RN | 2 |
| Hernández, E | 1 |
| Rodriguez-Noriega, E | 1 |
| Sanchez, A | 1 |
| Carrillo, B | 1 |
| Esparza-Ahumada, S | 1 |
| Silva-Sanchez, J | 2 |
| Juan, C | 4 |
| Beceiro, A | 2 |
| Gutiérrez, O | 1 |
| Albertí, S | 2 |
| Garau, M | 1 |
| Bou, G | 2 |
| Tanimoto, K | 1 |
| Tomita, H | 1 |
| Fujimoto, S | 1 |
| Okuzumi, K | 1 |
| Ike, Y | 1 |
| Duljasz, W | 1 |
| Gniadkowski, M | 1 |
| Sitter, S | 1 |
| Wojna, A | 1 |
| Jebelean, C | 1 |
| Vettoretti, L | 1 |
| Muller, C | 1 |
| El Garch, F | 1 |
| Phan, G | 1 |
| Ducruix, A | 1 |
| Llanes, C | 3 |
| Barrow, K | 1 |
| Kwon, DH | 1 |
| Mulet, X | 1 |
| Zamorano, L | 3 |
| Crandon, JL | 2 |
| Bulik, CC | 2 |
| Nicolau, DP | 6 |
| Doublet, B | 1 |
| Robin, F | 1 |
| Casin, I | 1 |
| Fabre, L | 1 |
| Le Fleche, A | 1 |
| Bonnet, R | 1 |
| Weill, FX | 1 |
| Samuelsen, O | 1 |
| Toleman, MA | 1 |
| Sundsfjord, A | 1 |
| Rydberg, J | 1 |
| Leegaard, TM | 1 |
| Walder, M | 1 |
| Lia, A | 1 |
| Ranheim, TE | 1 |
| Rajendra, Y | 1 |
| Hermansen, NO | 1 |
| Walsh, TR | 1 |
| Giske, CG | 1 |
| Ge, Y | 2 |
| Kuti, JL | 2 |
| Tomás, M | 1 |
| Doumith, M | 1 |
| Warner, M | 2 |
| Turton, JF | 1 |
| Livermore, DM | 1 |
| Woodford, N | 1 |
| Grégoire, N | 1 |
| Raherison, S | 1 |
| Grignon, C | 1 |
| Comets, E | 1 |
| Marliat, M | 1 |
| Ploy, MC | 1 |
| Couet, W | 2 |
| Valenza, G | 1 |
| Joseph, B | 1 |
| Elias, J | 1 |
| Claus, H | 1 |
| Oesterlein, A | 1 |
| Engelhardt, K | 1 |
| Turnwald, D | 1 |
| Frosch, M | 1 |
| Abele-Horn, M | 1 |
| Schoen, C | 1 |
| Dehecq, B | 2 |
| Mariotte, P | 1 |
| Brown, MF | 1 |
| Reilly, U | 1 |
| Abramite, JA | 1 |
| Arcari, JT | 1 |
| Oliver, R | 1 |
| Barham, RA | 1 |
| Che, Y | 1 |
| Chen, JM | 1 |
| Collantes, EM | 1 |
| Chung, SW | 1 |
| Desbonnet, C | 1 |
| Doty, J | 1 |
| Doroski, M | 1 |
| Engtrakul, JJ | 1 |
| Harris, TM | 1 |
| Huband, M | 1 |
| Knafels, JD | 1 |
| Leach, KL | 1 |
| Liu, S | 2 |
| Marfat, A | 1 |
| Marra, A | 2 |
| McElroy, E | 1 |
| Melnick, M | 1 |
| Menard, CA | 1 |
| Montgomery, JI | 1 |
| Mullins, L | 1 |
| Noe, MC | 1 |
| O'Donnell, J | 1 |
| Penzien, J | 1 |
| Plummer, MS | 1 |
| Price, LM | 1 |
| Shanmugasundaram, V | 1 |
| Thoma, C | 1 |
| Uccello, DP | 1 |
| Warmus, JS | 1 |
| Wishka, DG | 1 |
| Zaheer, Z | 1 |
| Khan, FA | 1 |
| Sangshetti, JN | 1 |
| Patil, RH | 1 |
| Lohar, KS | 1 |
| Gorityala, BK | 1 |
| Guchhait, G | 1 |
| Goswami, S | 1 |
| Fernando, DM | 1 |
| Kumar, A | 1 |
| Zhanel, GG | 1 |
| Schweizer, F | 1 |
| Dou, X | 1 |
| Zhu, X | 2 |
| Wang, J | 1 |
| Dong, N | 1 |
| Shan, A | 2 |
| Wei, W | 1 |
| Liu, Q | 1 |
| Li, ZZ | 1 |
| Shi, WK | 1 |
| Fu, X | 1 |
| Liu, J | 4 |
| Wang, XC | 1 |
| Xu, N | 1 |
| Li, TF | 1 |
| Jiang, FR | 1 |
| Xiao, ZP | 1 |
| Zhu, HL | 1 |
| Piizzi, G | 1 |
| Parker, DT | 1 |
| Peng, Y | 1 |
| Dobler, M | 1 |
| Patnaik, A | 1 |
| Wattanasin, S | 1 |
| Liu, E | 1 |
| Lenoir, F | 1 |
| Nunez, J | 1 |
| Kerrigan, J | 1 |
| McKenney, D | 1 |
| Osborne, C | 2 |
| Yu, D | 1 |
| Lanieri, L | 1 |
| Bojkovic, J | 1 |
| Dzink-Fox, J | 1 |
| Lilly, MD | 1 |
| Sprague, ER | 1 |
| Lu, Y | 1 |
| Wang, H | 3 |
| Ranjitkar, S | 1 |
| Xie, L | 1 |
| Wang, B | 1 |
| Glick, M | 1 |
| Hamann, LG | 1 |
| Tommasi, R | 1 |
| Yang, X | 1 |
| Dean, CR | 1 |
| Pratap Verma, D | 1 |
| Ansari, MM | 1 |
| Verma, NK | 1 |
| Saroj, J | 1 |
| Akhtar, S | 1 |
| Pant, G | 1 |
| Mitra, K | 1 |
| Singh, BN | 1 |
| Ghosh, JK | 1 |
| Hou, JS | 1 |
| Chang, YQ | 1 |
| Peng, LJ | 1 |
| Zhang, XY | 2 |
| Miao, ZY | 1 |
| Sun, PH | 1 |
| Lin, J | 2 |
| Chen, WM | 2 |
| Meiers, J | 1 |
| Rox, K | 1 |
| Titz, A | 1 |
| Rahuman, HBH | 1 |
| Dhandapani, R | 1 |
| Palanivel, V | 1 |
| Thangavelu, S | 1 |
| Paramasivam, R | 1 |
| Muthupandian, S | 1 |
| Mumtaz, K | 1 |
| Munir, S | 1 |
| Muddassir, M | 1 |
| Raza, A | 1 |
| Waqas, K | 1 |
| Shoaib Ahmed, S | 1 |
| Malik, A | 1 |
| Haider Naqvi, SZ | 1 |
| Žiemytė, M | 1 |
| Carda-Diéguez, M | 1 |
| Rodríguez-Díaz, JC | 1 |
| Ventero, MP | 1 |
| Mira, A | 1 |
| Ferrer, MD | 1 |
| Wang, Y | 1 |
| Carion, TW | 2 |
| Ebrahim, AS | 2 |
| Sosne, G | 2 |
| Berger, EA | 2 |
| Mehjabeen, - | 1 |
| Mehboob Khan, K | 1 |
| Mehboob, S | 1 |
| Mehboob, M | 1 |
| Khan, T | 1 |
| Rafi, ST | 1 |
| Jahan, N | 1 |
| Wazir, A | 1 |
| Owais, F | 1 |
| Laulund, AS | 2 |
| Schwartz, FA | 1 |
| Christophersen, L | 3 |
| Høiby, N | 18 |
| Svendsen, JSM | 1 |
| Stensen, W | 1 |
| Thomsen, K | 3 |
| Cavanagh, JP | 1 |
| Moser, C | 3 |
| Ye, Z | 1 |
| Silva, DM | 1 |
| Traini, D | 3 |
| Young, P | 2 |
| Cheng, S | 1 |
| Ong, HX | 3 |
| Sunman, B | 1 |
| Emiralioglu, N | 1 |
| Hazirolan, G | 1 |
| Şener, B | 1 |
| Ozsezen, B | 1 |
| Tural, DA | 1 |
| Buyuksahin, HN | 1 |
| Guzelkas, I | 1 |
| Yalcin, E | 1 |
| Dogru, D | 1 |
| Özçelik, U | 1 |
| Kiper, N | 1 |
| Cabrera, R | 2 |
| Fernández-Barat, L | 2 |
| Vázquez, N | 1 |
| Alcaraz-Serrano, V | 1 |
| Bueno-Freire, L | 2 |
| Amaro, R | 2 |
| López-Aladid, R | 2 |
| Oscanoa, P | 2 |
| Muñoz, L | 2 |
| Vila, J | 3 |
| Torres, A | 2 |
| Hernando-Amado, S | 2 |
| Laborda, P | 2 |
| Valverde, JR | 1 |
| Martínez, JL | 2 |
| Karabasevic, N | 1 |
| Roberts, JA | 2 |
| Stronach, L | 1 |
| Naicker, S | 1 |
| Wallis, SC | 3 |
| Sjövall, F | 1 |
| Sime, F | 1 |
| Calum, H | 2 |
| Trøstrup, H | 2 |
| Esgueira, VLR | 1 |
| Lopes, CPA | 1 |
| Dos Santos, ACA | 1 |
| Pinto, F | 1 |
| Sousa, SA | 1 |
| de Barros, DPC | 1 |
| Leitão, JH | 1 |
| Fonseca, LP | 1 |
| Holger, DJ | 1 |
| Lev, KL | 1 |
| Kebriaei, R | 1 |
| Morrisette, T | 1 |
| Shah, R | 1 |
| Alexander, J | 1 |
| Lehman, SM | 1 |
| Rybak, MJ | 1 |
| Khodaparast, S | 1 |
| Ghanbari, F | 1 |
| Zamani, H | 1 |
| Shahri, FN | 1 |
| Izanloo, A | 1 |
| Goharrizi, MASB | 1 |
| Jamali, A | 1 |
| Bagheri, H | 1 |
| Hjimohammadi, A | 1 |
| Ardebili, A | 1 |
| Alves, D | 1 |
| Lopes, H | 1 |
| Machado, I | 1 |
| Pereira, MO | 3 |
| Singla, A | 1 |
| Simbassa, SB | 1 |
| Chirra, B | 1 |
| Gairola, A | 1 |
| Southerland, MR | 1 |
| Shah, KN | 1 |
| Rose, RE | 1 |
| Chen, Q | 1 |
| Basharat, A | 1 |
| Baeza, J | 1 |
| Raina, R | 1 |
| Chapman, MJ | 1 |
| Hassan, AM | 1 |
| Ivanov, I | 1 |
| Sen, A | 1 |
| Wu, HJ | 1 |
| Cannon, CL | 1 |
| Ferran, AA | 1 |
| Lacroix, MZ | 1 |
| Gourbeyre, O | 1 |
| Huesca, A | 1 |
| Gaborieau, B | 1 |
| Debarbieux, L | 1 |
| Bousquet-Mélou, A | 1 |
| Huang, HW | 1 |
| Liu, HY | 2 |
| Chuang, HC | 1 |
| Chen, BL | 1 |
| Wang, EY | 1 |
| Tsao, LH | 1 |
| Ai, MY | 1 |
| Lee, YJ | 2 |
| Li, JJ | 1 |
| Hu, Y | 1 |
| Hu, B | 1 |
| Wang, W | 1 |
| Xu, H | 1 |
| Hu, XY | 1 |
| Ding, F | 1 |
| Li, HB | 1 |
| Wang, KR | 1 |
| Zhang, X | 1 |
| Guo, DS | 1 |
| Law, JP | 3 |
| Wood, AJ | 3 |
| Friman, VP | 3 |
| Foulkes, DM | 2 |
| McLean, K | 2 |
| Sloniecka, M | 2 |
| Rustidge, S | 2 |
| Byrne, DP | 2 |
| Haneef, AS | 2 |
| Winstanley, C | 3 |
| Berry, N | 2 |
| Fernig, DG | 2 |
| Kaye, SB | 2 |
| López-Causapé, C | 1 |
| Sanz-García, F | 1 |
| Wang, YY | 1 |
| Zhong, XL | 1 |
| Huang, YJ | 1 |
| Khan, M | 2 |
| Ma, K | 1 |
| Wan, I | 1 |
| Willcox, MD | 2 |
| Atassi, G | 1 |
| Medernach, R | 1 |
| Scheetz, M | 1 |
| Nozick, S | 1 |
| Rhodes, NJ | 1 |
| Murphy-Belcaster, M | 1 |
| Murphy, KR | 1 |
| Alisoltani, A | 1 |
| Ozer, EA | 1 |
| Hauser, AR | 1 |
| Vázquez Burgos, N | 1 |
| Alcaraz, V | 1 |
| Gabarrús, A | 1 |
| Palomeque, A | 1 |
| Ceccato, A | 1 |
| Motos, A | 1 |
| Bernardi, T | 1 |
| Provot, C | 1 |
| Soler-Comas, A | 1 |
| Koeppen, K | 1 |
| Hampton, TH | 1 |
| Barnaby, R | 1 |
| Roche, C | 1 |
| Gerber, SA | 1 |
| Goo, YA | 1 |
| Cho, BK | 1 |
| Vermilyea, DM | 1 |
| Hogan, DA | 1 |
| Stanton, BA | 1 |
| Langton Hewer, SC | 4 |
| Smith, S | 1 |
| Rowbotham, NJ | 1 |
| Yule, A | 1 |
| Smyth, AR | 4 |
| Dhariwal, A | 1 |
| Manjaly, JG | 1 |
| Patel, B | 1 |
| Morris-Jones, S | 1 |
| David, K | 1 |
| Khetarpal, P | 1 |
| Beale, T | 1 |
| Mehta, N | 1 |
| Logan, S | 1 |
| Shariati, A | 1 |
| Noei, M | 1 |
| Chegini, Z | 1 |
| Jabalameli, F | 1 |
| Emaneini, M | 1 |
| Beigverdi, R | 1 |
| Halimi, S | 1 |
| Siroosi, M | 1 |
| Lock, GA | 1 |
| Helfer, VE | 1 |
| Dias, BB | 1 |
| Torres, BGS | 2 |
| De Araújo, BV | 1 |
| Dalla Costa, T | 1 |
| Ali, MG | 1 |
| Almoneim, ZA | 1 |
| Kareem, SM | 1 |
| Lin, Y | 1 |
| Chang, RYK | 2 |
| Britton, WJ | 1 |
| Morales, S | 2 |
| Kutter, E | 2 |
| Li, J | 3 |
| Chan, HK | 2 |
| Chai, G | 1 |
| Park, H | 2 |
| Yu, S | 1 |
| Zhou, F | 1 |
| Xu, Q | 1 |
| Zhou, QT | 1 |
| Awad, R | 1 |
| Marchand, S | 1 |
| Tewes, F | 2 |
| Ramsay, KA | 1 |
| Wardell, SJT | 1 |
| Patrick, WM | 2 |
| Brockway, B | 1 |
| Reid, DW | 1 |
| Bell, SC | 1 |
| Lamont, IL | 2 |
| Lababidi, N | 2 |
| Ofosu Kissi, E | 1 |
| Elgaher, WAM | 1 |
| Sigal, V | 1 |
| Haupenthal, J | 1 |
| Schwarz, BC | 1 |
| Hirsch, AKH | 1 |
| Rades, T | 1 |
| Schneider, M | 3 |
| Millar, BC | 3 |
| Malnarcic, CM | 1 |
| McCaughan, J | 3 |
| Moore, JE | 3 |
| Lan, J | 1 |
| Ma, Q | 1 |
| Shao, C | 1 |
| Lim, DJ | 3 |
| McCormick, J | 2 |
| Skinner, D | 3 |
| Zhang, S | 2 |
| Elder, JB | 1 |
| McLemore, JG | 1 |
| Allen, M | 1 |
| West, JM | 1 |
| Grayson, JW | 1 |
| Rowe, SM | 1 |
| Woodworth, BA | 3 |
| Cho, DY | 3 |
| Dilhari, A | 1 |
| Pathirage, S | 1 |
| Gunasekara, C | 1 |
| Fernando, N | 1 |
| Weerasekara, D | 1 |
| McBain, A | 1 |
| Weerasekera, M | 1 |
| Feghhi, M | 1 |
| Sharif Makhmalzadeh, B | 1 |
| Farrahi, F | 1 |
| Akmali, M | 1 |
| Hasanvand, N | 1 |
| Dey, P | 1 |
| Parai, D | 1 |
| Banerjee, M | 1 |
| Hossain, ST | 1 |
| Mukherjee, SK | 1 |
| Chávez-Jacobo, VM | 2 |
| García Merinos, JP | 1 |
| López, Y | 1 |
| Meza-Carmen, V | 2 |
| Ramírez-Díaz, MI | 2 |
| Quan, AV | 1 |
| Huang, AM | 1 |
| Galor, A | 1 |
| Yazdi, MMK | 1 |
| Ghalavand, Z | 1 |
| Yazdi, AK | 1 |
| Kodori, M | 1 |
| Taheri, M | 1 |
| Tabriz, MS | 1 |
| Eslami, G | 2 |
| Gómez-Junyent, J | 1 |
| Rigo-Bonnin, R | 1 |
| Benavent, E | 1 |
| Soldevila, L | 1 |
| Padullés, A | 1 |
| Cabo, X | 1 |
| Murillo, O | 1 |
| Bahamondez-Canas, TF | 1 |
| Moraga-Espinoza, D | 1 |
| Smyth, HDC | 1 |
| Watts, AB | 1 |
| Daboor, SM | 1 |
| Rohde, JR | 1 |
| Cheng, Z | 2 |
| Hopkins, ME | 1 |
| Bennett, A | 1 |
| Henderson, N | 1 |
| MacSween, KF | 1 |
| Baring, D | 1 |
| Sutherland, R | 1 |
| Founou, RC | 1 |
| Founou, LL | 1 |
| Allam, M | 1 |
| Ismail, A | 1 |
| Essack, SY | 1 |
| Ahmed, FY | 1 |
| Farghaly Aly, U | 1 |
| Abd El-Baky, RM | 1 |
| Waly, NGFM | 1 |
| Chalmers, JD | 2 |
| Cipolla, D | 4 |
| Thompson, B | 2 |
| Davis, AM | 2 |
| O'Donnell, A | 1 |
| Tino, G | 1 |
| Gonda, I | 4 |
| Haworth, C | 1 |
| Froehlich, J | 2 |
| Rendall, JC | 1 |
| Molina-Mora, JA | 1 |
| Chinchilla-Montero, D | 1 |
| Chavarría-Azofeifa, M | 1 |
| Ulloa-Morales, AJ | 1 |
| Campos-Sánchez, R | 1 |
| Mora-Rodríguez, R | 1 |
| Shi, L | 1 |
| García, F | 1 |
| Alluri, S | 1 |
| Ebrahim, T | 1 |
| Parker, T | 1 |
| Burns, J | 1 |
| Jarjees, KK | 1 |
| Montefusco-Pereira, CV | 1 |
| de Souza Carvalho-Wodarz, C | 1 |
| Lehr, CM | 1 |
| Zainal Abidin, SS | 1 |
| Kew, TY | 1 |
| Azman, M | 1 |
| Mat Baki, M | 1 |
| Raouf, M | 1 |
| Essa, S | 1 |
| El Achy, S | 1 |
| Essawy, M | 1 |
| Rafik, S | 1 |
| Baddour, M | 1 |
| Opene, C | 1 |
| Fung, MA | 1 |
| Silverstein, M | 1 |
| Srivastava, P | 1 |
| Sivashanmugam, K | 1 |
| Xu, Y | 1 |
| Zhang, Y | 3 |
| Zheng, X | 1 |
| Yu, K | 1 |
| Sun, Y | 1 |
| Liao, W | 1 |
| Jia, H | 1 |
| Xu, C | 2 |
| Zhou, T | 1 |
| Shen, M | 1 |
| Liu, X | 2 |
| Xiang, L | 1 |
| Yin, Y | 1 |
| Li, H | 1 |
| Ma, D | 1 |
| Qu, Y | 1 |
| Alford, MA | 1 |
| Baquir, B | 1 |
| An, A | 1 |
| Choi, KG | 1 |
| Hancock, REW | 1 |
| Qureshi, R | 1 |
| Qamar, MU | 1 |
| Shafique, M | 1 |
| Muzammil, S | 1 |
| Rasool, MH | 1 |
| Ahmad, I | 2 |
| Ejaz, H | 1 |
| Monteiro, R | 2 |
| Magalhães, AP | 1 |
| Sousa, AM | 2 |
| Vallières, E | 1 |
| Tumelty, K | 1 |
| Tunney, MM | 1 |
| Hannah, R | 1 |
| Hewitt, O | 1 |
| Elborn, JS | 6 |
| Downey, DG | 1 |
| Tran, GM | 1 |
| Ho-Le, TP | 1 |
| Ha, DT | 1 |
| Tran-Nguyen, CH | 1 |
| Nguyen, TSM | 1 |
| Pham, TTN | 1 |
| Nguyen, TA | 1 |
| Nguyen, DA | 1 |
| Hoang, HQ | 1 |
| Tran, NV | 1 |
| Nguyen, TV | 1 |
| Gao, Y | 1 |
| Duan, J | 1 |
| Geng, X | 1 |
| Zhang, Z | 1 |
| Zhang, R | 1 |
| Li, X | 2 |
| Wang, S | 1 |
| Kang, J | 1 |
| Yin, D | 1 |
| Song, Y | 1 |
| Cartlidge, MK | 1 |
| Hill, AT | 1 |
| Chopra, R | 1 |
| Shaikh, S | 1 |
| Chatzinoff, Y | 1 |
| Munaweera, I | 1 |
| Cheng, B | 1 |
| Daly, SM | 1 |
| Xi, Y | 1 |
| Bing, C | 1 |
| Burns, D | 1 |
| Greenberg, DE | 1 |
| Goodlet, KJ | 1 |
| Nailor, MD | 1 |
| Mackey, C | 2 |
| Weeks, C | 1 |
| Gill, GS | 1 |
| Hergenrother, RW | 1 |
| Swords, WE | 1 |
| De Soyza, A | 3 |
| Aksamit, T | 2 |
| Bandel, TJ | 2 |
| Criollo, M | 2 |
| Operschall, E | 3 |
| Polverino, E | 2 |
| Roth, K | 2 |
| Winthrop, KL | 2 |
| Wilson, R | 3 |
| Rivadeneira, J | 1 |
| Audisio, MC | 1 |
| Gorustovich, A | 1 |
| Loo, CY | 1 |
| Lee, WH | 2 |
| Lauretani, G | 1 |
| Scalia, S | 1 |
| Heward, E | 1 |
| Cullen, M | 1 |
| Hobson, J | 1 |
| Lucca, F | 1 |
| Guarnieri, M | 1 |
| Ros, M | 1 |
| Muffato, G | 1 |
| Rigoli, R | 1 |
| Da Dalt, L | 1 |
| Wu, PF | 1 |
| Lin, YT | 1 |
| Wang, FD | 1 |
| Yang, TC | 1 |
| Fung, CP | 1 |
| Hernández-Ramírez, KC | 1 |
| Romo-Rodríguez, P | 1 |
| Pérez-Gallardo, RV | 1 |
| Campos-García, J | 1 |
| Gutiérrez-Corona, JF | 1 |
| García-Merinos, JP | 1 |
| McShane, PJ | 1 |
| Weers, JG | 1 |
| Tarara, TE | 1 |
| Haynes, A | 1 |
| Durbha, P | 1 |
| Miller, DP | 1 |
| Mundry, T | 1 |
| Rahdar, HA | 1 |
| Kazemian, H | 1 |
| Bimanand, L | 1 |
| Shahraki-Zahedani, S | 1 |
| Feyisa, SG | 1 |
| Taki, E | 1 |
| Havaei, SA | 1 |
| Karami-Zarandi, M | 1 |
| Al-Obaidi, H | 1 |
| Kalgudi, R | 1 |
| Zariwala, MG | 1 |
| Fadel, A | 1 |
| Mabrok, M | 1 |
| Aly, S | 1 |
| Durrani, M | 1 |
| Cackovic, C | 1 |
| Greer, J | 1 |
| Pescatore, R | 1 |
| Felix, LM | 1 |
| Grundy, S | 1 |
| Milan, SJ | 1 |
| Armstrong, R | 1 |
| Harrison, H | 1 |
| Lynes, D | 1 |
| Spencer, S | 1 |
| Tavafi, H | 1 |
| Ali, AA | 1 |
| Ghadam, P | 1 |
| Gharavi, S | 1 |
| García Callejo, J | 1 |
| Telling, K | 1 |
| Laht, M | 1 |
| Brauer, A | 1 |
| Remm, M | 1 |
| Kisand, V | 1 |
| Maimets, M | 1 |
| Tenson, T | 1 |
| Lutsar, I | 1 |
| Rehman, A | 1 |
| Van Stormbroek, B | 1 |
| Zampoli, M | 1 |
| Morrow, BM | 1 |
| Haworth, CS | 1 |
| Bilton, D | 4 |
| Wanner, A | 1 |
| O'Donnell, AE | 1 |
| Weeks, CG | 1 |
| Garcia, JAP | 1 |
| Henriksen, K | 1 |
| Rørbo, N | 1 |
| Rybtke, ML | 1 |
| Martinet, MG | 1 |
| Tolker-Nielsen, T | 2 |
| Middelboe, M | 1 |
| Ciofu, O | 5 |
| Issa, R | 1 |
| Chanishvili, N | 1 |
| Caplin, J | 1 |
| Kakabadze, E | 1 |
| Bakuradze, N | 1 |
| Makalatia, K | 1 |
| Cooper, I | 1 |
| Claude, F | 1 |
| Rochat, I | 1 |
| Hafen, GM | 1 |
| Patel, KK | 1 |
| Tripathi, M | 1 |
| Pandey, N | 1 |
| Agrawal, AK | 1 |
| Gade, S | 1 |
| Anjum, MM | 1 |
| Tilak, R | 1 |
| Singh, S | 1 |
| Das, T | 1 |
| Manos, J | 1 |
| Ušjak, D | 1 |
| Ivković, B | 1 |
| Božić, DD | 1 |
| Bošković, L | 1 |
| Milenković, M | 1 |
| Laulund, ASB | 1 |
| Lerche, CJ | 1 |
| Long, Y | 1 |
| Fu, W | 1 |
| Li, S | 1 |
| Ren, H | 1 |
| Li, M | 1 |
| Liu, C | 2 |
| Zhang, B | 1 |
| Xia, Y | 1 |
| Fan, Z | 1 |
| Jin, Y | 2 |
| Bai, F | 1 |
| Jin, S | 2 |
| Wu, W | 2 |
| Harun, SN | 1 |
| Holford, NHG | 1 |
| Grimwood, K | 2 |
| Wainwright, CE | 1 |
| Hennig, S | 1 |
| Klawonn, MA | 1 |
| Helm, MM | 1 |
| Helm, MF | 1 |
| Batlle-Ferrando, S | 1 |
| Peraza-Nieves, JE | 1 |
| Carreras-Castañer, X | 1 |
| Marin-Martinez, S | 1 |
| Miguel, L | 1 |
| Hazlett, LD | 1 |
| Ekanayaka, SA | 1 |
| McClellan, SA | 1 |
| Francis, R | 1 |
| Ruiz, J | 1 |
| Singh, N | 1 |
| Romero, M | 1 |
| Travanut, A | 1 |
| Monteiro, PF | 1 |
| Jordana-Lluch, E | 1 |
| Hardie, KR | 1 |
| Williams, P | 1 |
| Alexander, MR | 1 |
| Alexander, C | 1 |
| Royer, G | 1 |
| Fourreau, F | 1 |
| Boulanger, B | 1 |
| Mercier-Darty, M | 1 |
| Ducellier, D | 1 |
| Cizeau, F | 1 |
| Potron, A | 1 |
| Podglajen, I | 1 |
| Mongardon, N | 1 |
| Decousser, JW | 1 |
| Muraki, Y | 1 |
| Kitamura, M | 1 |
| Maeda, Y | 1 |
| Kitahara, T | 1 |
| Mori, T | 1 |
| Ikeue, H | 1 |
| Tsugita, M | 1 |
| Tadano, K | 1 |
| Takada, K | 1 |
| Akamatsu, T | 1 |
| Yamada, T | 2 |
| Shiraishi, T | 1 |
| Okuda, M | 1 |
| Nichols, DP | 1 |
| Caceres, S | 1 |
| Caverly, L | 1 |
| Fratelli, C | 1 |
| Kim, SH | 3 |
| Malcolm, K | 1 |
| Poch, KR | 1 |
| Saavedra, M | 1 |
| Solomon, G | 1 |
| Taylor-Cousar, J | 1 |
| Moskowitz, S | 1 |
| Nick, JA | 1 |
| Hesse, D | 2 |
| Ehlert, N | 1 |
| Lüenhop, T | 1 |
| Smoczek, A | 2 |
| Glage, S | 2 |
| Behrens, P | 2 |
| Müller, PP | 2 |
| Esser, KH | 2 |
| Lenarz, T | 1 |
| Stieve, M | 2 |
| Bleich, A | 2 |
| Prenzler, NK | 2 |
| Brauns, B | 1 |
| Schön, MP | 1 |
| Mempel, M | 1 |
| Serisier, DJ | 2 |
| Thompson, PJ | 1 |
| Kolbe, J | 1 |
| Greville, HW | 1 |
| Bruinenberg, P | 1 |
| Lu, Q | 2 |
| Yu, J | 2 |
| Bao, L | 1 |
| Ran, T | 2 |
| Zhong, H | 1 |
| Kumar, L | 1 |
| Chhibber, S | 5 |
| Harjai, K | 5 |
| Gabaldon, D | 1 |
| Wiggins, B | 1 |
| Tzamaloukas, AH | 1 |
| Moffett, BS | 1 |
| Valdes, SO | 1 |
| Kim, JJ | 1 |
| Lindholm, DA | 1 |
| Murray, CK | 1 |
| Akers, KS | 1 |
| O'Brien, SD | 1 |
| Alderete, JF | 1 |
| Vento, TJ | 1 |
| Molina-Leyva, A | 1 |
| Ruiz-Ruigomez, M | 1 |
| Stass, H | 2 |
| Weimann, B | 1 |
| Nagelschmitz, J | 2 |
| Rolinck-Werninghaus, C | 1 |
| Staab, D | 2 |
| Cowart, DW | 1 |
| Moradi, BN | 1 |
| Arora, NS | 1 |
| Pavlovic, RR | 1 |
| Jankovic, SM | 1 |
| Jensen, PØ | 1 |
| Briales, A | 1 |
| Brochmann, RP | 1 |
| Kragh, KN | 1 |
| Kolpen, M | 1 |
| Hempel, C | 1 |
| Bjarnsholt, T | 2 |
| Nakamura, I | 1 |
| Yamaguchi, T | 1 |
| Tsukimori, A | 1 |
| Sato, A | 2 |
| Fukushima, S | 1 |
| Mizuno, Y | 1 |
| Matsumoto, T | 1 |
| Sun, Z | 1 |
| Shi, J | 1 |
| Li, K | 1 |
| Chen, R | 1 |
| Kim, J | 1 |
| Kang, CI | 2 |
| Baek, JY | 1 |
| Cho, SY | 1 |
| Ko, KS | 1 |
| Chung, DR | 1 |
| Peck, KR | 1 |
| Song, JH | 1 |
| Li, SA | 1 |
| Xiang, Y | 1 |
| Wang, YJ | 1 |
| Siqueira, VL | 1 |
| Cardoso, RF | 1 |
| Caleffi-Ferracioli, KR | 1 |
| Scodro, RB | 1 |
| Fernandez, MA | 1 |
| Fiorini, A | 1 |
| Ueda-Nakamura, T | 1 |
| Dias-Filho, BP | 1 |
| Nakamura, CV | 1 |
| Mugnai, G | 1 |
| Pesarini, G | 1 |
| Vassanelli, C | 1 |
| Gupta, P | 2 |
| Hui, A | 1 |
| Willcox, M | 1 |
| Jones, L | 1 |
| Delesen, H | 1 |
| Elkhatib, W | 1 |
| Noreddin, A | 1 |
| D'Souza, BB | 1 |
| Padmaraj, SR | 1 |
| Rekha, PD | 1 |
| Tellis, RC | 1 |
| Prabhu, S | 1 |
| Pothen, P | 1 |
| Rodriguez, CA | 1 |
| Agudelo, M | 1 |
| Zuluaga, AF | 1 |
| Vesga, O | 1 |
| Buyck, JM | 2 |
| Tulkens, PM | 2 |
| Van Bambeke, F | 2 |
| Hua, X | 1 |
| Tan, S | 1 |
| Bandara, HM | 1 |
| Fu, Y | 1 |
| Smyth, HD | 1 |
| Saini, H | 1 |
| Chiriac, A | 1 |
| Brzezinski, P | 1 |
| Foia, L | 1 |
| Marincu, I | 1 |
| Kwan, BW | 1 |
| Chowdhury, N | 1 |
| Wood, TK | 1 |
| Ali, H | 1 |
| Orchard, C | 1 |
| Mariveles, M | 1 |
| Scott, S | 1 |
| Alshafi, K | 1 |
| Simmonds, N | 1 |
| Peyrusson, F | 1 |
| Gassiep, I | 1 |
| Chaudhuri, A | 1 |
| Lee, CH | 1 |
| Su, TY | 1 |
| Ye, JJ | 1 |
| Hsu, PC | 1 |
| Kuo, AJ | 1 |
| Chia, JH | 1 |
| Lee, MH | 1 |
| Orioli, L | 1 |
| Boute, C | 1 |
| Eloy, P | 1 |
| De Wispelaere, JF | 1 |
| De Coene, B | 1 |
| Huang, TD | 1 |
| Ausselet, N | 1 |
| Delaere, B | 1 |
| Firsov, AA | 3 |
| Strukova, EN | 2 |
| Portnoy, YA | 3 |
| Shlykova, DS | 1 |
| Zinner, SH | 5 |
| Connett, GJ | 1 |
| Pike, KC | 1 |
| Legg, JP | 1 |
| Cathie, K | 1 |
| Dewar, A | 1 |
| Foote, K | 1 |
| Harris, A | 1 |
| Faust, SN | 1 |
| Cazaubon, Y | 1 |
| Bourguignon, L | 1 |
| Goutelle, S | 1 |
| Martin, O | 2 |
| Maire, P | 1 |
| Ducher, M | 1 |
| Langan, KM | 1 |
| Kotsimbos, T | 1 |
| Peleg, AY | 2 |
| Fernandes, M | 1 |
| Vira, D | 1 |
| Medikonda, R | 1 |
| Kumar, N | 1 |
| Cheng, C | 1 |
| Du, L | 1 |
| He, Y | 1 |
| Vadekeetil, A | 1 |
| Alexandar, V | 1 |
| García-Martínez, FJ | 1 |
| López-Martín, I | 1 |
| Castellanos-González, M | 1 |
| Segurado-Rodríguez, MA | 1 |
| Furiga, A | 1 |
| Lajoie, B | 1 |
| El Hage, S | 1 |
| Baziard, G | 1 |
| Roques, C | 1 |
| Hengzhuang, W | 1 |
| Song, Z | 1 |
| Onsøyen, E | 1 |
| Rye, PD | 1 |
| Richardot, C | 1 |
| Juarez, P | 1 |
| Patry, I | 2 |
| Roger, C | 1 |
| Louart, B | 1 |
| Lefrant, JY | 1 |
| Lipman, J | 2 |
| Muller, L | 1 |
| Flinn, A | 1 |
| McDermott, M | 1 |
| Butler, KM | 1 |
| Walsh, CC | 1 |
| Landersdorfer, CB | 1 |
| McIntosh, MP | 1 |
| Hirsch, EB | 1 |
| Kirkpatrick, CM | 1 |
| Bergen, PJ | 1 |
| Park, MH | 1 |
| Kim, SY | 1 |
| Roh, EY | 1 |
| Lee, HS | 1 |
| Garcinuño, P | 1 |
| Santibañez, M | 1 |
| Gimeno, L | 1 |
| Sánchez-Bautista, A | 1 |
| Coy, J | 1 |
| Sánchez-Paya, J | 1 |
| Boix, V | 1 |
| Merino, E | 1 |
| Portilla, J | 1 |
| Rodríguez, JC | 2 |
| Fjaellegaard, K | 1 |
| Sin, MD | 1 |
| Browatzki, A | 1 |
| Ulrik, CS | 1 |
| Mellmann, A | 1 |
| Bletz, S | 1 |
| Böking, T | 1 |
| Kipp, F | 1 |
| Becker, K | 1 |
| Schultes, A | 1 |
| Prior, K | 1 |
| Harmsen, D | 1 |
| Kioomars, S | 1 |
| Heidari, S | 1 |
| Malaekeh-Nikouei, B | 1 |
| Shayani Rad, M | 1 |
| Khameneh, B | 1 |
| Mohajeri, SA | 1 |
| Valderrama, SL | 1 |
| González, PF | 1 |
| Caro, MA | 1 |
| Ardila, N | 1 |
| Ariza, B | 1 |
| Gil, F | 1 |
| Álvarez, C | 1 |
| Ang, JY | 1 |
| Abdel-Haq, N | 1 |
| Zhu, F | 1 |
| Thabit, AK | 1 |
| Satlin, MJ | 1 |
| van Duin, D | 1 |
| Günday Türeli, N | 1 |
| Türeli, AE | 1 |
| Tan, M | 1 |
| Lee, JS | 1 |
| Pan, JY | 1 |
| Ullah, O | 1 |
| Khan, A | 1 |
| Ambreen, A | 1 |
| Akhtar, T | 1 |
| Gandapor, AJ | 1 |
| Khan, AM | 1 |
| Oechslin, F | 1 |
| Piccardi, P | 1 |
| Mancini, S | 1 |
| Gabard, J | 1 |
| Moreillon, P | 1 |
| Entenza, JM | 1 |
| Resch, G | 1 |
| Que, YA | 1 |
| Paulsson, M | 1 |
| Granrot, A | 1 |
| Ahl, J | 1 |
| Tham, J | 1 |
| Resman, F | 1 |
| Riesbeck, K | 1 |
| Månsson, F | 1 |
| Conde-Díaz, C | 1 |
| Llenas-García, J | 1 |
| Parra Grande, M | 1 |
| Terol Esclapez, G | 1 |
| Masiá, M | 1 |
| Gutiérrez, F | 1 |
| Schultz, AN | 1 |
| Nielsen, XC | 1 |
| Pressler, T | 4 |
| Dalhoff, K | 1 |
| Duno, M | 1 |
| Buchard, A | 1 |
| Johansen, HK | 2 |
| Dalbøge, CS | 1 |
| Bhasker, D | 1 |
| Hartley, A | 1 |
| Agada, F | 1 |
| Kanellakopoulou, K | 3 |
| Sarafis, P | 1 |
| Galani, I | 1 |
| Giamarellou, H | 6 |
| Giamarellos-Bourboulis, EJ | 3 |
| Cook, PP | 2 |
| Das, TD | 1 |
| Gooch, M | 2 |
| Catrou, PG | 1 |
| Pappalardo, S | 1 |
| Tanteri, L | 1 |
| Brutto, D | 1 |
| Marescalco, M | 1 |
| Carlino, V | 1 |
| Consolo, G | 1 |
| Mauro, M | 1 |
| Cappello, V | 1 |
| Skindersoe, ME | 1 |
| Alhede, M | 1 |
| Phipps, R | 1 |
| Yang, L | 1 |
| Jensen, PO | 1 |
| Rasmussen, TB | 1 |
| Givskov, M | 1 |
| Wiegand, I | 1 |
| Marr, AK | 1 |
| Breidenstein, EB | 2 |
| Schurek, KN | 1 |
| Taylor, P | 1 |
| Hancock, RE | 2 |
| Hansen, CR | 1 |
| Karicherla, P | 1 |
| Hobden, JA | 8 |
| Işeri, L | 1 |
| Bayraktar, MR | 1 |
| Morgan, AE | 1 |
| Jang, CH | 3 |
| Cho, YB | 2 |
| Choi, CH | 2 |
| Park, IY | 1 |
| Réjiba, S | 1 |
| Aubry, A | 1 |
| Petitfrère, S | 1 |
| Jarlier, V | 1 |
| Cambau, E | 1 |
| Dambrauskiene, A | 1 |
| Adukauskiene, D | 1 |
| Jeroch, J | 1 |
| Vitkauskiene, A | 2 |
| Ogbolu, DO | 1 |
| Ogunledun, A | 1 |
| Adebiyi, OE | 1 |
| Daini, OA | 1 |
| Alli, AO | 1 |
| Terry, AO | 1 |
| Stangogiannis-Druya, E | 1 |
| Stangogiannis-Druya, C | 1 |
| Naranjo-Tackman, R | 1 |
| Vanzzini, V | 1 |
| Villar-Kurí, J | 1 |
| Hodson, M | 1 |
| Bertram, C | 1 |
| Braccini, G | 1 |
| Festini, F | 1 |
| Boni, V | 1 |
| Neri, AS | 1 |
| Galici, V | 1 |
| Campana, S | 2 |
| Zavataro, L | 2 |
| Trevisan, F | 2 |
| Braggion, C | 1 |
| Taccetti, G | 2 |
| Treggiari, MM | 3 |
| Rosenfeld, M | 3 |
| Mayer-Hamblett, N | 3 |
| Retsch-Bogart, G | 3 |
| Gibson, RL | 3 |
| Williams, J | 2 |
| Emerson, J | 1 |
| Kronmal, RA | 2 |
| Ramsey, BW | 3 |
| López-Dupla, M | 1 |
| Martínez, JA | 1 |
| Vidal, F | 1 |
| Almela, M | 1 |
| Soriano, A | 2 |
| Marco, F | 1 |
| López, J | 1 |
| Olona, M | 1 |
| Mensa, J | 2 |
| Diec, J | 1 |
| Carnt, N | 1 |
| Tilia, D | 1 |
| Evans, V | 1 |
| Rao, V | 1 |
| Ozkan, J | 1 |
| Holden, BA | 1 |
| Mehanna, MM | 1 |
| Elmaradny, HA | 1 |
| Samaha, MW | 1 |
| Guss, J | 1 |
| Abuzeid, WM | 1 |
| Doghramji, L | 1 |
| Edelstein, PH | 1 |
| Chiu, AG | 1 |
| Weckwerth, PH | 1 |
| de Magalhães Lopes, CA | 1 |
| Duarte, MA | 1 |
| Weckwerth, AC | 1 |
| Martins, CH | 1 |
| Neto, DL | 1 |
| de Aguiar, HF | 1 |
| Sengupta, J | 1 |
| Khetan, A | 1 |
| Saha, S | 1 |
| Ganguly, A | 1 |
| Pal, D | 1 |
| Lin, YC | 1 |
| Sun, KL | 1 |
| Chun, CL | 1 |
| Hsueh, PR | 2 |
| Scheepers, MA | 1 |
| Keel, S | 1 |
| Michaelides, M | 1 |
| Ali, T | 1 |
| Meade, K | 1 |
| Anari, S | 1 |
| ElBadawey, MR | 1 |
| Zammit-Maempel, I | 1 |
| Nakano, Y | 1 |
| Maybauer, MO | 1 |
| Maybauer, DM | 1 |
| Enkhbaatar, P | 1 |
| Traber, DL | 1 |
| Harji, DP | 1 |
| Rastall, S | 1 |
| Catchpole, C | 1 |
| Bright-Thomas, R | 1 |
| Thrush, S | 1 |
| Kowalski, RP | 3 |
| Romanowski, EG | 3 |
| Mah, FS | 3 |
| Shanks, RM | 1 |
| Gordon, YJ | 3 |
| Subrayan, V | 1 |
| Peyman, M | 1 |
| Lek Yap, S | 1 |
| Mohamed Ali, NA | 1 |
| Devi, S | 1 |
| García-Castillo, M | 2 |
| del Campo, R | 1 |
| Baquero, F | 3 |
| Morosini, MI | 1 |
| Turrientes, MC | 1 |
| Zamora, J | 1 |
| Cantón, R | 3 |
| Ghorashi, Z | 1 |
| Nezami, N | 1 |
| Ghotaslou, R | 1 |
| Ghorashi, S | 1 |
| Quintela Obregón, E | 1 |
| Palomar Fontanet, R | 1 |
| Salas, C | 1 |
| Rodrigo Calabia, E | 1 |
| Arias Rodríguez, M | 1 |
| Barbier, F | 1 |
| Wolff, M | 1 |
| Guillot, E | 1 |
| Sermet, I | 1 |
| Ferroni, A | 1 |
| Chhun, S | 1 |
| Pons, G | 1 |
| Zahar, JR | 1 |
| Jullien, V | 1 |
| Romero, VL | 1 |
| Manzo, RH | 1 |
| Alovero, FL | 1 |
| Edlich, RF | 1 |
| Growcott, EJ | 1 |
| Coulthard, A | 1 |
| Amison, R | 1 |
| Hardaker, EL | 1 |
| Saxena, V | 1 |
| Malt, L | 1 |
| Jones, P | 1 |
| Grevot, A | 1 |
| Poll, C | 1 |
| Banner, KH | 1 |
| Lillquist, YP | 1 |
| Cho, E | 1 |
| Davidson, AG | 1 |
| Miliani, K | 1 |
| L'Hériteau, F | 1 |
| Lacavé, L | 1 |
| Carbonne, A | 1 |
| Astagneau, P | 1 |
| Chen, YA | 1 |
| Chan, KC | 1 |
| Chen, CK | 1 |
| Wu, CM | 1 |
| Ning, FG | 1 |
| Zhao, XZ | 1 |
| Bian, J | 1 |
| Zhang, GA | 1 |
| Yang, Y | 1 |
| Tsifansky, MD | 2 |
| Shin, S | 1 |
| Lin, Q | 1 |
| Yeo, Y | 2 |
| Weng, TC | 1 |
| Chen, YH | 1 |
| Lee, CC | 1 |
| Wang, CY | 1 |
| Lai, CC | 1 |
| Tang, HJ | 1 |
| Ko, WC | 1 |
| Morero, NR | 1 |
| Monti, MR | 1 |
| Argaraña, CE | 1 |
| Kuwabara, M | 1 |
| Kusano, N | 1 |
| Shimizu, E | 1 |
| Shimizu, W | 1 |
| Kobayashi, K | 1 |
| Koda, S | 1 |
| Doi, M | 1 |
| Sugai, M | 1 |
| Kumon, H | 1 |
| Liu, MT | 1 |
| Sheng, MY | 1 |
| Li, Y | 1 |
| Burns, JL | 2 |
| Khan, U | 2 |
| Saiman, L | 1 |
| Cohen, MB | 1 |
| Kulich, M | 1 |
| Kronmal, R | 1 |
| Hiatt, P | 1 |
| Spencer, T | 1 |
| Orenstein, D | 1 |
| Chatfield, BA | 1 |
| Froh, DK | 1 |
| Sonnet, P | 1 |
| Izard, D | 1 |
| Mullié, C | 1 |
| Narten, M | 1 |
| Rosin, N | 1 |
| Schobert, M | 1 |
| Tielen, P | 1 |
| Mazloomi, E | 1 |
| Jazani, NH | 1 |
| Sohrabpour, M | 1 |
| Ilkhanizadeh, B | 1 |
| Shahabi, S | 1 |
| Coban, AY | 1 |
| Tanrıverdi Çaycı, Y | 1 |
| Yıldırım, T | 1 |
| Erturan, Z | 1 |
| Durupınar, B | 1 |
| Bozdoğan, B | 1 |
| Michl, RK | 1 |
| Rusche, T | 1 |
| Grimm, S | 1 |
| Limpert, E | 1 |
| Beck, JF | 1 |
| Dost, A | 1 |
| Gilbert, D | 2 |
| Greer, K | 1 |
| Medina Presentado, JC | 1 |
| Paciel López, D | 1 |
| Berro Castiglioni, M | 1 |
| Gerez, J | 1 |
| Bianchini, E | 1 |
| Cariani, L | 1 |
| Buzzetti, R | 1 |
| Costantini, D | 1 |
| Lewis, GJ | 1 |
| Fang, X | 1 |
| Komor, U | 1 |
| Bielecki, P | 1 |
| Loessner, H | 1 |
| Rohde, M | 1 |
| Wolf, K | 1 |
| Westphal, K | 1 |
| Weiss, S | 1 |
| Häussler, S | 1 |
| Lamb, L | 1 |
| Medina, I | 1 |
| George, D | 1 |
| Gibson, G | 1 |
| Hardink, J | 1 |
| Rugg, J | 1 |
| Van Deusen, J | 1 |
| O'Donnell, JP | 1 |
| Fernández-Olmos, A | 1 |
| Maiz, L | 1 |
| Lamas, A | 1 |
| Uldall Pallesen, KA | 1 |
| Andersen, KE | 1 |
| Mørtz, CG | 1 |
| De Wit, D | 1 |
| Newman, D | 1 |
| Proesmans, M | 1 |
| Vermeulen, F | 1 |
| Boulanger, L | 1 |
| Verhaegen, J | 1 |
| De Boeck, K | 1 |
| Pulcini, C | 2 |
| Mahdyoun, P | 2 |
| Cua, E | 1 |
| Gahide, I | 2 |
| Castillo, L | 2 |
| Guevara, N | 2 |
| Bebawy, M | 1 |
| Agus, H | 1 |
| Young, PM | 1 |
| To, F | 1 |
| Tam, P | 1 |
| Villanyi, D | 1 |
| Stockmann, C | 1 |
| Sherwin, CM | 1 |
| Zobell, JT | 1 |
| Young, DC | 1 |
| Waters, CD | 1 |
| Spigarelli, MG | 1 |
| Ampofo, K | 1 |
| Badar, M | 1 |
| Kieke, M | 1 |
| Spielmann, PM | 1 |
| Yu, R | 1 |
| Neeff, M | 1 |
| Janot, L | 1 |
| Strehmel, J | 1 |
| Fernandez, L | 1 |
| Taylor, PK | 1 |
| Kukavica-Ibrulj, I | 1 |
| Gellatly, SL | 1 |
| Levesque, RC | 1 |
| Overhage, J | 1 |
| Antonela Antoniu, S | 1 |
| Raffaelli, C | 1 |
| Afolabi, OA | 1 |
| Salaudeen, AG | 1 |
| Ologe, FE | 1 |
| Nwabuisi, C | 1 |
| Nwawolo, CC | 1 |
| Bakker-Woudenberg, IA | 1 |
| ten Kate, MT | 1 |
| Guo, L | 1 |
| Working, P | 1 |
| Mouton, JW | 1 |
| Venkata, N | 1 |
| Sharma, S | 4 |
| Gora, R | 1 |
| Chhabra, R | 1 |
| Aasuri, MK | 1 |
| Berenholz, L | 1 |
| Katzenell, U | 1 |
| Harell, M | 1 |
| Kljucar, S | 1 |
| Rost, KL | 1 |
| Landen, H | 1 |
| Erdem, I | 1 |
| Kaynar-Tascioglu, J | 1 |
| Kaya, B | 1 |
| Goktas, P | 1 |
| Zomorrodi, A | 1 |
| Wald, ER | 1 |
| Malamitsi, J | 1 |
| Dounis, E | 2 |
| Grecka, V | 1 |
| Christakopoulos, J | 1 |
| Koratzanis, G | 1 |
| Antoniadou, A | 1 |
| Panoutsopoulos, G | 1 |
| Batsakis, C | 1 |
| Proukakis, C | 1 |
| Wang, JZ | 1 |
| Nightingale, CH | 2 |
| Sweeney, KS | 1 |
| Xi, NZ | 1 |
| Wang, DM | 1 |
| Sakalauskas, R | 1 |
| Dudzevicius, V | 1 |
| Toraman, ZA | 1 |
| Yakupogullari, Y | 1 |
| Watson, A | 1 |
| Sloan, B | 1 |
| Pitt, TL | 1 |
| Sparrow, M | 1 |
| Stefanidou, M | 1 |
| Illinger, J | 1 |
| Mohammedi, I | 1 |
| Argaud, L | 1 |
| St Denis, M | 1 |
| Robert, D | 1 |
| Payen, S | 1 |
| Serreau, R | 1 |
| Munck, A | 1 |
| Aujard, Y | 2 |
| Aigrain, Y | 1 |
| Bressolle, F | 1 |
| Jacqz-Aigrain, E | 1 |
| Lomholt, JA | 1 |
| Kilian, M | 1 |
| Brito, DV | 1 |
| Oliveira, EJ | 1 |
| Matos, C | 1 |
| Abdallah, VO | 1 |
| Gontijo Filho, PP | 1 |
| Lee, KY | 1 |
| Lim, L | 1 |
| Barequet, IS | 1 |
| Denton, P | 1 |
| Osterhout, GJ | 1 |
| Tuli, S | 1 |
| O'Brien, TP | 2 |
| Sahm, DF | 2 |
| Thornsberry, C | 2 |
| Jones, ME | 2 |
| Karlowsky, JA | 2 |
| Lee, TW | 1 |
| Brownlee, KG | 1 |
| Denton, M | 1 |
| Littlewood, JM | 1 |
| Conway, SP | 1 |
| Belet, N | 1 |
| Haciömeroğlu, P | 1 |
| Küçüködük, S | 1 |
| De Vecchi, E | 1 |
| Drago, L | 1 |
| Nicola, L | 1 |
| Colombo, A | 1 |
| Guerra, A | 1 |
| Tocalli, L | 1 |
| Medaglia, M | 1 |
| Gismondo, MR | 1 |
| Ratjen, F | 2 |
| Prabhu, RM | 1 |
| Elliott, MA | 1 |
| Patel, R | 1 |
| Nørregaard, L | 1 |
| Gøtzsche, PC | 1 |
| Koch, C | 6 |
| Aoki, S | 1 |
| Hirakata, Y | 2 |
| Kondoh, A | 1 |
| Gotoh, N | 2 |
| Yanagihara, K | 2 |
| Miyazaki, Y | 2 |
| Tomono, K | 2 |
| Yamada, Y | 1 |
| Kohno, S | 2 |
| Kamihira, S | 1 |
| Zelenitsky, SA | 1 |
| Iacovides, H | 1 |
| Harding, GK | 1 |
| Ariano, RE | 1 |
| Jung, R | 1 |
| Fish, DN | 1 |
| Obritsch, MD | 1 |
| MacLaren, R | 1 |
| Schito, AM | 2 |
| Schito, GC | 2 |
| Kidd, JD | 1 |
| Park, SY | 1 |
| Dale, RM | 1 |
| Schnell, G | 1 |
| Wong, JP | 1 |
| Thibodeaux, BA | 1 |
| Dajcs, JJ | 1 |
| Caballero, AR | 1 |
| Marquart, ME | 1 |
| Girgis, DO | 1 |
| O'Callaghan, RJ | 9 |
| Rhee, MK | 1 |
| Ritterband, DC | 1 |
| Wenig, BM | 1 |
| Smirniotopoulos, JG | 1 |
| Heffner, DK | 1 |
| Aggarwal, P | 1 |
| Dutta, S | 1 |
| Garg, SK | 1 |
| Narang, A | 1 |
| Obara, Y | 1 |
| Nagai, T | 1 |
| Mori, M | 1 |
| Ohmine, K | 1 |
| Toshima, M | 1 |
| Komatsu, N | 1 |
| Ozawa, K | 1 |
| Friedland, I | 1 |
| Gallagher, G | 1 |
| King, T | 1 |
| Woods, GL | 1 |
| Naija, W | 1 |
| Matéo, J | 1 |
| Raskine, L | 1 |
| Timsit, JF | 1 |
| Lukascewicz, AC | 1 |
| George, B | 1 |
| Payen, D | 1 |
| Mebazaa, A | 1 |
| Solak, S | 1 |
| Willke, A | 1 |
| Ergönül, O | 1 |
| Tekeli, E | 1 |
| Lister, PD | 1 |
| Wolter, DJ | 1 |
| Evangelista, AT | 1 |
| Yee, YC | 1 |
| Jensen, H | 1 |
| Zerouala, C | 1 |
| Carrier, M | 1 |
| Short, B | 1 |
| Aliprandis, E | 1 |
| Ciralsky, J | 1 |
| Lai, H | 1 |
| Herling, I | 1 |
| Katz, HR | 1 |
| Park, WB | 1 |
| Lee, KD | 1 |
| Kim, HB | 1 |
| Kim, EC | 1 |
| Oh, MD | 1 |
| Choe, KW | 1 |
| McKnight, AJ | 1 |
| Shaw, A | 1 |
| Goldsmith, CE | 1 |
| Clarke, L | 1 |
| Reid, A | 1 |
| Mizunaga, S | 1 |
| Kamiyama, T | 1 |
| Fukuda, Y | 1 |
| Takahata, M | 1 |
| Mitsuyama, J | 1 |
| Burghardt, KM | 1 |
| Leonard, M | 1 |
| Feber, J | 1 |
| Halton, J | 1 |
| Filler, G | 1 |
| Frederiksen, B | 2 |
| Ray, GT | 1 |
| Baxter, R | 1 |
| DeLorenze, GN | 1 |
| Cobos, N | 1 |
| de Gracia, J | 1 |
| Honorato, J | 1 |
| Gartner, S | 1 |
| Alvarez, A | 1 |
| Salcedo, A | 1 |
| García-Quetglas, E | 1 |
| Tian, BW | 1 |
| Yang, YJ | 1 |
| Pang, XY | 1 |
| Fahim, K | 1 |
| Houghton, O | 1 |
| Dastjerdi, M | 1 |
| Mian, SI | 1 |
| Zelenitsky, S | 1 |
| Ariano, R | 1 |
| Harding, G | 1 |
| Forrest, A | 1 |
| Norris, P | 1 |
| Noble, M | 1 |
| Francolini, I | 1 |
| Vinogradov, AM | 1 |
| Stewart, PS | 1 |
| Ratner, BD | 1 |
| Costerton, JW | 1 |
| Stoodley, P | 1 |
| Roveta, S | 1 |
| Marchese, A | 1 |
| Shefelbine, SE | 1 |
| Young, LJ | 1 |
| Antonelli, PJ | 1 |
| Wydmuch, Z | 1 |
| Skowronek-Ciołek, O | 1 |
| Cholewa, K | 1 |
| Mazurek, U | 1 |
| Pacha, J | 1 |
| Kepa, M | 1 |
| Idzik, D | 1 |
| Wojtyczka, RD | 1 |
| Segura, M | 1 |
| Gómez, C | 1 |
| Battikhi, MN | 1 |
| Ismail, H | 1 |
| Battikhi, Q | 1 |
| Sharma, N | 1 |
| Sinha, R | 1 |
| Singhvi, A | 1 |
| Tandon, R | 1 |
| Tennenberg, AM | 1 |
| Davis, NB | 1 |
| Wu, SC | 1 |
| Kahn, J | 1 |
| Kaye, KS | 1 |
| Kanafani, ZA | 1 |
| Dodds, AE | 1 |
| Engemann, JJ | 1 |
| Weber, SG | 1 |
| Carmeli, Y | 1 |
| Van Der Vliet, D | 1 |
| Le Guern, AS | 1 |
| Freitag, S | 1 |
| Gounod, N | 1 |
| Therby, A | 1 |
| Darie, H | 1 |
| Buffet, PA | 1 |
| Onlen, Y | 1 |
| Tamer, C | 1 |
| Oksuz, H | 1 |
| Duran, N | 1 |
| Altug, ME | 1 |
| Yakan, S | 1 |
| Bernstein, JM | 1 |
| Holland, NJ | 1 |
| Porter, GC | 1 |
| Maw, AR | 1 |
| Moore, GC | 1 |
| Redfern, J | 1 |
| Shiach, CR | 1 |
| Webb, K | 1 |
| Jones, AM | 1 |
| Ludwig, E | 1 |
| Konkoly-Thege, M | 1 |
| Henig, N | 1 |
| Morrissey, B | 1 |
| Gotfried, M | 1 |
| Marinkovic, M | 1 |
| Witmer, JP | 1 |
| Sirvent, E | 1 |
| Ruiz, M | 1 |
| Royo, G | 1 |
| Suman, G | 1 |
| Sabitha, K | 1 |
| Jamil, K | 1 |
| Manca, DP | 1 |
| Levy, M | 1 |
| Tariq, K | 1 |
| Tanase-Derkaoui, D | 1 |
| le Huidoux, P | 1 |
| Farnoux, C | 1 |
| El-Moussawi, F | 1 |
| Baud, O | 1 |
| Pino Rivero, V | 1 |
| Pantoja Hernández, CG | 1 |
| González Palomino, G | 1 |
| Mora Santos, ME | 1 |
| Pardo Romero, G | 1 |
| Blasco Huelva, A | 1 |
| Sripriya, R | 1 |
| Kumar, MS | 1 |
| Ahmed, MR | 1 |
| Sehgal, PK | 1 |
| Yates, KA | 1 |
| Bu, P | 1 |
| Riske, PS | 1 |
| Zaya, NE | 1 |
| Carey, R | 1 |
| Bouchard, CS | 1 |
| Al-Shakarchi, F | 1 |
| Yu, Y | 1 |
| Cheng, AS | 1 |
| Wang, L | 1 |
| Dunne, WM | 1 |
| Bayliss, SJ | 1 |
| Segatore, B | 1 |
| Perilli, M | 1 |
| Larosa, M | 1 |
| Setacci, D | 1 |
| Celenza, G | 1 |
| Amicosante, G | 1 |
| Oxley, KS | 1 |
| Thomas, JG | 1 |
| Ramadan, HH | 1 |
| Losanoff, JE | 1 |
| Millis, JM | 1 |
| Kienbacher, G | 1 |
| Maurer-Ertl, W | 1 |
| Glehr, M | 1 |
| Feierl, G | 1 |
| Leithner, A | 1 |
| Elwood, ET | 1 |
| Sommerville, DN | 1 |
| Murray, JD | 1 |
| Saltzstein, D | 1 |
| Wachs, B | 1 |
| Perroncel, R | 1 |
| Benson, A | 1 |
| Herrington, J | 1 |
| Haverstock, D | 1 |
| Pertel, P | 1 |
| Mueller, MR | 1 |
| Hayden, MK | 1 |
| Fridkin, SK | 1 |
| Warren, DK | 1 |
| Phillips, L | 1 |
| Lolans, K | 1 |
| Quinn, JP | 1 |
| Khorasani, G | 1 |
| Salehifar, E | 1 |
| Kawazoe, H | 1 |
| Takiguchi, Y | 1 |
| Inoue, T | 1 |
| Yamaguchi, K | 1 |
| Tanaka, H | 1 |
| Kaji, M | 1 |
| Tsuji, S | 1 |
| Ninomiya, M | 1 |
| Fukuoka, N | 1 |
| Ohnishi, H | 1 |
| Ishida, T | 1 |
| Houchi, H | 1 |
| Thivaios, GC | 1 |
| Kolia, M | 1 |
| Dontas, I | 1 |
| Nakopoulou, L | 1 |
| Andreopoulos, A | 1 |
| Karagiannakos, P | 1 |
| Evgenov, OV | 1 |
| Bellas, E | 1 |
| Benjamin, J | 1 |
| Kohane, DS | 1 |
| Sierra, JM | 1 |
| Rodriguez-Puig, D | 1 |
| Piera, C | 1 |
| Schiff, JB | 1 |
| Small, GJ | 2 |
| Pennington, JE | 2 |
| Owusu-Ababio, G | 1 |
| Rogers, JA | 1 |
| Morck, DW | 1 |
| Olson, ME | 1 |
| Raz, R | 2 |
| Miron, D | 1 |
| Pedersen, SS | 5 |
| Jensen, T | 4 |
| Valerius, NH | 2 |
| Yu, L | 1 |
| Chen, YL | 1 |
| Zhu, YJ | 1 |
| Xiong, YQ | 2 |
| Potel, G | 2 |
| Caillon, J | 2 |
| Stephant, G | 1 |
| Jehl, F | 1 |
| Bugnon, D | 2 |
| Le Conte, P | 1 |
| Baron, D | 2 |
| Drugeon, H | 1 |
| Dunn, M | 1 |
| Wunderink, RG | 2 |
| Xie, W | 1 |
| Conte, PL | 1 |
| Drugeon, HB | 1 |
| Chidiac, C | 1 |
| Guery, B | 1 |
| Beaucaire, G | 1 |
| Burdge, DR | 1 |
| Nakielna, EM | 1 |
| Rabin, HR | 3 |
| Engel, LS | 4 |
| Callegan, MC | 3 |
| Reidy, JJ | 4 |
| Hill, JM | 8 |
| Lucena, MI | 1 |
| Marquez, M | 1 |
| Velasco, JL | 1 |
| Andrade, RJ | 1 |
| Legent, F | 1 |
| Bordure, P | 1 |
| Beauvillain, C | 1 |
| Berche, P | 1 |
| Fombeur, JP | 1 |
| Barrault, S | 1 |
| Koubbi, G | 1 |
| Laurier, JN | 1 |
| Ebbo, D | 1 |
| Lecomte, F | 1 |
| Sorrel, N | 1 |
| Dobler, S | 1 |
| Gehanno, P | 1 |
| Guzek, JP | 1 |
| Chacko, D | 1 |
| Kettering, JD | 1 |
| Wessels, IF | 1 |
| Aprecio, RM | 1 |
| Jumaa, P | 1 |
| Chattopadhyay, B | 1 |
| Lorian, V | 1 |
| Pavletich, K | 1 |
| Giwercman, B | 1 |
| Rayner, CF | 1 |
| Tillotson, G | 1 |
| Cole, PJ | 1 |
| Reid, G | 1 |
| Advikolanu, K | 1 |
| Tieszer, C | 1 |
| Martin, RA | 1 |
| Bruce, AW | 2 |
| Pasadakis, P | 1 |
| Thodis, E | 1 |
| Eftimimiadou, A | 1 |
| Panagoutsos, S | 1 |
| Papazoglou, D | 1 |
| Kaliengidou, M | 1 |
| Kartali, S | 1 |
| Vargemezis, V | 1 |
| Vickers, MH | 1 |
| Price, T | 1 |
| Court, EA | 1 |
| Watson, AD | 1 |
| Martin, P | 1 |
| Vedia, C | 1 |
| Costa, J | 1 |
| Olivé, A | 1 |
| Tena, X | 1 |
| Fink, MP | 1 |
| Snydman, DR | 1 |
| Niederman, MS | 1 |
| Leeper, KV | 1 |
| Johnson, RH | 1 |
| Heard, SO | 1 |
| Caldwell, JW | 1 |
| Schentag, JJ | 3 |
| Siami, GA | 1 |
| Higgins, SP | 1 |
| Stedman, YF | 1 |
| Bundred, NJ | 1 |
| Woolley, PD | 1 |
| Chandiok, P | 1 |
| Chandler P [corrected to Chandiok, P] | 1 |
| de Miguel, J | 1 |
| Collazos, J | 1 |
| Ayarza, R | 1 |
| Abaitua, JM | 1 |
| Quilez, J | 1 |
| Chayakul, P | 1 |
| Krisanapan, S | 1 |
| Kalnauwakul, S | 1 |
| Marchbanks, CR | 1 |
| McKiel, JR | 1 |
| Gilbert, DH | 1 |
| Robillard, NJ | 2 |
| Painter, B | 1 |
| Dudley, MN | 2 |
| Lauffenburger, MD | 1 |
| Cohen, KL | 1 |
| Taylor, RF | 1 |
| Hodson, ME | 6 |
| Sheldon, CD | 1 |
| Assoufi, BK | 1 |
| Ganz, H | 2 |
| Capdevila, JA | 1 |
| Segarra, A | 1 |
| Planes, AM | 1 |
| Ramírez-Arellano, M | 1 |
| Pahissa, A | 2 |
| Piera, L | 1 |
| Martínez-Vázquez, JM | 1 |
| Orenstein, DM | 2 |
| Pattishall, EN | 2 |
| Noyes, BE | 1 |
| Kurland, G | 1 |
| Hartigan, ER | 1 |
| Yu, VL | 2 |
| Romulo, RL | 1 |
| Palardy, JE | 3 |
| Opal, SM | 4 |
| Kelman, GJ | 1 |
| Roland, GC | 1 |
| Beagley, MJ | 1 |
| Mirelis, B | 2 |
| Miro, E | 2 |
| Navarro, F | 2 |
| Ogalla, CA | 1 |
| Bonal, J | 1 |
| Prats, G | 1 |
| Frisolone, J | 1 |
| Manzo, J | 1 |
| Leviton, IM | 1 |
| Vazquez, C | 1 |
| Municio, M | 1 |
| Corera, M | 1 |
| Gaztelurrutia, L | 1 |
| Sojo, A | 1 |
| Vitoria, JC | 1 |
| Insler, MS | 3 |
| Corti, G | 1 |
| Paradisi, F | 1 |
| Giganti, E | 1 |
| Buffini, G | 1 |
| Tortoli, E | 1 |
| Martelli, L | 1 |
| Pecile, P | 1 |
| Nicoletti, P | 1 |
| Grecka, P | 1 |
| March, F | 1 |
| Sanchez, F | 1 |
| Porco, FV | 1 |
| Visconte, EB | 1 |
| Brouqui, P | 1 |
| Rousseau, MC | 1 |
| Stein, A | 1 |
| Drancourt, M | 1 |
| Raoult, D | 1 |
| Klepser, ME | 1 |
| Patel, KB | 1 |
| Quintiliani, R | 1 |
| Alemany Francés, ML | 1 |
| Romero Candeira, S | 1 |
| Fernández Aracil, C | 1 |
| Kim, IT | 1 |
| Chung, KH | 1 |
| Koo, BS | 1 |
| Sakamoto, M | 1 |
| Saruta, K | 1 |
| Nakazawa, Y | 1 |
| Shindo, N | 1 |
| Maezawa, H | 1 |
| Yoshikawa, K | 1 |
| Yoshida, M | 1 |
| Shiba, K | 1 |
| Sakai, O | 1 |
| Saito, A | 1 |
| Folkens, AT | 1 |
| Shimomura, Y | 1 |
| Church, DA | 2 |
| Kanga, JF | 1 |
| Kuhn, RJ | 2 |
| Rubio, TT | 4 |
| Spohn, WA | 1 |
| Stevens, JC | 1 |
| Painter, BG | 1 |
| Thurberg, BE | 1 |
| Haverstock, DC | 1 |
| Perroncel, RY | 1 |
| Echols, RM | 2 |
| Schaad, UB | 4 |
| Wedgwood, J | 2 |
| Ruedeberg, A | 1 |
| Kraemer, R | 2 |
| Hampel, B | 1 |
| Miles, MV | 1 |
| Lettieri, JT | 1 |
| Redmond, AO | 3 |
| Kitazawa, H | 1 |
| Hayakawa, H | 1 |
| Chida, K | 1 |
| Iwata, M | 1 |
| Yagel, SK | 1 |
| Barrett, JF | 1 |
| Amaratunga, DJ | 1 |
| Frosco, MB | 1 |
| Wintermeyer, SM | 1 |
| Hart, MC | 1 |
| Nahata, MC | 1 |
| Richard, DA | 1 |
| Nousia-Arvanitakis, S | 1 |
| Sollich, V | 1 |
| Hampel, BJ | 1 |
| Sommerauer, B | 1 |
| Elewski, BE | 1 |
| Fradis, M | 2 |
| Brodsky, A | 1 |
| Ben-David, J | 2 |
| Srugo, I | 2 |
| Larboni, J | 2 |
| Podoshin, L | 2 |
| Wong-Beringer, A | 1 |
| Beringer, P | 1 |
| Lovett, MA | 1 |
| Paramsothy, M | 1 |
| Khanijow, V | 1 |
| Ong, TO | 1 |
| Suvarna, SK | 1 |
| al-Wali, WI | 1 |
| Locke, TJ | 1 |
| Majtán, V | 1 |
| Hostacká, A | 1 |
| Brodzki, A | 1 |
| Shapiro, MA | 1 |
| Sesnie, JC | 1 |
| Desaty, TM | 1 |
| Griffin, TJ | 1 |
| Heifetz, CL | 1 |
| Canver, CC | 1 |
| Patel, AK | 1 |
| Kosolcharoen, P | 1 |
| Voytovich, MC | 1 |
| Colsky, AS | 1 |
| Kirsner, RS | 1 |
| Kerdel, FA | 1 |
| Richards, RM | 1 |
| Hamilton, VE | 1 |
| Thomas, MR | 1 |
| Chaudhry, NA | 1 |
| Tabandeh, H | 1 |
| Rosenfeld, PJ | 1 |
| Miller, D | 1 |
| Davis, J | 1 |
| Dohar, JE | 1 |
| Alper, CM | 1 |
| Rose, EA | 1 |
| Doyle, WJ | 1 |
| Casselbrant, ML | 1 |
| Kenna, MA | 1 |
| Bluestone, CD | 1 |
| Jhung, JW | 1 |
| Keith, JC | 1 |
| Parejo, NA | 1 |
| Young, LD | 1 |
| Bhattacharjee, A | 1 |
| Petersen, W | 1 |
| Laprell, H | 1 |
| Peterson, LR | 1 |
| Postelnick, M | 1 |
| Pozdol, TL | 1 |
| Reisberg, B | 1 |
| Noskin, GA | 1 |
| DiTizio, V | 1 |
| Ferguson, GW | 1 |
| Mittelman, MW | 1 |
| Khoury, AE | 1 |
| DiCosmo, F | 1 |
| Blondeau, JM | 1 |
| Suter, ME | 1 |
| Borsos, S | 1 |
| Misfeldt, C | 1 |
| Trautmann, M | 1 |
| Heinemann, M | 1 |
| Zick, R | 1 |
| Möricke, A | 1 |
| Seidelmann, M | 1 |
| Berger, D | 1 |
| Gilad, J | 1 |
| Borer, A | 1 |
| Maimon, N | 1 |
| Riesenberg, K | 1 |
| Klein, M | 1 |
| Schlaeffer, F | 1 |
| Rodríguez Hermosa, JI | 1 |
| Rodríguez Higueras, MI | 1 |
| Sirvent Calvera, JM | 1 |
| García Oria, MJ | 1 |
| Mader, R | 1 |
| Yeromenco, E | 1 |
| Vikram, HR | 1 |
| Shore, ET | 1 |
| Venkatesh, PR | 1 |
| Wu, YL | 1 |
| Scott, EM | 2 |
| Po, AL | 1 |
| Tariq, VN | 1 |
| Redmond, A | 1 |
| Sweeney, L | 1 |
| MacFarland, M | 1 |
| Mitchell, M | 1 |
| Daggett, S | 1 |
| Kubin, R | 1 |
| Garg, P | 2 |
| Rao, GN | 2 |
| Kepple, SR | 1 |
| Lesne-Hulin, A | 1 |
| Bourget, P | 1 |
| Ravat, F | 1 |
| Goudin, C | 1 |
| Latarjet, J | 1 |
| Jaffé, A | 1 |
| Bush, A | 1 |
| Hyatt, JM | 1 |
| Jalal, S | 1 |
| Hoiby, N | 1 |
| Wretlind, B | 1 |
| Mayer, I | 2 |
| Nagy, E | 2 |
| Ghosh, SK | 1 |
| Burgess, DS | 1 |
| Hastings, RW | 1 |
| Allworth, A | 1 |
| Sridhar, MS | 1 |
| MacLeod, W | 1 |
| Bald, M | 1 |
| Nikolaizik, W | 1 |
| Wingen, AM | 1 |
| Sherman, JA | 1 |
| Paul, AC | 1 |
| Justus, A | 1 |
| Balraj, A | 1 |
| Job, A | 1 |
| Kirubakaran, CP | 1 |
| Le Thomas, I | 1 |
| Clermont, O | 1 |
| Brahimi, N | 1 |
| Garg, PK | 1 |
| Khanna, S | 1 |
| Bohidar, NP | 1 |
| Kapil, A | 1 |
| Tandon, RK | 1 |
| Pascual A, A | 1 |
| Joyanes, P | 1 |
| Martínez-Martínez, L | 1 |
| del Carmen Conejo, M | 1 |
| Hernández, G | 1 |
| Chaves, J | 1 |
| Perea, EJ | 1 |
| Beach, ML | 1 |
| Pfaller, MA | 1 |
| Ermertcan, S | 1 |
| Hoşgör, M | 1 |
| Tünger, O | 1 |
| Coşar, G | 1 |
| Kaneko, Y | 1 |
| Kuroki, M | 1 |
| Ohi, H | 1 |
| Kakeya, H | 1 |
| Higashiyama, Y | 1 |
| Kadota, JI | 1 |
| Elies, W | 1 |
| Marchetti, F | 1 |
| Candusso, M | 1 |
| Faraguna, D | 1 |
| Assael, BM | 1 |
| Griese, M | 1 |
| Müller, I | 1 |
| Reinhardt, D | 1 |
| Gillespie, T | 1 |
| Masterton, RG | 1 |
| Díaz Valle, D | 1 |
| Alós Cortés, JI | 1 |
| Arteaga Sánchez, A | 1 |
| Toledano Fernández, N | 1 |
| Poza Morales, Y | 1 |
| Díaz-Valle, T | 1 |
| Uzun, O | 1 |
| Akalin, HE | 1 |
| Unal, S | 1 |
| Demircin, M | 1 |
| Yorgancioglu, AC | 1 |
| Ugurlu, B | 1 |
| Denamur, E | 1 |
| Picard, B | 1 |
| Goullet, P | 1 |
| Lambert-Zechovsky, N | 1 |
| Foucaud, P | 1 |
| Navarro, J | 1 |
| Elion, J | 1 |
| Gallen, IW | 1 |
| Molitch, ME | 1 |
| Barrie, JR | 1 |
| Mousdale, S | 1 |
| Baciewicz, AM | 1 |
| Georges, G | 1 |
| Becker, M | 1 |
| Schnall, AM | 1 |
| Christensson, BA | 1 |
| Nilsson-Ehle, I | 2 |
| Ljungberg, B | 2 |
| Lindblad, A | 2 |
| Malmborg, AS | 2 |
| Hjelte, L | 2 |
| Strandvik, B | 2 |
| Froidefond, S | 1 |
| Saivin, S | 1 |
| Lemozy, J | 1 |
| Marchou, B | 1 |
| Auvergnat, JC | 1 |
| Dabernat, H | 1 |
| Hagenah, M | 1 |
| Kazmi, HR | 1 |
| Raffone, FD | 1 |
| Kliger, AS | 1 |
| Finkelstein, FO | 1 |
| Ravaoarinoro, M | 1 |
| Toma, E | 1 |
| Fallara, A | 1 |
| Diver, JM | 1 |
| Schollaardt, T | 1 |
| Thorson, C | 1 |
| Bryan, LE | 1 |
| Zhang, YP | 1 |
| Collins, MS | 3 |
| Ladehoff, D | 1 |
| Mehton, NS | 1 |
| Sahai, J | 1 |
| Memish, Z | 1 |
| Conway, B | 1 |
| Kindelan, JM | 1 |
| Jurado, R | 1 |
| No-Louis, E | 1 |
| López-Villarejo, P | 1 |
| Levenson, MJ | 1 |
| Parisier, SC | 1 |
| Dolitsky, J | 1 |
| Bindra, G | 1 |
| Forman, K | 1 |
| LeBel, M | 1 |
| Taber, TE | 1 |
| Hegeman, TF | 1 |
| York, SM | 1 |
| Kinney, RA | 1 |
| Webb, DH | 1 |
| Cokingtin, CD | 1 |
| Hyndiuk, RA | 1 |
| Stoupis, C | 1 |
| Tschaeppeler, H | 1 |
| Vock, P | 1 |
| Dronda, F | 1 |
| Villodres, J | 1 |
| Padeĭskaia, EN | 1 |
| Mnatsakanian, VE | 1 |
| Bosso, JA | 2 |
| Saxon, BA | 1 |
| Matsen, JM | 1 |
| Strauss, M | 1 |
| Esposito, S | 2 |
| D'Errico, G | 2 |
| Montanaro, C | 2 |
| Ball, P | 1 |
| Cross, AS | 2 |
| Kelly, NM | 1 |
| Sadoff, JC | 2 |
| Bodmer, MW | 1 |
| Victor, GH | 1 |
| Masecar, BL | 1 |
| Celesk, RA | 1 |
| Phillips, G | 1 |
| Fleming, LW | 2 |
| Stewart, WK | 2 |
| Nixon, PA | 1 |
| Ross, EA | 1 |
| Kaplan, RM | 1 |
| Trygg, KJ | 1 |
| Madison, KC | 1 |
| Aswapokee, N | 1 |
| Pruksachatvuthi, S | 1 |
| Aswapokee, P | 1 |
| Rivas Lacarte, MP | 1 |
| Pumarola Segura, F | 1 |
| Black, A | 1 |
| Steen, HJ | 2 |
| Oborska, IT | 1 |
| Fowler, JF | 1 |
| Stege, GC | 1 |
| Lang, R | 2 |
| Goshen, S | 2 |
| Kitzes-Cohen, R | 2 |
| Sadé, J | 2 |
| Pickard, RE | 1 |
| Dan, M | 1 |
| Siegman-Igra, Y | 1 |
| Pitlik, S | 1 |
| Gordon, JJ | 1 |
| Kauffman, CA | 2 |
| Roca, R | 1 |
| Segura, A | 1 |
| González, J | 1 |
| Peters, B | 1 |
| Pinching, AJ | 1 |
| To, M | 1 |
| Woods, DE | 1 |
| Valiant, ME | 1 |
| Gilfillan, EC | 1 |
| Gadebusch, HH | 1 |
| Pelak, BA | 1 |
| Rubin, J | 1 |
| Stoehr, G | 1 |
| Muder, RR | 1 |
| Matador, A | 1 |
| Kamerer, DB | 1 |
| Hickey, SA | 1 |
| Ford, GR | 1 |
| O'Connor, AF | 1 |
| Eykyn, SJ | 1 |
| Sönksen, PH | 1 |
| Peloquin, CA | 1 |
| Cumbo, TJ | 1 |
| Nix, DE | 1 |
| Sands, MF | 1 |
| Wedgwood-Krucko, J | 1 |
| Guenin, K | 1 |
| Buehlmann, U | 1 |
| Humphreys, H | 1 |
| Speller, DC | 1 |
| Stange, G | 1 |
| Valtonen, V | 1 |
| Karppinen, L | 1 |
| Kariniemi, AL | 1 |
| Stevenson, MI | 1 |
| Black, AE | 1 |
| Collier, PS | 2 |
| Piccirillo, JF | 1 |
| Parnes, SM | 1 |
| Norrby, SR | 1 |
| Jawad, AS | 1 |
| Noel, SB | 1 |
| Scallan, P | 1 |
| Meadors, MC | 1 |
| Meek, TJ | 1 |
| Pankey, GA | 1 |
| Collins, HH | 1 |
| Dobek, A | 1 |
| McClain, JB | 1 |
| Osborne, JE | 1 |
| Blair, RL | 1 |
| Davey, P | 2 |
| Crook, SM | 1 |
| Selkon, JB | 1 |
| McLardy Smith, PD | 1 |
| Scully, BE | 3 |
| Neu, HC | 4 |
| Parry, MF | 1 |
| Mandell, W | 1 |
| Smith, MJ | 3 |
| Batten, JC | 3 |
| Millar, MR | 1 |
| Bransby-Zachary, MA | 1 |
| Tompkins, DS | 1 |
| Hawkey, PM | 1 |
| Myles Gibson, R | 1 |
| Preheim, LC | 2 |
| Cuevas, TA | 1 |
| Roccaforte, JS | 1 |
| Mellencamp, MA | 1 |
| Bittner, MJ | 1 |
| Roberts, CM | 1 |
| Butland, RJ | 1 |
| Salh, B | 1 |
| Webb, AK | 1 |
| McEwan, SR | 1 |
| Davey, PG | 2 |
| Lewandowski, A | 1 |
| Strunk, RW | 1 |
| Gratz, JC | 1 |
| Maserati, R | 1 |
| Scheld, WM | 2 |
| Haller, I | 1 |
| Van Poppel, H | 2 |
| Wegge, M | 2 |
| Dammekens, H | 2 |
| Chysky, V | 2 |
| Ingerman, MJ | 1 |
| Pitsakis, PG | 1 |
| Rosenberg, AF | 1 |
| Levison, ME | 1 |
| Davies, BI | 2 |
| Maesen, FP | 2 |
| Teengs, JP | 1 |
| Baur, C | 2 |
| Kurz, CC | 1 |
| Marget, W | 1 |
| Harms, K | 1 |
| Bertele, RM | 1 |
| Boerema, JB | 1 |
| Chin, NX | 1 |
| Jules, K | 1 |
| Eron, LJ | 1 |
| Harvey, L | 1 |
| Hixon, DL | 1 |
| Poretz, DM | 1 |
| Isaacs, D | 1 |
| Slack, MP | 1 |
| Wilkinson, AR | 1 |
| Westwood, AW | 1 |
| Kemmerich, B | 1 |
| Daphnis, E | 2 |
| Dendrinos, C | 2 |
| Daikos, GK | 2 |
| Galanakis, N | 1 |
| Stefanou, J | 1 |
| Follath, F | 1 |
| Bindschedler, M | 1 |
| Wenk, M | 1 |
| Frei, R | 1 |
| Stalder, H | 1 |
| Reber, H | 1 |
| Mehtar, S | 1 |
| Drabu, Y | 1 |
| Blakemore, P | 1 |
| Saavedra, S | 1 |
| Ramírez-Ronda, CH | 1 |
| Nevárez, M | 1 |
| Bayer, AS | 3 |
| Blomquist, IK | 2 |
| Kim, KS | 2 |
| Shapiro, C | 1 |
| Hackbarth, CJ | 2 |
| Chambers, HF | 1 |
| Stella, F | 1 |
| Shibl, AM | 1 |
| Sande, MA | 3 |
| Barza, M | 2 |
| Stuart, M | 2 |
| Azadian, BS | 2 |
| Bendig, JW | 2 |
| Samson, DM | 2 |
| Johnson, M | 1 |
| Miniter, P | 1 |
| Andriole, VT | 2 |
| Zeiler, HJ | 1 |
| Voigt, WH | 1 |
| Hector, RF | 2 |
| Roby, RE | 2 |
| Edwards, AA | 1 |
| Ladehoff, DK | 1 |
| Dorsey, JH | 2 |
| Kyle, PW | 1 |
| Giangrande, PL | 1 |
| Alfaham, M | 1 |
| Holt, ME | 1 |
| Goodchild, MC | 2 |
| Tsay, GC | 1 |
| Michéa-Hamzehpour, M | 1 |
| Auckenthaler, R | 1 |
| Regamey, P | 1 |
| Pechère, JC | 1 |
| Mattie, H | 3 |
| Hoogeterp, JJ | 2 |
| Terporten, P | 2 |
| Zervos, MJ | 1 |
| Bacon, AE | 1 |
| Patterson, JE | 1 |
| Schaberg, DR | 1 |
| Gargallo, D | 1 |
| Moros, M | 1 |
| Coll, R | 1 |
| Esteve, M | 1 |
| Parés, J | 1 |
| Xicota, MA | 1 |
| Guinea, J | 1 |
| Daikos, GL | 1 |
| Kathpalia, SB | 1 |
| Lolans, VT | 1 |
| Jackson, GG | 1 |
| Fosslien, E | 1 |
| Sawusch, MR | 1 |
| Dick, JD | 1 |
| Gottsch, JD | 1 |
| Hoen, MM | 1 |
| Downs, RH | 1 |
| LaBounty, GL | 1 |
| Nespeca, JA | 1 |
| Haverkorn, MJ | 2 |
| Grave, W | 1 |
| Sturm, AW | 1 |
| Mannan, P | 1 |
| Kibbler, CC | 1 |
| Noone, P | 1 |
| Barnett, F | 1 |
| Axelrod, P | 1 |
| Tronstad, L | 1 |
| Slots, J | 1 |
| Graziani, A | 1 |
| Talbot, G | 1 |
| Guibert, JM | 1 |
| Destree, DM | 1 |
| Acar, JF | 1 |
| Norden, CW | 1 |
| Shinners, E | 1 |
| Gordin, FM | 1 |
| Scott, KG | 1 |
| Morrison, GA | 1 |
| Bailey, CM | 1 |
| Leggett, JM | 1 |
| Prendergast, K | 1 |
| Fernandes, PB | 2 |
| Chu, DT | 2 |
| Swanson, RN | 1 |
| Ramer, NR | 2 |
| Hanson, CW | 1 |
| Bower, RR | 2 |
| Stamm, JM | 1 |
| Hardy, DJ | 1 |
| Breuer, J | 1 |
| Bragman, SG | 1 |
| Sahatlevan, MD | 1 |
| Philpott-Howard, JN | 1 |
| Casewell, MW | 1 |
| Willems, FT | 1 |
| Haverman, FE | 1 |
| Scott, AC | 1 |
| van den Broek, PJ | 1 |
| Bakker, W | 1 |
| van Gulpen, C | 1 |
| Stuyck, J | 1 |
| Verbist, L | 1 |
| Mulier, JC | 1 |
| Hvidberg, EF | 1 |
| Nielsen, CH | 1 |
| Jarvis, KP | 1 |
| Shipkowitz, N | 1 |
| Lindsay, P | 1 |
| Yih, J | 1 |
| Hirano, L | 1 |
| Lee, D | 1 |
| Dürig, M | 1 |
| Braun, R | 1 |
| Heberer, M | 1 |
| Schlegel, P | 1 |
| Harder, F | 1 |
| Leigh, DA | 1 |
| Emmanuel, FX | 1 |
| Petch, VJ | 1 |
| Goldfarb, J | 1 |
| Stern, RC | 1 |
| Reed, MD | 1 |
| Yamashita, TS | 1 |
| Myers, CM | 1 |
| Blumer, JL | 1 |
| Shalit, I | 1 |
| Stutman, HR | 1 |
| Marks, MI | 1 |
| Chartrand, SA | 1 |
| Hilman, BC | 1 |
| Nakatomi, M | 1 |
| Ores, C | 1 |
| Davidson, S | 1 |
| Lesse, AJ | 1 |
| Freer, C | 1 |
| Salata, RA | 1 |
| Francis, JB | 1 |
| Gilbert, DN | 1 |
| Tice, AD | 1 |
| Marsh, PK | 1 |
| Craven, PC | 1 |
| Ryan, JL | 1 |
| Berenson, CS | 1 |
| Greco, TP | 1 |
| Mangi, RJ | 1 |
| Sims, M | 1 |
| Thornton, GF | 1 |
| Mandler, HD | 1 |
| Ericson, J | 1 |
| Mayer, KH | 1 |
| Greenberg, RN | 1 |
| Kennedy, DJ | 1 |
| Reilly, PM | 1 |
| Luppen, KL | 1 |
| Weinandt, WJ | 1 |
| Bollinger, MR | 1 |
| Aguirre, F | 1 |
| Kodesch, F | 1 |
| Saeed, AM | 1 |
| Brooks-Fournier, RA | 1 |
| Gerberding, JL | 1 |
| Raeburn, JA | 1 |
| Govan, JR | 1 |
| McCrae, WM | 1 |
| Greening, AP | 1 |
| Dibble, JB | 1 |
| Acomb, C | 1 |
| Campbell, L | 1 |
| White, LO | 2 |
| Brownjohn, AM | 1 |
| Fu, KP | 1 |
| Hetzel, N | 1 |
| Gregory, FJ | 1 |
| Hung, PP | 1 |
| Bowyer, H | 1 |
| Willis, J | 1 |
| Brown, EM | 1 |
| Morris, R | 1 |
| Stephenson, TP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Subjects With Non-Cystic Fibrosis Bronchiectasis, Including 28 [NCT01515007] | Phase 3 | 278 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 [NCT02104245] | Phase 3 | 304 participants (Actual) | Interventional | 2014-05-28 | Completed | ||
| Efficacy and Safety of tobRamycin Inhalation Solution for Pseudomonas AeruginoSa Eradication in Bronchiectasis (ERASE): Study Protocol for a Multi-center, 2×2 Factorial Randomized, Double-blind, Placebo-controlled Trial[NCT06093191] | Phase 4 | 364 participants (Anticipated) | Interventional | 2023-09-25 | Recruiting | ||
| Research on the Mechanism Affecting Progression of Bronchiectasis Based on Omics Method[NCT05731427] | 150 participants (Anticipated) | Observational | 2021-02-01 | Recruiting | |||
| Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmona[NCT01764841] | Phase 3 | 416 participants (Actual) | Interventional | 2013-05-02 | Completed | ||
| Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmona[NCT02106832] | Phase 3 | 521 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Transfer Routes of Antibiotic Resistance[NCT03343119] | 708 participants (Actual) | Observational | 2012-03-27 | Active, not recruiting | |||
| Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease[NCT04803695] | 96 participants (Anticipated) | Observational | 2018-03-01 | Recruiting | |||
| Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Non-cystic Fibrosis Bronchiectasis: a Cross-over, Unicentric, Double-blind and Placebo-controlled Study[NCT03988816] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-12-06 | Recruiting | ||
| Longitudinal Assessment of Risk Factors For and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children With CF[NCT00676169] | 1,248 participants (Actual) | Observational | 2004-10-31 | Completed | |||
| Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic Fibrosis[NCT00097773] | Phase 2 | 304 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Prospective Randomized Trial Comparing Oral Ciproxin Plus Inhaled Colistin With Tobramycin for Inhalation for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis.[NCT01400750] | Phase 4 | 61 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Supplementary Oral Azithromycin in Treatment of Intermittent Pseudomonas Aeruginosa Colonization in CF-patients With Inhaled Colistin and Oral Ciprofloxacin; Postponing Next Isolate of Pseudomonas and Prevention of Chronic Infection. A Prospective, Double[NCT00411736] | Phase 4 | 45 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Efficacy and Safety of Inhaled Tobramycin on Bronchiectasis Colonized With Pseudomonas Aeruginosa: A Randomized, Double-blind, Parallel-group Multicenter Trial[NCT03715322] | Phase 3 | 350 participants (Anticipated) | Interventional | 2018-10-26 | Recruiting | ||
| Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Hospitalized Subjects With Pneumonia Requiring Mechanical Ventilation[NCT01570192] | Phase 2 | 43 participants (Actual) | Interventional | 2010-09-30 | Terminated (stopped due to NIAID terminated the study due to low subject enrollment) | ||
| Endobronchial Valve for Emphysema PalliatioN Trial (VENT) Cost-effectiveness Sub-Study[NCT00137956] | Phase 3 | 270 participants | Interventional | 2004-12-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
FEV1 was defined as the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS). (NCT01764841)
Timeframe: Baseline and end of treatment (Week 44/46)
| Intervention | Liter (Mean) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | -0.012 |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | -0.026 |
| Placebo 28 Days on/Off (Placebo 28) | 0.024 |
| Placebo 14 Days on/Off (Placebo 14) | 0.022 |
The QoL-B was a disease-specific questionnaire developed for non-Cystic fibrosis Bronchiectasis. It covers 8 dimensions: physical functioning, role functioning, emotional functioning, social functioning, vitality, treatment burden, health perceptions, and respiratory symptoms. Each dimension was scored separately on a scale of 0 to 100, and higher scores represent better outcomes. For this outcome measure, the respiratory symptoms domain score was reported. (NCT01764841)
Timeframe: Baseline and end of treatment (Week 44/46)
| Intervention | Score on a scale (Mean) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 7.70 |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 6.72 |
| Placebo 28 Days on/Off (Placebo 28) | 8.22 |
| Placebo 14 Days on/Off (Placebo 14) | 4.45 |
The SGRQ was a validated, disease-specific instrument that measures health-related quality of life (HRQoL) in adults with chronic obstructive pulmonary disease (COPD) and asthma and was later validated for use in bronchiectasis. The SGRQ covers 3 dimensions: symptoms, activity and impact on daily life. To determine the outcome, a score ranging from 1 to 100 was calculated for each individual domain and for the total score, and smaller scores indicate better health status. For this outcome measure, the symptoms component score was reported. (NCT01764841)
Timeframe: Baseline and end of treatment (Week 44/46)
| Intervention | Score on a scale (Mean) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | -8.17 |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | -7.20 |
| Placebo 28 Days on/Off (Placebo 28) | -4.23 |
| Placebo 14 Days on/Off (Placebo 14) | 2.78 |
Time to first exacerbation was defined as the time from randomization until the visit at which the first qualifying exacerbation is recorded by the investigator. Exacerbation events are defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms. (NCT01764841)
Timeframe: Up to Week 48
| Intervention | Days (Median) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 336 |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | NA |
| Pooled Placebo | 186 |
For this outcome measure, exacerbation events were defined as exacerbations with systemic antibiotic use and worsening of at least one sign/symptom over 48 weeks. (NCT01764841)
Timeframe: Up to Week 48
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Number of exacerbations: 0 | Number of exacerbations: 1 | Number of exacerbations: 2 | Number of exacerbations: 3 | Number of exacerbations: 4 | Number of exacerbations: 5 | Number of exacerbations: 6 | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 68 | 42 | 15 | 5 | 2 | 3 | 2 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 58 | 47 | 12 | 14 | 4 | 4 | 2 |
| Pooled Placebo | 46 | 43 | 31 | 11 | 5 | 2 | 0 |
For this outcome measure, exacerbation events were defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms over 48 weeks. (NCT01764841)
Timeframe: Up to Week 48
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Number of exacerbations: 0 | Number of exacerbations: 1 | Number of exacerbations: 2 | Number of exacerbations: 3 | Number of exacerbations: 4 | Number of exacerbations: 5 | Number of exacerbations: 6 | Number of exacerbations: 7 | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 72 | 38 | 13 | 8 | 3 | 2 | 0 | 1 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 66 | 44 | 12 | 12 | 3 | 1 | 0 | 3 |
| Pooled Placebo | 44 | 58 | 19 | 7 | 8 | 0 | 1 | 1 |
New pathogens were any of the pre-specified organisms not cultured before start of study medication. There was no imputation for participants who discontinued the study prematurely. (NCT01764841)
Timeframe: End of treatment (Week 44/46)
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| No | Yes | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 49.6 | 5.1 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 60.3 | 3.5 |
| Pooled Placebo | 42.8 | 8.0 |
Pathogen eradication was defined as a negative culture result for all pre-specified pathogens at end of treatment (week 44 or 46 depending on treatment regimen) that were present in the participant at baseline. There was no imputation for participants who discontinued the study prematurely. (NCT01764841)
Timeframe: End of treatment (Week 44/46)
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| No | Yes | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 26.3 | 28.5 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 39.0 | 24.1 |
| Pooled Placebo | 33.3 | 16.7 |
FEV1 was defined as the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS). (NCT02106832)
Timeframe: Baseline and end of treatment (Week 44/46)
| Intervention | Liter (Mean) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 0.038 |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | -0.037 |
| Placebo 28 Days on/Off (Placebo 28) | -0.038 |
| Placebo 14 Days on/Off (Placebo 14) | 0.037 |
The QoL-B was a disease-specific questionnaire developed for non-Cystic fibrosis Bronchiectasis. It covers 8 dimensions: physical functioning, role functioning, emotional functioning, social functioning, vitality, treatment burden, health perceptions, and respiratory symptoms. Each dimension was scored separately on a scale of 0 to 100, and higher scores represent better outcomes. For this outcome measure, the respiratory symptoms domain score was reported. (NCT02106832)
Timeframe: Baseline and end of treatment (Week 44/46)
| Intervention | Score on a scale (Mean) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 11.57 |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 10.90 |
| Placebo 28 Days on/Off (Placebo 28) | 7.08 |
| Placebo 14 Days on/Off (Placebo 14) | 10.70 |
The SGRQ was a validated, disease-specific instrument that measures health-related quality of life (HRQoL) in adults with chronic obstructive pulmonary disease (COPD) and asthma and was later validated for use in bronchiectasis. The SGRQ covers 3 dimensions: symptoms, activity and impact on daily life. To determine the outcome, a score ranging from 1 to 100 was calculated for each individual domain and for the total score, and smaller scores indicate better health status. For this outcome measure, the symptoms component score was reported. (NCT02106832)
Timeframe: Baseline and end of treatment (Week 44/46)
| Intervention | Score on a scale (Mean) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | -8.92 |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | -9.02 |
| Placebo 28 Days on/Off (Placebo 28) | -2.91 |
| Placebo 14 Days on/Off (Placebo 14) | -11.50 |
Time to first exacerbation was defined as the time from randomization until the visit at which the first qualifying exacerbation is recorded by the investigator. Exacerbation events are defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms. (NCT02106832)
Timeframe: Up to Week 48
| Intervention | Days (Median) |
|---|---|
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | NA |
| Pooled Placebo | NA |
Time to first exacerbation was defined as the time from randomization until the visit at which the first qualifying exacerbation is recorded by the investigator. Exacerbation events are defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms. (NCT02106832)
Timeframe: Up to Week 48
| Intervention | Days (Median) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | NA |
| Pooled Placebo | NA |
For this outcome measure, exacerbation events were defined as exacerbations with systemic antibiotic use and worsening of at least one sign/symptom over 48 weeks. (NCT02106832)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Number of exacerbations: 0 | Number of exacerbations: 1 | Number of exacerbations: 2 | Number of exacerbations: 3 | Number of exacerbations: 4 | Number of exacerbations: 5 | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 96 | 46 | 26 | 4 | 3 | 1 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 102 | 51 | 14 | 3 | 1 | 0 |
| Pooled Placebo | 90 | 45 | 22 | 11 | 4 | 2 |
For this outcome measure, exacerbation events were defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms over 48 weeks. (NCT02106832)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Number of exacerbations: 0 | Number of exacerbations: 1 | Number of exacerbations: 2 | Number of exacerbations: 3 | Number of exacerbations: 4 | Number of exacerbations: 5 | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 108 | 40 | 23 | 4 | 1 | 0 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 115 | 46 | 8 | 2 | 0 | 0 |
| Pooled Placebo | 101 | 41 | 19 | 10 | 2 | 1 |
New pathogens were any of the pre-specified organisms not cultured before start of study medication. There was no imputation for participants who discontinued the study prematurely. (NCT02106832)
Timeframe: End of treatment (Week 44/46)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| No | Yes | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 67.6 | 4.0 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 62.6 | 4.1 |
| Pooled Placebo | 61.5 | 10.3 |
Pathogen eradication was defined as a negative culture result for all pre-specified pathogens at end of treatment (week 44 or 46 depending on treatment regimen) that were present in the participant at baseline. There was no imputation for participants who discontinued the study prematurely. (NCT02106832)
Timeframe: End of treatment (Week 44/46)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| No | Yes | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 35.8 | 35.8 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 35.1 | 31.6 |
| Pooled Placebo | 40.2 | 31.6 |
"The primary comparison is between the pooled culture-based group and the pooled cycled group. A secondary comparison is between the pooled ciprofloxacin group vs the pooled placebo group. Descriptive results are provided for the pooled treatment groups.~Participants are represented once in the cycled and culture-based therapy columns, and once in the cipro and placebo columns." (NCT00097773)
Timeframe: Measured over the 18 month study
| Intervention | number of participants (Number) |
|---|---|
| Cycled TIS | 24 |
| Culture-Based TIS | 26 |
| Oral Ciprofloxacin | 29 |
| Oral Placebo | 21 |
"The primary comparison is between the pooled culture-based group and the pooled cycled group. No interactions with ciprofloxacin were identified. A secondary comparison is between the pooled ciprofloxacin group vs the pooled placebo group. Descriptive results are provided for the pooled treatment groups.~Participants are represented once in the cycled and culture-based therapy columns, and once in the cipro and placebo columns." (NCT00097773)
Timeframe: Measured over the 18 month time period
| Intervention | participants (Number) |
|---|---|
| Cycled TIS | 70 |
| Culture-Based TIS | 81 |
| Oral Ciprofloxacin | 83 |
| Oral Placebo | 68 |
"Proportion of participants with a Pa positive culture compared between (1) the pooled cycled therapy group (n=152) and pooled culture-based therapy group (n=152), and (2) between the pooled oral placebo (n=152)and pooled cipro groups (n=152).~Participants are included once in the cycled and culture-based columns, and once in the oral cipro and placebo columns" (NCT00097773)
Timeframe: Week 10 (after initial treatment course for Pa) through Month 18
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| No Pa positive cultures | 1 Pa positive culture | 2 Pa positive cultures | 3 or more Pa positive cultures | Missing | |
| Culture-Based TIS | 85 | 38 | 18 | 9 | 2 |
| Cycled TIS | 109 | 17 | 9 | 13 | 4 |
| Oral Cipro | 97 | 22 | 13 | 14 | 6 |
| Oral Placebo | 97 | 33 | 14 | 8 | 0 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| MEGroup - Meropenem Only | 8 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 8 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 2 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 1 |
| m-MITT Group - Meropenem Only | 2 |
Percentage of patients who died by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 0 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 2 |
Percentage of patients who died by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| ME Group - Meropenem Only | 1 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 3 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: Day 5/Early Extubation
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 3 |
| ME Group - Meropenem Only | 6 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 7 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| ME Group - Meropenem Only | 6 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 7 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 3 |
| ME Group - Meropenem Only | 9 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 11 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: Day 5/Early Extubation
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 1 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 1 |
| m-MITT Group - Meropenem Only | 2 |
The emergence of resistance is defined as a change of meropenem MIC or aminoglycoside MIC by two tube dilutions (fourfold) from baseline when assessed at the second BAL procedure on day 5/early extubation. Patients are evaluable for this endpoint IF they had baseline BAL and Day 5/early extubation and if they had positive cultures on baseline and Day/EE. (NCT01570192)
Timeframe: up to 28 days after enrollment
| Intervention | participants (Number) | |
|---|---|---|
| suppression of emergence of resistance | emergence of resistance | |
| I.V. Meropenem | 5 | 1 |
37 reviews available for ciprofloxacin and Infections, Pseudomonas
| Article | Year |
|---|---|
Murine burn lesion model for studying acute and chronic wound infections.
Topics: Animals; Biofilms; Burns; Calgranulin A; Ciprofloxacin; Disease Models, Animal; Humans; Mice; Pseudo | 2022 |
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Colistin; | 2023 |
Bacteriophages: The promising therapeutic approach for enhancing ciprofloxacin efficacy against bacterial infection.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Bacteriophages; Ciprofloxacin; Mice; Pseudomon | 2023 |
A retrospective review and multi-specialty, evidence-based guideline for the management of necrotising otitis externa.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Cranial Nerve Diseases; Disease Progr | 2020 |
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adult; Anti-Bacterial Agents; Child; Ciprofloxacin | 2017 |
Inhaled or nebulised ciprofloxacin for the maintenance treatment of bronchiectasis.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Drug Resi | 2017 |
Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug-device combination.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Dry Powder Inhaler | 2018 |
Community Acquired Pseudomonas Aeruginosa Pneumonia in a Young Athlete Man: A Case Report and Literature Review.
Topics: Adult; Athletes; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Fatal Outcome; Femal | 2018 |
Dual antibiotics for bronchiectasis.
Topics: Adult; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Gentamicins; Humans; Middle Aged; Pseud | 2018 |
Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new approaches to an old problem.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Hu | 2019 |
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adult; Anti-Bacterial Agents; Child; Ciprofloxacin | 2014 |
Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Anti-Bacterial Agents; Chronic Disease; Ciprofloxa | 2015 |
Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Bronchiectasis; Ciprofloxacin; Colistin; Disease | 2017 |
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adult; Anti-Bacterial Agents; Child; Ciprofloxacin | 2009 |
Pseudomonal breast infection.
Topics: Abscess; Anti-Bacterial Agents; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Mastitis; | 2010 |
Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Ciprofloxacin; Drug Resistance, Bacter | 2011 |
[Multi-drug resistant Pseudomonas aeruginosa: towards a therapeutic dead end?].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colistin; Cross Infection; Drug Resistance, Multiple; Humans; | 2010 |
Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Clinical | 2012 |
Antibiotic therapy in necrotising external otitis: case series of 32 patients and review of the literature.
Topics: Adult; Aged; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Drug Therapy, Combination; Female; F | 2012 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Disease Progression; Dr | 2013 |
Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Clinical Trials a | 2012 |
Ecthyma gangrenosum: considerations in a previously healthy child.
Topics: Administration, Oral; Chronic Disease; Ciprofloxacin; Ecthyma; Female; Follow-Up Studies; Granulocyt | 2002 |
Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Humans; Italy; Levofloxacin; Micro | 2004 |
Eradication of early Pseudomonas aeruginosa infection.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Colistin; Cystic Fibro | 2005 |
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchopneumonia; Cefepime; Ceftazidime; Cep | 2005 |
Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Re | 2006 |
[Two cases of Pseudomonas aeruginosa neonatal meningitis treated by ciprofloxacine].
Topics: Anti-Infective Agents; Ciprofloxacin; Female; Humans; Infant, Newborn; Male; Meningitis, Bacterial; | 2006 |
Fluoroquinolones in the treatment of cystic fibrosis.
Topics: Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Ofloxacin; Pseudomonas Infections | 1993 |
Cystic fibrosis and endobronchial pseudomonas infection.
Topics: Bronchial Diseases; Burkholderia cepacia; Child; Ciprofloxacin; Cystic Fibrosis; Humans; Lung Transp | 1993 |
Ventilator-associated pneumonia caused by Pseudomonas infection.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactam Resistance; Ciprofloxacin; Drug Resistance, Micr | 1995 |
Ciprofloxacin in the treatment of malignant external otitis.
Topics: Administration, Oral; Aged; Ciprofloxacin; Drug Administration Schedule; Enterobacteriaceae; Female; | 1994 |
Laryngeal edema related to ciprofloxacin therapy.
Topics: Aged; Aged, 80 and over; Ciprofloxacin; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Del | 1992 |
Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.
Topics: Adolescent; Adult; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Mi | 1991 |
Insights from experimental data on ciprofloxacin in the treatment of bacterial keratitis and ocular infections.
Topics: Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; Eye Diseases; Humans; Keratitis; Ps | 1991 |
Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches.
Topics: Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Osteomyelitis; Pseudomonas aerug | 1990 |
Ciprofloxacin in the treatment of acute and chronic osteomyelitis: a review.
Topics: Bacterial Infections; Ciprofloxacin; Drug Evaluation; Gram-Negative Bacteria; Humans; Osteomyelitis; | 1989 |
[Ciprofloxacin--a new antibacterial drug].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Clinical Trials as Topic; Enterobacteriaceae Infections; Human | 1985 |
60 trials available for ciprofloxacin and Infections, Pseudomonas
| Article | Year |
|---|---|
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
Multidrug resistant Pseudomonas aeruginosa in Estonian hospitals.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Ciprofloxacin; Disease Outbreaks; DNA, Bacterial; Drug | 2018 |
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind Metho | 2019 |
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind Metho | 2019 |
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind Metho | 2019 |
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind Metho | 2019 |
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Delayed-Acti | 2013 |
Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Drug Admin | 2013 |
Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Cip | 2015 |
Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cys | 2015 |
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Topics: Age Factors; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cohort Studies; Cystic F | 2009 |
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Topics: Age Factors; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cohort Studies; Cystic F | 2009 |
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Topics: Age Factors; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cohort Studies; Cystic F | 2009 |
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Topics: Age Factors; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cohort Studies; Cystic F | 2009 |
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Male | 2012 |
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Chil | 2011 |
Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
Topics: Administration, Inhalation; Administration, Oral; Anti-Bacterial Agents; Chi-Square Distribution; Ch | 2012 |
Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Child; Child, | 2013 |
Infecton: a 99mTc-ciprofloxacin radiopharmaceutical for the detection of bone infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Ciprofloxacin; Citrates; Diphosphonates; Female; | 2003 |
Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-B | 2006 |
Complicated urinary tract infections treated with extended-release ciprofloxacin with emphasis on Pseudomonas aeruginosa.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Delayed-Action Preparations; D | 2007 |
Controlled prospective study of oral ciprofloxacin versus amoxycillin/clavulanic acid in chronic suppurative otitis media in adults.
Topics: Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacterial Infections; Chronic Dis | 1994 |
Study of the efficacy and safety of ciprofloxacin in the treatment of chronic otitis.
Topics: Adult; Bacterial Infections; Chronic Disease; Ciprofloxacin; Earache; Female; Humans; Male; Middle A | 1994 |
Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis.
Topics: Adult; Aged; Bronchiectasis; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Sc | 1994 |
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.
Topics: Adult; Aged; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin | 1994 |
Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa.
Topics: Administration, Oral; Adult; Chronic Disease; Ciprofloxacin; Cystic Fibrosis; Double-Blind Method; D | 1993 |
Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.
Topics: Adolescent; Aerosols; Bronchial Diseases; Child; Child, Preschool; Chronic Disease; Ciprofloxacin; C | 1993 |
Treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; D | 1995 |
Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.
Topics: Adult; Anti-Infective Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross-Over Studies; Drug R | 1995 |
Sepsis associated with hematological malignancies: prophylaxis of Pseudomonas aeruginosa sepsis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Bacteremia; Ciprofloxacin; Drug | 1996 |
Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
Topics: Acute Disease; Adolescent; Anti-Infective Agents; Arthralgia; Ceftazidime; Child; Child, Preschool; | 1997 |
Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis.
Topics: Adolescent; Adult; Amikacin; Anti-Infective Agents; Ceftazidime; Child; Ciprofloxacin; Cystic Fibros | 1997 |
Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
Topics: Acute Disease; Administration, Oral; Adolescent; Anti-Infective Agents; Biological Availability; Chi | 1997 |
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Carrier State; Child; Child, Presch | 1997 |
Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group.
Topics: Administration, Oral; Adolescent; Cartilage; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Cy | 1997 |
Chronic otitis media treated topically with ciprofloxacin or tobramycin.
Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; | 1997 |
[Local treatment of purulent chronic otitis media with ciprofloxacin].
Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; | 1998 |
Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosi | 1998 |
Clinical pharmacokinetics of ciprofloxacin in patients with major burns.
Topics: Adult; Aged; Anti-Infective Agents; Area Under Curve; Burns; Ciprofloxacin; Female; Humans; Male; Me | 1999 |
Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Case-Control Studies; Ceftazidi | 2002 |
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment.
Topics: Child; Child, Preschool; Chronic Disease; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Therapy, Co | 1991 |
Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.
Topics: Adolescent; Adult; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Mi | 1991 |
Oral ciprofloxacin for treatment of acute bacterial pharyngotonsillitis.
Topics: Administration, Oral; Adult; Aged; Ciprofloxacin; Clinical Trials as Topic; Drug Administration Sche | 1990 |
Ciprofloxacin in severe infections.
Topics: Adolescent; Adult; Aged; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Middle Aged; Pse | 1990 |
Topical and oral treatment of chronic otitis media with ciprofloxacin. A preliminary study.
Topics: Administration, Oral; Administration, Topical; Adult; Chronic Disease; Ciprofloxacin; Drug Administr | 1990 |
Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin.
Topics: Adolescent; Adult; Amikacin; Aztreonam; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Cystic | 1989 |
A comparative study of ciprofloxacin and conventional therapy in the treatment of patients with chronic lower leg ulcers infected with Pseudomonas aeruginosa or other gram-negative rods.
Topics: Administration, Oral; Aged; Bacterial Infections; Chlorhexidine; Ciprofloxacin; Disinfectants; Drug | 1989 |
Use of ciprofloxacin in cystic fibrosis patients.
Topics: Adult; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; Lung Diseases; Ma | 1989 |
Ciprofloxacin for the treatment of chronic ear disease.
Topics: Adult; Aged; Cholesteatoma; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Female; Humans | 1989 |
Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Azlocillin; Ciprofloxacin; Clinical Trials a | 1987 |
[Ciprofloxacin--a new antibacterial drug].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Clinical Trials as Topic; Enterobacteriaceae Infections; Human | 1985 |
[A cross-over study on the effectiveness of ofloxacin and ciprofloxacin administered orally].
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Clinical Trials as To | 1986 |
Ciprofloxacin in the treatment of urinary tract infections caused by Pseudomonas aeruginosa and multiresistant bacteria.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Clinical Trials a | 1986 |
Ciprofloxacin for respiratory tract infection with Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bronchitis; Ciprofloxacin; Clinical Trials as Topic; Dru | 1987 |
Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.
Topics: Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibro | 1987 |
Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients.
Topics: Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Double-Blind Method; Femal | 1987 |
The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Double-Blind Method; Drug | 1987 |
Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis.
Topics: Adolescent; Adult; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Female; Humans; Kinetic | 1987 |
Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis.
Topics: Adolescent; Adult; Bronchopneumonia; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Femal | 1987 |
Ciprofloxacin: comparative data in cystic fibrosis.
Topics: Adolescent; Adult; Azlocillin; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Therap | 1987 |
Ciprofloxacin therapy in cystic fibrosis.
Topics: Adolescent; Adult; Azlocillin; Child; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug | 1987 |
Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis.
Topics: Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Drug Tolerance; Female; Gram-Negative | 1987 |
Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli.
Topics: Adult; Aged; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Digestive System; Female | 1987 |
Oral ciprofloxacin in resistant urinary tract infections.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Clinical | 1987 |
Treatment of serious infections with intravenous ciprofloxacin.
Topics: Administration, Oral; Adult; Aged; Arthritis, Infectious; Bacterial Infections; Ciprofloxacin; Clini | 1987 |
572 other studies available for ciprofloxacin and Infections, Pseudomonas
| Article | Year |
|---|---|
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Carboxylic Acids; Escherichia coli Infections; | 1992 |
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Drug Interactions; Fluoroquinolones; Male; Mice; Micro | 1990 |
7-Azetidinylquinolones as antibacterial agents. 3. Synthesis, properties and structure-activity relationships of the stereoisomers containing a 7-(3-amino-2-methyl-1-azetidinyl) moiety.
Topics: Animals; Anti-Bacterial Agents; Azetidinecarboxylic Acid; Chemical Phenomena; Chemistry, Physical; C | 1995 |
In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.
Topics: Animals; beta-Lactamases; Burns; Cephalosporins; Drug Resistance, Multiple, Bacterial; Lung Diseases | 2007 |
Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Drug Resistance, Multiple, Bacterial; Female; Hu | 2007 |
Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil.
Topics: Amino Acid Sequence; Aminoglycosides; beta-Lactamases; Brazil; Carbapenems; Cloning, Molecular; Drug | 2007 |
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Drug Resistance, Bacterial; Humans; Long | 2007 |
Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Carrier State; Critical Ill | 2007 |
Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Resistance, | 2007 |
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactams; DNA, Bacterial; Drug Resistance, B | 2007 |
Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; Cefep | 2008 |
Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbenicillin; Ceftazidime; Ciprofloxacin; Drug Resistance, | 2008 |
Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Ciprofloxacin; DNA Primers; D | 2008 |
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
Topics: Bacterial Proteins; beta-Lactamases; Cross Infection; Electrophoresis, Gel, Pulsed-Field; Humans; In | 2008 |
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactam Resistanc | 2008 |
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
Topics: Base Sequence; beta-Lactam Resistance; Carbapenems; DNA Primers; DNA, Bacterial; Doripenem; Fluoroqu | 2008 |
First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
Topics: Austria; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Humans; Microbia | 2009 |
Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta- | 2009 |
Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Gene Expression Regulation, Bacterial; Humans; Microbial | 2009 |
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavula | 2009 |
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Administration Schedule; Female; Humans | 2009 |
Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Catheters, Indwelling; Chromosomes, Bac | 2010 |
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion.
Topics: Alleles; beta-Lactamases; Conjugation, Genetic; Drug Resistance, Bacterial; Electrophoresis, Gel, Pu | 2010 |
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bact | 2010 |
Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Humans; Mal | 2010 |
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; | 2010 |
Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Cystic Fibrosis; Drug Resist | 2010 |
Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Ciprofloxacin; Colony Count, Microbial; Cr | 2010 |
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Drug Resistance, Bacterial; Germany; Hospitals, | 2010 |
Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Cephalosporin Resistance; France; Humans; Micro | 2010 |
Potent inhibitors of LpxC for the treatment of Gram-negative infections.
Topics: Amidohydrolases; Animals; Anti-Bacterial Agents; Biphenyl Compounds; Catalytic Domain; Crystallograp | 2012 |
Novel amalgamation of phthalazine-quinolines as biofilm inhibitors: One-pot synthesis, biological evaluation and in silico ADME prediction with favorable metabolic fate.
Topics: Anti-Infective Agents; Biofilms; Candida albicans; Candidiasis; Computer Simulation; Humans; Phthala | 2016 |
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; | 2016 |
Novel Design of Heptad Amphiphiles To Enhance Cell Selectivity, Salt Resistance, Antibiofilm Properties and Their Membrane-Disruptive Mechanism.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Biofilms; Circular Dichr | 2017 |
Synthesis and evaluation of adenosine containing 3-arylfuran-2(5H)-ones as tyrosyl-tRNA synthetase inhibitors.
Topics: Adenosine; Anti-Bacterial Agents; Enzyme Inhibitors; Escherichia coli; Escherichia coli Infections; | 2017 |
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Topics: Amidohydrolases; Animals; Anti-Bacterial Agents; Chemistry Techniques, Synthetic; Crystallography, X | 2017 |
Tandem Repeat of a Short Human Chemerin-Derived Peptide and Its Nontoxic d-Lysine-Containing Enantiomer Display Broad-Spectrum Antimicrobial and Antitubercular Activities.
Topics: Animals; Antimicrobial Peptides; Antitubercular Agents; Cell Survival; Chemokines; Dose-Response Rel | 2021 |
New
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Line; Cell Survival; Colony Count, Microbial; Drug Re | 2022 |
Lectin-Targeted Prodrugs Activated by
Topics: Anti-Bacterial Agents; Biofilms; Fluoroquinolones; Humans; Lectins; Prodrugs; Pseudomonas aeruginosa | 2022 |
Bioengineered phytomolecules-capped silver nanoparticles using Carissa carandas leaf extract to embed on to urinary catheter to combat UTI pathogens.
Topics: Anti-Bacterial Agents; Apocynaceae; Biofilms; Ciprofloxacin; Escherichia coli; Escherichia coli Infe | 2021 |
Antibiogram and molecular characterization of multi-drug resistant microorganisms isolated from urinary tract infections.
Topics: Amikacin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ciprofloxacin; Drug | 2021 |
Real-time monitoring of
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Humans; Microbial Sensitivity Tests; Microbial Viabi | 2021 |
Adjunctive Thymosin Beta-4 Treatment Influences MΦ Effector Cell Function to Improve Disease Outcome in
Topics: Animals; Ciprofloxacin; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Inflammation; | 2021 |
Effects of ciprofloxacin or co-amoxicillin with and without antidepressants on behavioral deficit in rats induced with chronic suppurative otitis media.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Antidepressive Agents; Anxiety; Behavior, Animal; Cipro | 2021 |
Lactoferricin-inspired peptide AMC-109 augments the effect of ciprofloxacin against Pseudomonas aeruginosa biofilm in chronic murine wounds.
Topics: Animals; Biofilms; Ciprofloxacin; Mice; Mice, Inbred BALB C; Peptides; Pseudomonas aeruginosa; Pseud | 2022 |
An adaptable microreactor to investigate the influence of interfaces on Pseudomonas aeruginosa biofilm growth.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Humans; Microbial Sensitivity Tests; Pseudomonas aer | 2022 |
Effectiveness of different eradication treatment protocols for new-onset Pseudomonas aeruginosa in children with cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Child; Ciprofloxacin; Clinical Protocols; Cystic | 2022 |
Resistance mechanisms and molecular epidemiology of Pseudomonas aeruginosa strains from patients with bronchiectasis.
Topics: Anti-Bacterial Agents; beta-Lactamases; Bronchiectasis; Ceftazidime; Ciprofloxacin; Humans; Microbia | 2022 |
Mutational background influences
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Collateral Sensitivity; Drug Resistance, Bacterial; Human | 2022 |
Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant Pseudomonas aeruginosa Clinical Isolates.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Humans; Meropenem; Microbial Sensitivity Tests; Pseudomonas ae | 2022 |
LipNanoCar Technology - A Versatile and Scalable Technology for the Production of Lipid Nanoparticles.
Topics: Animals; Anti-Bacterial Agents; Caenorhabditis elegans; Ciprofloxacin; Cystic Fibrosis; Liposomes; N | 2022 |
Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: In vitro synergy testing.
Topics: Anti-Bacterial Agents; Bacteriophages; Ciprofloxacin; Colistin; Drug Resistance, Multiple, Bacterial | 2022 |
Evaluation of the effect of ibuprofen in combination with ciprofloxacin on the virulence-associated traits, and efflux pump genes of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Ciprofloxacin; Humans; Ibuprofen; Membrane | 2022 |
Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Colistin; Deoxyribonucleases; Drug Resi | 2022 |
Colistin conditioning surfaces combined with antimicrobial treatment to prevent ventilator-associated infections.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Biofilms; Ciprofloxacin; Colistin; Humans; Pseudomonas | 2022 |
Hetero-Multivalent Targeted Liposomal Drug Delivery to Treat
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Liposomes; Mice; Microbial Sen | 2022 |
The Selection of Antibiotic- and Bacteriophage-Resistant Pseudomonas aeruginosa Is Prevented by Their Combination.
Topics: Anti-Bacterial Agents; Bacteriophages; Ciprofloxacin; Humans; Pseudomonas aeruginosa; Pseudomonas In | 2022 |
Correlation between antibiotic consumption and resistance of Pseudomonas aeruginosa in a teaching hospital implementing an antimicrobial stewardship program: A longitudinal observational study.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antimicrobial Stewardship; Ciprofloxacin; Hospitals, T | 2023 |
Lactose azocalixarene drug delivery system for the treatment of multidrug-resistant pseudomonas aeruginosa infected diabetic ulcer.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Biofilms; Ciprofloxacin; Delayed-Action Preparations; | 2022 |
The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colistin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests | 2022 |
The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colistin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests | 2022 |
The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colistin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests | 2022 |
The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colistin; Cystic Fibrosis; Humans; Microbial Sensitivity Tests | 2022 |
Impact of fluoroquinolones and aminoglycosides on P. aeruginosa virulence factor production and cytotoxicity.
Topics: ADP Ribose Transferases; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Pr | 2022 |
Impact of fluoroquinolones and aminoglycosides on P. aeruginosa virulence factor production and cytotoxicity.
Topics: ADP Ribose Transferases; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Pr | 2022 |
Impact of fluoroquinolones and aminoglycosides on P. aeruginosa virulence factor production and cytotoxicity.
Topics: ADP Ribose Transferases; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Pr | 2022 |
Impact of fluoroquinolones and aminoglycosides on P. aeruginosa virulence factor production and cytotoxicity.
Topics: ADP Ribose Transferases; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Pr | 2022 |
Rapid Phenotypic Convergence towards Collateral Sensitivity in Clinical Isolates of Pseudomonas aeruginosa Presenting Different Genomic Backgrounds.
Topics: Anti-Bacterial Agents; Aztreonam; Ciprofloxacin; Drug Collateral Sensitivity; Genomics; Humans; Micr | 2023 |
Design and Synthesis of 3-Hydroxy-pyridin-4(1
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Humans; Microbial Sensitivity Tests; Pseudomonas aer | 2023 |
Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates.
Topics: Agar; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Gentamicins; Humans; Imipenem; Keratitis; L | 2023 |
Genomics of Aminoglycoside Resistance in Pseudomonas aeruginosa Bloodstream Infections at a United States Academic Hospital.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ciprofloxacin; Colistin; Drug Resistance, Bacterial; Genomic | 2023 |
The value of biofilm testing to guide antimicrobial stewardship in chronic respiratory diseases.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Biofilms; Ciprofloxacin; Humans; Phenotype; Pseudo | 2023 |
An rRNA fragment in extracellular vesicles secreted by human airway epithelial cells increases the fluoroquinolone sensitivity of
Topics: Anti-Bacterial Agents; Ciprofloxacin; Extracellular Vesicles; Fluoroquinolones; Humans; Pseudomonas | 2023 |
Management and Clinical Outcomes of 37 Patients with Necrotizing Otitis Externa: Retrospective Review of a Standardized 6-Week Treatment Pathway.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Humans; Otitis Externa; Pseudo | 2023 |
Determining effects of nitrate, arginine, and ferrous on antibiotic recalcitrance of clinical strains of Pseudomonas aeruginosa in biofilm-inspired alginate encapsulates.
Topics: Alginates; Amikacin; Anti-Bacterial Agents; Arginine; Biofilms; Ciprofloxacin; Cystic Fibrosis; Huma | 2023 |
Population pharmacokinetic modeling of the influence of chronic and acute biofilm-forming Pseudomonas aeruginosa lung infection on ciprofloxacin free pulmonary and epithelial lining fluid concentrations.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Humans; Lung; Microbial Sensitivity Tests; | 2023 |
Evaluated gene expressions of Metallo beta lactamase genes GIM and , VIM, SPM in Pseudomonas aeruginosa clinical isolates.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Child; Ciprofloxacin; Gene Expression; Humans; | 2023 |
Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Bacteriophages; Chemistry, Pharmaceutic | 2019 |
Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model.
Topics: Anti-Bacterial Agents; Cell Line; Ciprofloxacin; Colistin; Epithelial Cells; Humans; Liposomes; Lung | 2019 |
In vitro evaluation of Pseudomonas aeruginosa chronic lung infection models: Are agar and calcium-alginate beads interchangeable?
Topics: Agar; Alginates; Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Lung; Pseudo | 2019 |
Genomic and phenotypic comparison of environmental and patient-derived isolates of
Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Bacterial; Envi | 2019 |
Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Animals; Anti-Bacterial Agents; Azithromycin; Biofilms; | 2019 |
Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).
Topics: Anti-Bacterial Agents; Awareness; Ciprofloxacin; Cystic Fibrosis; Health Occupations; Humans; Levofl | 2020 |
Expression of T9W in Pichia pastoris and the protective roles of T9W in ICR Mice.
Topics: Animals; Anti-Infective Agents; Antimicrobial Cationic Peptides; Ciprofloxacin; Disease Models, Anim | 2020 |
Controlled delivery of ciprofloxacin and ivacaftor via sinus stent in a preclinical model of Pseudomonas sinusitis.
Topics: Aminophenols; Animals; Chronic Disease; Ciprofloxacin; Maxillary Sinus; Pseudomonas; Pseudomonas Inf | 2020 |
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Cefuroxime; Ciprofloxacin; Cloxacillin; D | 2020 |
Anti-microbial Effect and in Vivo Ocular Delivery of Ciprofloxacin-loaded Liposome through Rabbit's Eye.
Topics: Acrylic Resins; Animals; Anti-Bacterial Agents; Aqueous Humor; Area Under Curve; Biological Availabi | 2020 |
Naringin sensitizes the antibiofilm effect of ciprofloxacin and tetracycline against Pseudomonas aeruginosa biofilm.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Line; Ciprofloxacin; Flavanones; Macrophages; Mice; M | 2020 |
Identification of Essential Residues for Ciprofloxacin Resistance of Ciprofloxacin-Modifying Enzyme (CrpP) of pUM505.
Topics: Amino Acids; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ciprofloxacin; Drug Resista | 2020 |
Ciprofloxacin Corneal Deposits With Complete Dissipation After Switching to Moxifloxacin.
Topics: Administration, Ophthalmic; Aged; Anti-Bacterial Agents; Chemical Precipitation; Ciprofloxacin; Corn | 2020 |
Chronic Suppurative Otitis Media: A Case Report.
Topics: Adult; Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; | 2020 |
Efficacy and Therapeutic Drug Monitoring of Continuous Beta-Lactam Infusion for Osteoarticular Infections Caused by Fluoroquinolone-Resistant Pseudomonas aeruginosa: A Prospective Cohort Study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Bone Diseases, Infectious; Ciprofloxacin; Cohort Studies; | 2020 |
In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Biofilms; Chemistry, Pharmaceutical; Cip | 2020 |
Disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate lyase enhances pathogen eradication by antibiotics.
Topics: Biofilms; Ciprofloxacin; Cystic Fibrosis; Drug Synergism; Polysaccharide-Lyases; Pseudomonas aerugin | 2021 |
First report of a clinical multidrug-resistant Pseudomonas aeruginosa ST532 isolate harbouring a ciprofloxacin-modifying enzyme (CrpP) in South Africa.
Topics: Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Humans; Pseudomonas aeruginosa; Pseudomonas Inf | 2020 |
Comparative Study of Antibacterial Effects of Titanium Dioxide Nanoparticles Alone and in Combination with Antibiotics on MDR
Topics: Anti-Bacterial Agents; Calorimetry; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Humans; Mic | 2020 |
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Humans; Pseudomona | 2020 |
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Humans; Pseudomona | 2020 |
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Humans; Pseudomona | 2020 |
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Humans; Pseudomona | 2020 |
Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Fluoroquinolones; Humans; Microbial Se | 2021 |
Transcriptomic determinants of the response of ST-111 Pseudomonas aeruginosa AG1 to ciprofloxacin identified by a top-down systems biology approach.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Ciprofloxacin; Computational Biology; Gene Expr | 2020 |
Antimicrobial Effects of Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy in
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cornea; Drug Synergism; Epithelial Cells; Humans; Keratitis; L | 2020 |
Molecular detection of type III secretory toxins in Pseudomonas aeruginosa isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Ciprofloxacin; Drug Resistance, Multipl | 2020 |
Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles.
Topics: Acetylcysteine; Administration, Inhalation; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithro | 2020 |
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cough; Deglutition Disorders; Diagnosis, Differential; Dysphon | 2020 |
Evaluation of Combined Ciprofloxacin and azithromycin free and nano formulations to control biofilm producing Pseudomonas aeruginosa isolated from burn wounds.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Biofilms; Burns; Ciprofloxacin; Drug Therapy, Combinat | 2021 |
Orf progressiva: giant progressive and destructive infections in the immunocompromised.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Ciprofloxacin; Debridement; Drug Therapy, Combinatio | 2021 |
Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Diabetic Foot; Drug Resistance; Humans; Merope | 2021 |
The prevalence and functional characteristics of CrpP-like in Pseudomonas aeruginosa isolates from China.
Topics: Anti-Bacterial Agents; Bacterial Proteins; China; Ciprofloxacin; Humans; Microbial Sensitivity Tests | 2021 |
Pneumonia caused by Pseudomonas fluorescens: a case report.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Humans; Lung; Male; Microbial Sensitivity Tests; Pneumon | 2021 |
NtrBC Selectively Regulates Host-Pathogen Interactions, Virulence, and Ciprofloxacin Susceptibility of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Host-Pathogen Interactions; Humans; Mice; P | 2021 |
Antibacterial efficacy of silver nanoparticles against metallo-β-lactamase (blaNDM, blaVIM, blaOXA) producing clinically isolated Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Ciprofloxacin; D | 2021 |
Long-term coexistence of
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Pseudomon | 2021 |
Efficacy of
Topics: Administration, Intravenous; Administration, Oral; Aged; Anti-Bacterial Agents; Bronchiectasis; Cipr | 2017 |
Patterns of antimicrobial resistance in intensive care unit patients: a study in Vietnam.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; beta-Lactams; Ceftaz | 2017 |
Deficiency of quorum sensing system inhibits the resistance selection of Pseudomonas aeruginosa to ciprofloxacin and levofloxacin in vitro.
Topics: Bacterial Proteins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gene Exp | 2017 |
Employing high-frequency alternating magnetic fields for the non-invasive treatment of prosthetic joint infections.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cattle; Ciprofloxacin; Computer Simulation; Extracellular | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug | 2017 |
Preclinical therapeutic efficacy of the ciprofloxacin-eluting sinus stent for Pseudomonas aeruginosa sinusitis.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Biofilms; Cells, Cultured; Ciprofloxacin; Disease Mo | 2018 |
Films based on soy protein-agar blends for wound dressing: Effect of different biopolymer proportions on the drug release rate and the physical and antibacterial properties of the films.
Topics: Agar; Anti-Bacterial Agents; Bandages; Ciprofloxacin; Drug Carriers; Drug Delivery Systems; Drug Lib | 2018 |
Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Biofilms; Cell Line, Tumor; Chronic Disease; Cipr | 2018 |
Microbiology and antimicrobial susceptibility of otitis externa: a changing pattern of antimicrobial resistance.
Topics: Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Candida; Candidiasis; Ciprofloxacin | 2018 |
Antibiotic resistance evolution of Pseudomonas aeruginosa in cystic fibrosis patients (2010-2013).
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Ceftazidime; Child; Ciprofloxacin; Cystic Fibros | 2018 |
Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Ciprofloxacin; Cohort Stud | 2018 |
CrpP Is a Novel Ciprofloxacin-Modifying Enzyme Encoded by the Pseudomonas aeruginosa pUM505 Plasmid.
Topics: Bacterial Proteins; Ciprofloxacin; Gene Expression Regulation, Bacterial; Phosphorylation; Plasmids; | 2018 |
Fabrication of inhaled hybrid silver/ciprofloxacin nanoparticles with synergetic effect against Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Biofilms; Chemical Engineering; Ciprofloxacin; Cy | 2018 |
Epizootics of Pseudomonas anguilliseptica among cultured seabream (Sparus aurata) populations: Control and treatment strategies.
Topics: Animal Feed; Animals; Anti-Bacterial Agents; Aquaculture; Ciprofloxacin; Dietary Supplements; Egypt; | 2018 |
Adolescent Female With Right Ear Redness.
Topics: Adolescent; Anti-Bacterial Agents; Body Piercing; Cartilage Diseases; Ciprofloxacin; Ear; Ear Cartil | 2018 |
Screening, cloning and expression of a novel alginate lyase gene from P. aeruginosa TAG 48 and its antibiofilm effects on P. aeruginosa biofilm.
Topics: Alginates; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Cloning, Molecular; Humans; Mic | 2018 |
Psoas and neck abscess by Nocardia farcinica.
Topics: Aged; Aminoglycosides; Ciprofloxacin; Coinfection; Drainage; Humans; Linezolid; Male; Neck; Nocardia | 2019 |
Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
Topics: Adaptation, Physiological; Anti-Bacterial Agents; Bacterial Translocation; Biofilms; Ciprofloxacin; | 2018 |
Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Anti-Bacterial Agents; Child; Child, P | 2019 |
In-vitro evaluation of a ciprofloxacin- and ivacaftor-coated sinus stent against Pseudomonas aeruginosa biofilms.
Topics: Aminophenols; Anti-Bacterial Agents; Biofilms; Chloride Channel Agonists; Ciprofloxacin; Drug Libera | 2019 |
P. aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage-ciprofloxacin combination.
Topics: Alginates; Biofilms; Ciprofloxacin; Combined Modality Therapy; Host Specificity; Host-Pathogen Inter | 2019 |
Antibiofilm potential of purified environmental bacteriophage preparations against early stage Pseudomonas aeruginosa biofilms.
Topics: Anti-Bacterial Agents; Bacteriophages; Biofilms; Ciprofloxacin; Drug Resistance, Bacterial; Drug Syn | 2019 |
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis.
Topics: Anti-Bacterial Agents; Child; Ciprofloxacin; Clinical Protocols; Cystic Fibrosis; Female; Humans; Ma | 2019 |
Alginate lyase immobilized chitosan nanoparticles of ciprofloxacin for the improved antimicrobial activity against the biofilm associated mucoid P. aeruginosa infection in cystic fibrosis.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Chitosan; Ciprofloxacin; Cystic Fibrosis; Drug Liberation; | 2019 |
Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients.
Topics: Anti-Bacterial Agents; Biofilms; Biological Therapy; Cell Line; Ciprofloxacin; Combined Modality The | 2019 |
Antimicrobial activity of novel chalcones and modulation of virulence factors in hospital strains of Acinetobacter baumannii and Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Anti-Infective A | 2019 |
Synergistic effect of immunomodulatory S100A8/A9 and ciprofloxacin against Pseudomonas aeruginosa biofilm in a murine chronic wound model.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Calgranulin A; Chronic Disease; Ciprofloxacin; Colony Coun | 2020 |
Identification of novel genes that promote persister formation by repressing transcription and cell division in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Cell Division; Ciprofloxacin; Gene Expression P | 2019 |
Topics: Anti-Bacterial Agents; Bronchoalveolar Lavage; Ceftazidime; Child, Preschool; Ciprofloxacin; Clavula | 2019 |
Erythematous swollen ear.
Topics: Adult; Anti-Bacterial Agents; Cartilage Diseases; Ciprofloxacin; Diagnosis, Differential; Ear Cartil | 2019 |
Crystalline corneal deposits after one month of ciprofloxacin treatment for bacterial keratitis.
Topics: Aged; Anti-Bacterial Agents; Chemical Precipitation; Ciprofloxacin; Cornea; Crystallization; Female; | 2019 |
Glycyrrhizin Use for Multi-Drug Resistant Pseudomonas aeruginosa: In Vitro and In Vivo Studies.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Ciprofloxacin; Corneal Ulcer; Drug Resista | 2019 |
CrpP, a passenger or a hidden stowaway in the Pseudomonas aeruginosa genome?
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Genes, MDR; Genome, Bacterial; Genomic Isl | 2019 |
Dual bioresponsive antibiotic and quorum sensing inhibitor combination nanoparticles for treatment of Pseudomonas aeruginosa biofilms in vitro and ex vivo.
Topics: Animals; Biofilms; Cell Line; Ciprofloxacin; Humans; Hydrogen-Ion Concentration; Microbial Sensitivi | 2019 |
Local outbreak of extended-spectrum β-lactamase SHV2a-producing Pseudomonas aeruginosa reveals the emergence of a new specific sub-lineage of the international ST235 high-risk clone.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cepha | 2020 |
Nationwide surveillance of antimicrobial consumption and resistance to Pseudomonas aeruginosa isolates at 203 Japanese hospitals in 2010.
Topics: Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Utilizati | 2013 |
Effects of azithromycin in Pseudomonas aeruginosa burn wound infection.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Burns; Ciprofloxacin; Disease Models, Animal; Drug Syn | 2013 |
Nanoporous silica coatings as a drug delivery system for ciprofloxacin: outcome of variable release rates in the infected middle ear of rabbits.
Topics: Animals; Anti-Bacterial Agents; Behavior, Animal; Ceramics; Ciprofloxacin; Delayed-Action Preparatio | 2013 |
Papulopustular eruption after holiday in a 44-year-old man. Whirlpool dermatitis (pseudomonas folliculitis).
Topics: Adrenal Cortex Hormones; Adult; Baths; Ciprofloxacin; Diagnosis, Differential; Folliculitis; Humans; | 2013 |
Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model.
Topics: Ambroxol; Animals; Anti-Bacterial Agents; Biofilms; Catheters; Ciprofloxacin; Disease Models, Animal | 2013 |
Zingerone inhibit biofilm formation and improve antibiofilm efficacy of ciprofloxacin against Pseudomonas aeruginosa PAO1.
Topics: Anti-Bacterial Agents; Biofilms; Cell Movement; Ciprofloxacin; Drug Resistance, Multiple; Guaiacol; | 2013 |
Pseudomonas luteola peritonitis with favorable outcome in continuous peritoneal dialysis.
Topics: Aged; Anti-Bacterial Agents; Catheters, Indwelling; Ceftazidime; Ciprofloxacin; Diabetic Nephropathi | 2013 |
Possible digoxin toxicity associated with concomitant ciprofloxacin therapy.
Topics: Adult; Anorexia; Anti-Bacterial Agents; Cardiotonic Agents; Ciprofloxacin; Digoxin; Drug Interaction | 2013 |
Novel Pseudomonas fluorescens septic sacroiliitis in a healthy soldier.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Humans; Magnetic Resonance Imaging; Male; Microbial Sen | 2013 |
Pseudomonas folliculitis in Arabian baths.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; Baths; Chlorhexidine; Ciprofloxacin; Fol | 2013 |
A 50-year-old man with blistering skin lesions on both feet.
Topics: Blister; Ciprofloxacin; Disease Progression; Follow-Up Studies; Hawaii; Humans; Male; Middle Aged; N | 2013 |
Inverse correlation of Acinetobacter spp. resistance rate and ciprofloxacin utilization.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bact | 2014 |
Formation of hydroxyl radicals contributes to the bactericidal activity of ciprofloxacin against Pseudomonas aeruginosa biofilms.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Cystic Fibrosis; Humans; Hydroxyl Radical; Pseudomon | 2014 |
Effectiveness of antibiotic combination therapy as evaluated by the Break-point Checkerboard Plate method for multidrug-resistant Pseudomonas aeruginosa in clinical use.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Dru | 2014 |
PrtR homeostasis contributes to Pseudomonas aeruginosa pathogenesis and resistance against ciprofloxacin.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Bronchoalveolar Lavage | 2014 |
Treatment failure due to induction of ciprofloxacin resistance during combination therapy with colistin and ciprofloxacin in multidrug-resistant Pseudomonas aeruginosa bacteraemia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Drug Re | 2014 |
Therapeutic potential of the antimicrobial peptide OH-CATH30 for antibiotic-resistant Pseudomonas aeruginosa keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimicrobial Cation | 2014 |
Structural changes and differentially expressed genes in Pseudomonas aeruginosa exposed to meropenem-ciprofloxacin combination.
Topics: Anti-Bacterial Agents; Brazil; Ciprofloxacin; Colony Count, Microbial; DNA, Bacterial; Drug Combinat | 2014 |
Osteomyelitis of the clavicle following to a pacemaker implantation.
Topics: Anti-Bacterial Agents; Cardiac Pacing, Artificial; Cefepime; Cephalosporins; Ciprofloxacin; Clavicle | 2014 |
Efficacy of purified lactonase and ciprofloxacin in preventing systemic spread of Pseudomonas aeruginosa in murine burn wound model.
Topics: Animals; Anti-Bacterial Agents; Burns; Chemokine CXCL2; Ciprofloxacin; Disease Models, Animal; Inter | 2015 |
In vitro and in vivo evaluation of novel ciprofloxacin-releasing silicone hydrogel contact lenses.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Coated Materials, Biocompatible; Contact Lenses, Exte | 2014 |
Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Drug The | 2014 |
In vitro synergistic activity of colistin and ceftazidime or ciprofloxacin against multidrug-resistant clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Colistin; Drug Resistance, Multiple, Bacterial; D | 2014 |
Impact on resistance of the use of therapeutically equivalent generics: the case of ciprofloxacin.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Drugs, Generic; Mice; Microbial Sensitivity Tests; Ne | 2015 |
Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.
Topics: Anti-Bacterial Agents; Cell Line; Ciprofloxacin; Colistin; Drug Resistance, Bacterial; Drug Synergis | 2015 |
Externally controlled triggered-release of drug from PLGA micro and nanoparticles.
Topics: Biofilms; Ciprofloxacin; Delayed-Action Preparations; Drug Delivery Systems; Humans; Lactic Acid; Ma | 2014 |
Azithromycin and ciprofloxacin: a possible synergistic combination against Pseudomonas aeruginosa biofilm-associated urinary tract infections.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bacterial Load; Biofilms; Ciprofloxacin; Cytokines; Di | 2015 |
Chloronychia: green nail syndrome caused by Pseudomonas aeruginosa in elderly persons.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Humans; Male; Middle Aged; Nails; Pseudomonas aeruginosa | 2015 |
Combatting bacterial infections by killing persister cells with mitomycin C.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Biofilms; Caenorhabditis elegans; Ciprofloxacin; Cross-L | 2015 |
Effective strategies for managing new Pseudomonas cultures in adults with cystic fibrosis.
Topics: Adolescent; Adult; Analysis of Variance; Anti-Bacterial Agents; Chi-Square Distribution; Ciprofloxac | 2015 |
RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria.
Topics: Anti-Bacterial Agents; Ceftazidime; Cells, Cultured; Ciprofloxacin; Daptomycin; Drug Resistance, Mul | 2015 |
Is there a role for antimicrobial stewardship in bronchiectasis?
Topics: Administration, Intravenous; Administration, Oral; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxa | 2015 |
Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Blood Culture; Carbapenem-Resistant | 2017 |
Central skull base osteomyelitis: a rare but life-threatening disease.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Delayed Diagnosis; Earache; Humans; Magnetic Resonance I | 2015 |
Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Test | 2015 |
Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Bacteremia; Ciprofloxacin; Drug Re | 2015 |
Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colistin; Corneal Ulcer; Drug Resistance, Multiple, Bacterial; | 2016 |
Ciprofloxacin plus erythromycin or ambroxol ameliorates endotracheal tube-associated Pseudomonas aeruginosa biofilms in a rat model.
Topics: Ambroxol; Animals; Anti-Bacterial Agents; Biofilms; Catheters, Indwelling; Ciprofloxacin; Disease Mo | 2015 |
Adjuvant effect of cranberry proanthocyanidin active fraction on antivirulent property of ciprofloxacin against Pseudomonas aeruginosa.
Topics: 4-Butyrolactone; Acyl-Butyrolactones; Adjuvants, Pharmaceutic; Anti-Bacterial Agents; Biofilms; Cipr | 2016 |
Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
Topics: Anti-Bacterial Agents; Area Under Curve; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Microbia | 2016 |
Green foot ulcers.
Topics: Acetic Acid; Anti-Bacterial Agents; Ciprofloxacin; Combined Modality Therapy; Dermoscopy; Female; Fl | 2017 |
Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
Topics: Amides; Anti-Bacterial Agents; Bacterial Adhesion; Biofilms; Ciprofloxacin; Colistin; Cystic Fibrosi | 2015 |
OligoG CF-5/20 Disruption of Mucoid Pseudomonas aeruginosa Biofilm in a Murine Lung Infection Model.
Topics: Animals; Biofilms; Ciprofloxacin; Colistin; Female; Interleukin-1alpha; Mice; Mice, Inbred BALB C; M | 2016 |
Amino Acid Substitutions Account for Most MexS Alterations in Clinical nfxC Mutants of Pseudomonas aeruginosa.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Protein | 2016 |
Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; Ciprofloxacin; Criti | 2016 |
A Child With Septic Shock and Purpura.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Diagnosis, Differential; Drug Therapy, Combination; Female; Hu | 2016 |
Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Interactions; Drug Resistance, Bacterial; Fosfomycin; Hum | 2016 |
Difference of Type 3 secretion system (T3SS) effector gene genotypes (exoU and exoS) and its implication to antibiotics resistances in isolates of Pseudomonas aeruginosa from chronic otitis media.
Topics: ADP Ribose Transferases; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; | 2017 |
Subinhibitory concentration of ciprofloxacin targets quorum sensing system of Pseudomonas aeruginosa causing inhibition of biofilm formation & reduction of virulence.
Topics: Biofilms; Ciprofloxacin; Dose-Response Relationship, Drug; Humans; Pseudomonas aeruginosa; Pseudomon | 2016 |
Empirical monotherapy with meropenem or combination therapy: the microbiological point of view.
Topics: Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Therapy, Combinatio | 2016 |
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infection Control in an Institutional Setting.
Topics: Anti-Bacterial Agents; Cefotaxime; Ciprofloxacin; Cross Infection; Enterococcus faecium; Escherichia | 2016 |
Ciprofloxacin-imprinted hydrogels for drug sustained release in aqueous media.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross-Linking Reagents; Delayed-Action Preparations; Drug Libe | 2017 |
Risk factors for hospital-acquired bacteremia due to carbapenem-resistant Pseudomonas aeruginosa in a Colombian hospital.
Topics: Bacteremia; beta-Lactams; Carbapenems; Case-Control Studies; Ciprofloxacin; Drug Resistance, Bacteri | 2016 |
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cystic Fibrosis; Drug Hype | 2016 |
Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: Design of experiments approach.
Topics: Anti-Bacterial Agents; Biofilms; Chemistry, Pharmaceutical; Ciprofloxacin; Cystic Fibrosis; Drug Car | 2016 |
A Case of Recalcitrant Actinomycosis Unresponsive to Antibiotic Therapy.
Topics: Actinomycosis; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agen | 2016 |
Antibiotic Sensitivity pattern of Bacterial Isolates of Neonatal Septicemia in Peshawar, Pakistan.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacteri | 2016 |
Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Endocarditis; F | 2017 |
Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Drug T | 2017 |
Severe skull base osteomyelitis caused by Pseudomonas aeruginosa with successful outcome after prolonged outpatient therapy with continuous infusion of ceftazidime and oral ciprofloxacin: a case report.
Topics: Aged; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Diagnostic Errors; Drug Therapy, Combinatio | 2017 |
Individual pharmacokinetic variation leads to underdosing of ciprofloxacin in some cystic fibrosis patients.
Topics: Adult; Anti-Bacterial Agents; Breath Tests; Ciprofloxacin; Cystic Fibrosis; Cytochrome P-450 CYP3A; | 2017 |
Is malignant otitis externa on the increase? A retrospective review of cases.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Female; Humans; Male; Middle A | 2017 |
In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Ciprofloxacin; DNA Fingerprinting; DNA, Bacteria | 2008 |
Effect of a program to reduce hospital ciprofloxacin use on nosocomial Pseudomonas aeruginosa susceptibility to quinolones and other antimicrobial agents.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Hospital Bed Capa | 2008 |
Mandibular osteomyelitis due to Pseudomonas aeruginosa. Case report.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Combined Modality Therapy; Debridement; Drug Resistance | 2008 |
Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azithromycin; Base Sequence; Ceftazidime; Ciprofloxacin; DNA Primers; DNA, Ba | 2008 |
Mutator genes giving rise to decreased antibiotic susceptibility in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; DNA Repair; DNA Transposable Elements; DNA, B | 2008 |
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Child; C | 2008 |
Nona-D-arginine therapy for Pseudomonas aeruginosa keratitis.
Topics: Animals; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Ulcer; Disease Models, Animal; Drug | 2009 |
Changes in the rates of antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa between 2002 and 2004 in a tertiary-care teaching hospital in Turkey.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Bacterial; Ho | 2008 |
Pseudomonas aeruginosa infection due to acupunctural ear stapling.
Topics: Acupuncture, Ear; Adolescent; Anti-Bacterial Agents; Ciprofloxacin; Female; Humans; Needlestick Inju | 2008 |
The use of piperacillin-tazobactam coated tympanostomy tubes against ciprofloxacin-resistant Pseudomonas biofilm formation: an in vitro study.
Topics: Anti-Bacterial Agents; Bacterial Adhesion; Bacteriological Techniques; Biofilms; Ciprofloxacin; Coat | 2009 |
Contribution of ParE mutation and efflux to ciprofloxacin resistance in Pseudomonas aeruginosa clinical isolates.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; | 2008 |
[Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Bacteriological Techniques; Ceftazidime; Ciprofloxacin; | 2009 |
Antibiotic susceptibility patterns of Pseudomonas aeruginosa to available antipseudomonal drugs in Ibadan, Nigeria.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple, | 2008 |
[Bacterial corneal ulcer treated with intrastromal antibiotic. Experimental model in vivo].
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cornea; | 2009 |
Implementation of European standards of care for cystic fibrosis--control and treatment of infection.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Bacterial Infections; Burkholderia cepacia | 2009 |
The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Child, Preschool; Chronic Disease; Ciprofloxacin; Clavula | 2009 |
Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistanc | 2009 |
Prompt diagnosis and treatment of microbial keratitis in a daily wear lens.
Topics: Administration, Topical; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Contact Lenses; | 2009 |
Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment.
Topics: Adhesiveness; Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Chitosan; Ciprofloxacin; D | 2010 |
Fluoroquinolone-resistant Pseudomonas aeruginosa in chronic rhinosinusitis.
Topics: Anti-Bacterial Agents; Chronic Disease; Ciprofloxacin; Comorbidity; Drug Resistance, Bacterial; Fluo | 2009 |
Chronic suppurative otitis media in cleft palate: microorganism etiology and susceptibilities.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacteria; Child; Child, Preschool; Chronic Disease; Ciprof | 2009 |
Bacterial keratitis after manual descemet stripping endothelial keratoplasty--a different pathophysiology?
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Corneal Transplantation; Descemet Membrane; Dexamethason | 2010 |
Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; | 2010 |
Bilateral necrotising fasciitis of the ocular adnexa secondary to Pseudomonas aeruginosa septicaemia in a HIV-positive child.
Topics: Anti-Bacterial Agents; Bacteremia; CD4 Lymphocyte Count; Ceftazidime; Ciprofloxacin; Drug Therapy, C | 2010 |
Malignant otitis externa: case series.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Cranial Nerve Diseases; Diabetes Mell | 2010 |
A novel antibiotic based long-term model of ovine smoke inhalation injury and septic shock.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Disease Models, Animal; Female; Nitric Ox | 2010 |
Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Colony Count, Mic | 2010 |
Assessment of polymerase chain reaction in the detection of pseudomonas aeruginosa in contact lens-induced severe infectious keratitis.
Topics: Adult; Ceftazidime; Ciprofloxacin; Contact Lenses; Diagnosis, Differential; DNA, Bacterial; Dose-Res | 2010 |
Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Biofilms; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Bacte | 2011 |
Pattern of Pseudomonas aeruginosa drug resistance in Tabriz Children Hospital.
Topics: Adolescent; Anti-Infective Agents; Child; Child, Preschool; Ciprofloxacin; Cross-Sectional Studies; | 2010 |
[Ochrobactrum anthropi and polymicrobial peritonitis in peritoneal dialysis: a resistance predictor].
Topics: Anti-Bacterial Agents; Antifungal Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug | 2010 |
Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
Topics: Adolescent; Anti-Bacterial Agents; Child; Ciprofloxacin; Computer Simulation; Cystic Fibrosis; Dose- | 2010 |
Enhanced bacterial uptake and bactericidal properties of ofloxacin loaded on bioadhesive hydrogels against Pseudomonas aeruginosa.
Topics: Acrylic Resins; Adhesiveness; Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Humans; Hydrog | 2010 |
Guardian ad litem, a potentially expensive invitation to either the mismanagement or management of patients with cognitive disorders.
Topics: Aged; Catheters; Ciprofloxacin; Cognition Disorders; Cystostomy; Elder Abuse; Fever; Humans; Legal G | 2010 |
Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin.
Topics: Acute Disease; Agar; Animals; Anti-Infective Agents; Bacterial Load; Bronchoalveolar Lavage Fluid; C | 2011 |
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Burkholderia cepacia | 2011 |
Imipenem and ciprofloxacin consumption as factors associated with high incidence rates of resistant Pseudomonas aeruginosa in hospitals in northern France.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; | 2011 |
Differential diagnosis and treatments of necrotizing otitis externa: a report of 19 cases.
Topics: Adult; Aged; Aged, 80 and over; Ciprofloxacin; Comorbidity; Diabetes Complications; Diagnosis, Diffe | 2011 |
Large-area burns with pandrug-resistant Pseudomonas aeruginosa infection and respiratory failure.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Burns; Carbapenems; Ciprofloxacin; Drug Resistance, Multip | 2011 |
Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model.
Topics: Administration, Inhalation; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Drug Carriers; Hu | 2011 |
Correlation between fluoroquinolone consumption in hospitals and ciprofloxacin resistance amongst Pseudomonas aeruginosa isolates causing healthcare-associated infections, Taiwan, 2000-2009.
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Fluoroquinolones; Hosp | 2011 |
Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomera | 2011 |
[Epidemiology and drug susceptibility of Pseudomonas aeruginosa strains isolated in the Chugoku region of Japan. Infection Forum in the Chugoku Region].
Topics: Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resis | 2011 |
[Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].
Topics: Animals; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combinatio | 2011 |
What have we learned about early treatment of Pseudomonas aeruginosa infection in infants and children with cystic fibrosis?
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Male; | 2011 |
Role of the MexEF-OprN efflux system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Ciprofloxacin; Drug Resistance, Bacterial; | 2011 |
Prevalence of efflux-mediated ciprofloxacin and levofloxacin resistance in recent clinical isolates of Pseudomonas aeruginosa and its reversal by the efflux pump inhibitors 1-(1-naphthylmethyl)-piperazine and phenylalanine-arginine-β-naphthylamide.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Dipeptides; Drug Resistance, Multiple, Bacterial; Fluoroquinol | 2012 |
Susceptibility of Pseudomonas aeruginosa urinary tract isolates and influence of urinary tract conditions on antibiotic tolerance.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Humans; Iron; | 2012 |
Synergistic effects of glutamine and ciprofloxacin in reduction of Pseudomonas aeruginosa-induced septic shock severity.
Topics: Animals; Ciprofloxacin; Drug Synergism; Drug Therapy, Combination; Glutamine; HSP70 Heat-Shock Prote | 2011 |
[Investigation of plasmid-mediated quinolone resistance in Pseudomonas aeruginosa strains isolated from cystic fibrosis patients].
Topics: Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Bacterial; Humans; Microbial | 2011 |
Outbreak of hot-foot syndrome - caused by Pseudomonas aeruginosa.
Topics: Adult; Anti-Infective Agents; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Diagnosis, Differ | 2012 |
Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model.
Topics: Anti-Bacterial Agents; Area Under Curve; Carbapenems; Ciprofloxacin; Doripenem; Dose-Response Relati | 2012 |
Ceftriaxone and ciprofloxacin restriction in an intensive care unit: less incidence of Acinetobacter spp. and improved susceptibility of Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Ceftriaxone; Ciprofloxacin; Cross In | 2011 |
Decreased resistance of Pseudomonas aeruginosa with restriction of ciprofloxacin in a large teaching hospital's intensive care and intermediate care units.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; | 2012 |
Biofilm formation by Pseudomonas aeruginosa in solid murine tumors - a novel model system.
Topics: 4-Quinolones; Animals; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Colony Count, Microbial; Dise | 2012 |
Effect of linezolid on the 50% lethal dose and 50% protective dose in treatment of infections by Gram-negative pathogens in naive and immunosuppressed mice and on the efficacy of ciprofloxacin in an acute murine model of septicemia.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Administration Routes; Drug Administ | 2012 |
In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
Topics: Bacterial Typing Techniques; Biofilms; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Levofloxacin; | 2012 |
[Pseudomonas folliculitis after spa bath exposure].
Topics: Adult; Anti-Infective Agents; Baths; Ciprofloxacin; Female; Folliculitis; Humans; Pseudomonas aerugi | 2012 |
Novel antibiotic regime for pseudomonal scleritis complicating scleral buckling surgery.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftazidime; Ciprofloxacin; Humans; Male; Middle Aged; | 2010 |
Effect of ion-bombarded silicone tympanostomy tube on ciprofloxacin-resistant Pseudomonas aeruginosa biofilm formation.
Topics: Anti-Bacterial Agents; Bacterial Adhesion; Biofilms; Ciprofloxacin; Coated Materials, Biocompatible; | 2012 |
Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia.
Topics: Anti-Bacterial Agents; Cell Line; Ciprofloxacin; Humans; Liposomes; Microbial Sensitivity Tests; Nan | 2012 |
Septic arthritis of the pubic symphysis from Pseudomonas aeruginosa: reconsidering traditional risk factors and symptoms in the elderly patient.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Arthritis, Infectious; Balanitis; Ciprofloxacin; Circumcis | 2012 |
Layered double hydroxides as efficient drug delivery system of ciprofloxacin in the middle ear: an animal study in rabbits.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Delivery Systems; Ear, Middle; Hydroxides; Male; | 2013 |
Skull base osteomyelitis: current microbiology and management.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anti-Infective Agents; Aspergillosis; Ceftazidime; Cipro | 2013 |
The Lon protease is essential for full virulence in Pseudomonas aeruginosa.
Topics: Animals; Cell Division; Ciprofloxacin; Disease Models, Animal; Gene Expression Regulation, Bacterial | 2012 |
Initial management of necrotizing external otitis: errors to avoid.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents, Local; Ceftazidime; Ci | 2013 |
Pattern of bacterial isolates in the middle ear discharge of patients with chronic suppurative otitis media in a tertiary hospital in North central Nigeria.
Topics: Adolescent; Adult; Age Distribution; Anti-Bacterial Agents; Child; Child, Preschool; Chronic Disease | 2012 |
Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.
Topics: Acute Disease; Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Progression; | 2002 |
Clinical presentation of microbial keratitis with daily wear frequent-replacement hydrogel lenses: a case series.
Topics: Adolescent; Adult; Aeromonas; Anti-Infective Agents; Ciprofloxacin; Contact Lenses, Hydrophilic; Eye | 2002 |
Evolving resistant pseudomonas to ciprofloxacin in malignant otitis externa.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Female; H | 2002 |
[Ciprofloxacin in the treatment of hospital-acquired pneumonia: a surveillance study in 676 patients].
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Therapy, Combination; Germany; Humans; I | 2002 |
The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combinatio | 2002 |
An approach for the evaluation of synergy between antimicrobials.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Ciprofloxacin; Drug Resistance, Bacterial; | 2003 |
[The impact of antibiotic use on hospital-acquired pneumonia: data of etiology tests].
Topics: Acinetobacter; Acinetobacter Infections; Amikacin; Ampicillin; Anti-Bacterial Agents; Anti-Infective | 2003 |
Carbapenemase-producing Pseudomonas aeruginosa and ciprofloxcacin use in neonatal intensive care units.
Topics: Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Central Nervous System; Ciprofloxacin; C | 2003 |
Ecthyma gangrenosum arising from Pseudomonas aeruginosa dacryocystitis.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Dacryocystitis; Dacryocystorhinostomy; Debridement; Drug | 2003 |
Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Resistance | 2003 |
[Community-acquired Pseudomonas aeruginosa bacteremic pneumonia in a "healthy" subject].
Topics: Adult; Anti-Infective Agents; Bacteremia; Bronchoalveolar Lavage; Ciprofloxacin; Community-Acquired | 2003 |
Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Bayes Theorem; Body Weight; Child; Child, Pr | 2003 |
Ciprofloxacin susceptibility of Pseudomonas aeruginosa isolates from keratitis.
Topics: Anti-Infective Agents; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Eye Infections, Ba | 2003 |
An outbreak of conjunctivitis caused by multiresistant Pseudomonas aeruginosa in a Brazilian newborn intensive care unit.
Topics: Anti-Bacterial Agents; Brazil; Ciprofloxacin; Conjunctivitis; Cross Infection; Disease Outbreaks; Dr | 2003 |
Pseudomonas keratitis associated with continuous wear silicone-hydrogel soft contact lens: a case report.
Topics: Adult; Cefazolin; Ciprofloxacin; Contact Lenses, Extended-Wear; Corneal Ulcer; Drug Therapy, Combina | 2003 |
Treatment of experimental bacterial keratitis with topical trovafloxacin.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Biological Availability; Ciprofloxacin; Col | 2004 |
Factors influencing fluoroquinolone resistance.
Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Microbia | 2003 |
Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center.
Topics: Adolescent; Anti-Infective Agents; Child; Child, Preschool; Chronic Disease; Ciprofloxacin; Cystic F | 2004 |
Ciprofloxacin treatment in newborns with multi-drug-resistant nosocomial Pseudomonas infections.
Topics: Birth Weight; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Gestatio | 2004 |
[Resistance of Pseudomonas aeruginosa to ciprofloxacin and levofloxacin: 1998-2002].
Topics: Body Fluids; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Levofloxacin; Ofloxacin; Pseudomonas | 2003 |
Early interventions in CF.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Bronchoalveolar Lavage Fluid; | 2004 |
Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation.
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Female; Fluoroquinolones; Hematopoi | 2004 |
Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Child; Ciprofloxacin; Cohort St | 2004 |
Virulence of metallo-beta-lactamase-producing Pseudomonas aeruginosa in vitro and in vivo.
Topics: Animals; Bacteremia; beta-Lactamases; Ceftazidime; Cephalosporins; Cilastatin; Ciprofloxacin; Drug T | 2004 |
Effect of antibiotic sequence on combination regimens against Pseudomonas aeruginosa in a multiple-dose, in vitro infection model.
Topics: Ceftazidime; Ciprofloxacin; Culture Media, Conditioned; Dose-Response Relationship, Drug; Drug Admin | 2004 |
Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactam Resistance; Ceftazidime; Ciprofloxacin; Co | 2004 |
Ciprofloxacin in the treatment of chronic suppurative otitis media.
Topics: Acetates; Administration, Topical; Adult; Aged; Anti-Infective Agents; Child; Chronic Disease; Cipro | 2004 |
Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Drug Resistance, Bac | 2004 |
Therapeutic efficacy of "nubiotics" against burn wound infection by Pseudomonas aeruginosa.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Burns; Ciprofloxacin | 2004 |
Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Cornea; Eye I | 2004 |
A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Disease Models, Anim | 2004 |
Botryomycosis ('bacterial ball') of the sinonasal tract caused by Pseudomonas aeruginosa.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Drug Therapy, Combination; Fem | 1996 |
Multiple dose pharmacokinetics of ciprofloxacin in preterm babies.
Topics: Anti-Infective Agents; Birth Weight; Ciprofloxacin; Humans; Infant, Newborn; Infant, Premature; Infa | 2004 |
[Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Cytarabine; Ec | 2004 |
Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States.
Topics: Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Humans; | 2004 |
Case report: greater meningeal inflammation in lumbar than in ventricular region in human bacterial meningitis.
Topics: Adult; Anti-Infective Agents; Cerebral Ventricles; Cerebrospinal Fluid Shunts; Chordoma; Ciprofloxac | 2004 |
In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests | 2005 |
Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Comb | 2005 |
Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies.
Topics: beta-Lactams; Ceftazidime; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Ga | 2005 |
Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Ulcer; Disea | 2005 |
Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, | 2005 |
Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Drug Resistance, Bacteria | 2005 |
Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Female; | 2005 |
Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems.
Topics: Animals; Carbapenems; Ciprofloxacin; Fluoroquinolones; Male; Mice; Mice, Inbred ICR; Microbial Sensi | 2005 |
[Bacterial infections in cancer patients].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteria | 2005 |
Pseudomonas aeruginosa infection: an uncommon cause of post-renal obstruction following induction therapy for acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anuria; Ciprofloxacin; Humans; Hypertension; Infant; | 2006 |
Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; | 2005 |
[Dynamic analysis of drug resistance of Pseudomonas aeruginosa in laboratory and clinical two-drug regimen].
Topics: Amikacin; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Mi | 2005 |
Posterior scleritis secondary to Pseudomonas aeruginosa keratitis.
Topics: Anti-Infective Agents; Ciprofloxacin; Corneal Ulcer; Disease Progression; Eye Enucleation; Eye Infec | 2005 |
Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.
Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Computer Simulation; Female; Humans; Male; M | 2005 |
Ultrasonically controlled release of ciprofloxacin from self-assembled coatings on poly(2-hydroxyethyl methacrylate) hydrogels for Pseudomonas aeruginosa biofilm prevention.
Topics: Anti-Infective Agents; Biofilms; Ciprofloxacin; Coated Materials, Biocompatible; Hydrogels; Methacry | 2005 |
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, B | 2005 |
Mitigation of hearing loss from semi-circular canal transection in pseudomonas otitis media with ciprofloxacin-dexamethasone irrigation.
Topics: Animals; Anti-Infective Agents; Auditory Threshold; Ciprofloxacin; Dexamethasone; Glucocorticoids; G | 2006 |
GyrA mutations in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa in a Silesian Hospital in Poland.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; Ciprofloxacin; DNA Gyrase; DNA, Bacterial | 2005 |
Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; D | 2006 |
Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Ciprofloxaci | 2006 |
Pseudomonas keratitis after laser in situ keratomileusis.
Topics: Adult; Anti-Bacterial Agents; Cefazolin; Cephalosporin Resistance; Ciprofloxacin; Corneal Ulcer; Dru | 2006 |
Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Case-Control Studies; Ciprofloxacin; Cross Infection | 2006 |
Pseudomonas aeruginosa otochondritis complicating localized cutaneous leishmaniasis: prevention of mutilation by early antibiotic therapy.
Topics: Adult; Animals; Anti-Infective Agents; Antimony; Antiprotozoal Agents; Cartilage; Ciprofloxacin; Ear | 2006 |
Comparative trial of different anti-bacterial combinations with propolis and ciprofloxacin on Pseudomonas keratitis in rabbits.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Opacity; Dexamethaso | 2007 |
Resistance of Pseudomonas to ciprofloxacin: implications for the treatment of malignant otitis externa.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Female; H | 2007 |
Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin.
Topics: Adolescent; Adult; Anti-Infective Agents; Blood Coagulation Disorders; Ciprofloxacin; Cystic Fibrosi | 2007 |
Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Computer Simulation; Dr | 2006 |
[Diagnostic image (299). An oncology patient suffering from conjunctivitis].
Topics: Anti-Infective Agents; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Small Cell; Cipro | 2006 |
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Dr | 2006 |
Mutation in mexR-gene leading to drug resistance in corneal keratitis in human.
Topics: Amino Acid Sequence; Anti-Infective Agents; Bacterial Proteins; Base Sequence; Ciprofloxacin; Drug R | 2006 |
Case Report: infected ear cartilage piercing.
Topics: Adult; Anti-Bacterial Agents; Body Piercing; Ciprofloxacin; Debridement; Ear Cartilage; Ear, Externa | 2006 |
[Pseudomonas and acute external otitis. Results of a microbiological study in patients without previous antibiotic treatment].
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Age Factors; Aged; Anti-Bacterial Agents; An | 2007 |
Collagen bilayer dressing with ciprofloxacin, an effective system for infected wound healing.
Topics: Animals; Anti-Bacterial Agents; Cattle; Ciprofloxacin; Collagen; Disease Models, Animal; Infections; | 2007 |
Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Ulcer; Disease Model | 2007 |
A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Anti-Infective Agents, Local; Cefazolin; Chlorhexidine; Ciprofloxa | 2007 |
Initial therapy for suppurative microbial keratitis in Iraq.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Eye Infections, Bacterial; Eye Infe | 2007 |
Hot tub folliculitis or hot hand-foot syndrome caused by Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Disease Outbreaks; | 2007 |
An in vitro investigation of levofloxacin and ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Humans; Italy; Levofloxacin; Microbial Sensitivity Tests; Oflo | 2007 |
Effect of ototopical medications on tympanostomy tube biofilms.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Biofilms; Ciprofloxacin; Dexamethasone; Drug Admini | 2007 |
Giant necrotizing abscess of a liver transplant after gunshot injury.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Humans; Liver Abscess; Liver Transplantation; | 2007 |
[A case of a tumorsimulating expansion caused by anabolic androgen steroids in body building].
Topics: Abscess; Adult; Anabolic Agents; Androgens; Arm; Ciprofloxacin; Debridement; Diagnosis, Differential | 2007 |
Periorbital necrotizing fasciitis.
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Breast Neoplasms; | 2007 |
Nosocomial acquisition of Pseudomonas aeruginosa resistant to both ciprofloxacin and imipenem: a risk factor and laboratory analysis.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Blotting, Western; Case-Control Studies; C | 2008 |
Profile of microorganisms and antimicrobial resistance at a tertiary care referral burn centre in Iran: emergence of Citrobacter freundii as a common microorganism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Burns; Child; Ciprofloxacin; Citr | 2008 |
[Infection treatment caused by multiple-drug-resistant Pseudomonas aeruginosa in a patient undergoing allogeneic hematopoietic stem cell transplantation].
Topics: Aged; Amikacin; Aztreonam; Ciprofloxacin; Drug Administration Schedule; Drug Resistance, Multiple, B | 2008 |
Local treatment of experimental Pseudomonas aeruginosa osteomyelitis with a biodegradable dilactide polymer releasing ciprofloxacin.
Topics: Absorbable Implants; Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Drug Imp | 2008 |
Microparticles for inhalational delivery of antipseudomonal antibiotics.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchitis; Ceftazidime; Chromatography, High Pre | 2008 |
Accumulation of 99mTc-ciprofloxacin in Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: Bacterial Outer Membrane Proteins; Bacterial Proteins; Ciprofloxacin; Gene Expression; Genes, Bacter | 2008 |
Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Guinea Pigs; Kinetics; Pneumonia; Pseudomonas aerugin | 1984 |
Efficacy of sustained release ciprofloxacin microspheres against device-associated Pseudomonas aeruginosa biofilm infection in a rabbit peritoneal model.
Topics: Absorption; Animals; Anti-Infective Agents; Biofilms; Ciprofloxacin; Delayed-Action Preparations; Di | 1995 |
Oral ciprofloxacin for treatment of infection following nail puncture wounds of the foot.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Cellulitis; Ciprofloxacin; Female; F | 1995 |
[Clinical analysis of 60 cases of nosocomal pneumonias].
Topics: Adult; Ciprofloxacin; Cross Infection; Humans; Klebsiella Infections; Klebsiella pneumoniae; Pneumon | 1994 |
Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa.
Topics: Animals; Ciprofloxacin; Drug Resistance, Multiple; Drug Therapy, Combination; Endocarditis, Bacteria | 1995 |
Experience in treating secondary systemic mycotic infection after severe burns associated with electric injury.
Topics: Adult; Amputation, Surgical; Burns, Electric; Candidiasis; Ciprofloxacin; Fluconazole; Humans; Male; | 1995 |
[Critical serum concentration of antibiotics. A therapeutic tool and means of comparative evaluation].
Topics: Animals; Ceftazidime; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Evaluation; Endocarditis | 1995 |
Should Pseudomonas aeruginosa isolates resistant to one of the fluorinated quinolones be tested for the others? Studies with an experimental model of pneumonia.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Lung; Male; Microbial Sen | 1995 |
Photosensitivity associated with ciprofloxacin use in adult patients with cystic fibrosis.
Topics: Adult; Ciprofloxacin; Cystic Fibrosis; Humans; Photosensitivity Disorders; Pseudomonas Infections | 1995 |
Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Dexamethasone; Disea | 1995 |
Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome.
Topics: Acute Kidney Injury; Adult; AIDS-Related Opportunistic Infections; Ciprofloxacin; Humans; Male; Pneu | 1995 |
Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Ciprofloxacin; Cornea; Corneal Ulcer; Disea | 1994 |
Outbreak of gentamicin, ciprofloxacin-resistant Pseudomonas aeruginosa in an intensive care unit, traced to contaminated quivers.
Topics: Ciprofloxacin; Cross Infection; Disease Outbreaks; Drug Resistance, Microbial; Equipment Contaminati | 1994 |
Oral ciprofloxacin versus intravenous therapy with other non-quinolone agents: a study of 291 infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial I | 1994 |
Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbenicillin; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; | 1994 |
Effects of ciprofloxacin, norfloxacin, and ofloxacin on in vitro adhesion and survival of Pseudomonas aeruginosa AK1 on urinary catheters.
Topics: Anti-Infective Agents; Bacterial Adhesion; Biofilms; Chromatography, High Pressure Liquid; Ciproflox | 1994 |
Treatment and prevention of relapses of CAPD Pseudomonas peritonitis.
Topics: Ceftazidime; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Male; Peritoneal Dialysis, Co | 1993 |
Recurrent pseudomonas septic arthritis.
Topics: Aged; Arthritis, Infectious; Blood Vessel Prosthesis; Cefsulodin; Ciprofloxacin; Drug Therapy, Combi | 1993 |
Pseudomonas aeruginosa bacteraemia in a dog.
Topics: Animals; Bacteremia; Ciprofloxacin; Dog Diseases; Dogs; Male; Microbiological Techniques; Pseudomona | 1994 |
[Hydrarthrosis due to ciprofloxacin].
Topics: Adult; Ciprofloxacin; Humans; Hydrarthrosis; Male; Pseudomonas Infections; Respiratory Insufficiency | 1994 |
Periareolar breast abscess due to Pseudomonas aeruginosa in an HIV antibody positive male.
Topics: Abscess; Acquired Immunodeficiency Syndrome; Adult; Breast Diseases; Ciprofloxacin; Humans; Male; Ps | 1994 |
Pubic osteomyelitis due to Pseudomonas aeruginosa.
Topics: Aged; Ciprofloxacin; Female; Humans; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections; | 1993 |
Sequential intravenous/oral ciprofloxacin in the treatment of severe multiresistant gram-negative infections.
Topics: Administration, Oral; Adolescent; Adult; Ciprofloxacin; Drug Resistance, Microbial; Female; Gram-Neg | 1993 |
Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection.
Topics: Ciprofloxacin; Culture Media; DNA Probes; Drug Resistance, Microbial; Humans; Methicillin Resistance | 1993 |
Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen.
Topics: Aging; Animals; Aqueous Humor; Biological Assay; Ciprofloxacin; Cornea; Drug Therapy, Combination; F | 1993 |
Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Cefazolin; Ciprofloxacin; Colony Count, Microbial; Cornea; Disease | 1993 |
Cystic fibrosis: antibiotic prescribing practices in the United Kingdom and Eire.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aminoglycosides; Anti-Bacterial Agents; Cef | 1993 |
[Bacterial otitis externa with invasion of organ limits--systemic and local combination treatment with ciprofloxacin].
Topics: Administration, Topical; Bacterial Infections; Ciprofloxacin; Humans; Microbial Sensitivity Tests; O | 1993 |
Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis.
Topics: Animals; Aqueous Humor; Ciprofloxacin; Corneal Ulcer; Disease Models, Animal; Drug Therapy, Combinat | 1993 |
Successful treatment of haemodialysis catheter-related sepsis without catheter removal.
Topics: Adult; Aged; Aged, 80 and over; Bacteremia; Catheterization, Central Venous; Catheters, Indwelling; | 1993 |
Safety of ciprofloxacin in children with cystic fibrosis.
Topics: Administration, Oral; Adolescent; Alkaline Phosphatase; Child; Ciprofloxacin; Cystic Fibrosis; Drug | 1993 |
Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis.
Topics: Animals; Antibodies, Monoclonal; Bacteremia; Ciprofloxacin; Combined Modality Therapy; Endotoxins; F | 1993 |
Acute Pseudomonas infection following total hip replacement.
Topics: Acute Disease; Aged; Ciprofloxacin; Drug Delivery Systems; Hip Prosthesis; Humans; Male; Methylmetha | 1993 |
Increased resistance to quinolone in Catalonia, Spain.
Topics: Anti-Infective Agents; Campylobacter Infections; Ciprofloxacin; Drug Resistance, Microbial; Enteroba | 1993 |
Criteria for use of intravenous ciprofloxacin for infections in adult patients.
Topics: Adult; Ciprofloxacin; Drug Resistance, Microbial; Humans; Male; Prostatitis; Pseudomonas Infections; | 1993 |
Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental Pseudomonas keratitis.
Topics: Animals; Ciprofloxacin; Eye Infections, Bacterial; Keratitis; Ointments; Ophthalmic Solutions; Pseud | 1993 |
Ciprofloxacin resistance in clinical isolates of Pseudomonas aeruginosa from Italian patients.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Humans; Italy; Ps | 1995 |
Comparative in vitro activity of ciprofloxacin vs 8 antimicrobial agents against nosocomial multiresistant P. aeruginosa strains.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple; Greece; Humans; Ph | 1995 |
Emergence of different resistance mechanisms in Pseudomonas aeruginosa in a patient treated with imipenem.
Topics: Anti-Infective Agents; beta-Lactam Resistance; Ciprofloxacin; Humans; Imipenem; Microbial Sensitivit | 1995 |
Pseudomonas aeruginosa as a cause of infectious diarrhea successfully treated with oral ciprofloxacin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Cross Infection | 1995 |
[Spontaneous bilateral pneumothorax].
Topics: Administration, Oral; Aged; Anti-Infective Agents; Bronchography; Ciprofloxacin; Female; Humans; Pne | 1996 |
Efficacy of ciprofloxacin and dexamethasone in experimental pseudomonas endophthalmitis.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; Dexamethasone; Disease Mode | 1996 |
The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis.
Topics: Animals; Anti-Infective Agents; Benzalkonium Compounds; Chelating Agents; Ciprofloxacin; Colony Coun | 1996 |
Risk-benefit experience of ciprofloxacin use in pediatric patients in the United Kingdom.
Topics: Acute Disease; Anti-Infective Agents; Child; Ciprofloxacin; Humans; Joint Diseases; Pseudomonas Infe | 1997 |
Effect of 6-fluoro-8-methoxy quinolone (AM-1155) against chronic airway infection with Pseudomonas aeruginosa in a rat model.
Topics: Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Models, Animal; Fluoroquinol | 1997 |
In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Female; Levofloxaci | 1996 |
Efficacy of ototopical ciprofloxacin in pediatric patients with otorrhea.
Topics: Administration, Topical; Adolescent; Anti-Infective Agents; Child; Child, Preschool; Ciprofloxacin; | 1997 |
Bacterial infection in a patient with onychomycosis.
Topics: Anti-Infective Agents; Antifungal Agents; Ciprofloxacin; Fluconazole; Humans; Male; Middle Aged; Nai | 1997 |
Successful treatment of multidrug-resistant Pseudomonas aeruginosa meningitis with high-dose ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Multiple; Humans; Male; Meningitis, Bacterial | 1997 |
Use of gallium-67 in the assessment of response to antibiotic therapy in malignant otitis externa--a case report.
Topics: Anti-Infective Agents; Ciprofloxacin; Gallium Radioisotopes; Humans; Male; Middle Aged; Otitis Exter | 1997 |
Morphological changes in Pseudomonas aeruginosa secondary to ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Humans; Lung; Male; Middle Aged; Pseudomonas aeruginosa; Pseud | 1997 |
Influence of the postantibiotic effect and postantibiotic sub-MICs effect of netilmicin, tobramycin, ciprofloxacin and pefloxacin on alginate production by Pseudomonas aeruginosa.
Topics: Alginates; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Depression, | 1996 |
Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model.
Topics: Abscess; Animals; Anti-Infective Agents; Area Under Curve; Ceftazidime; Cilastatin; Cilastatin, Imip | 1998 |
Fungal purulent constrictive pericarditis in a heart transplant patient.
Topics: Amphotericin B; Anti-Infective Agents; Antifungal Agents; Candidiasis; Ciprofloxacin; Disease Suscep | 1998 |
Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Dermatitis; Drug Resistance, Microbial; | 1998 |
In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combinati | 1998 |
Scleral buckle infection with ciprofloxacin-resistant Pseudomonas aeruginosa.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Eye | 1998 |
Treatment of chronic suppurative otitis media with topical ciprofloxacin.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Mod | 1998 |
Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals.
Topics: Animals; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Com | 1998 |
[Insidious rupture of the Achilles tendon after ciprofloxacin-induced tendopathy. A case report].
Topics: Achilles Tendon; Adult; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Necrosis; Otitis Media | 1998 |
Management of fluoroquinolone resistance in Pseudomonas aeruginosa--outcome of monitored use in a referral hospital.
Topics: Anti-Infective Agents; Ciprofloxacin; Disease Management; Drug Monitoring; Drug Resistance, Microbia | 1998 |
A liposomal hydrogel for the prevention of bacterial adhesion to catheters.
Topics: Anti-Infective Agents; Bacterial Adhesion; Bacterial Infections; Biocompatible Materials; Biofilms; | 1998 |
Canadian Pseudomonas aeruginosa susceptibility study from 48 medical centers: focus on ciprofloxacin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Canada; Carbenicillin; Ceftazidime; Cephalosporins; Ci | 1998 |
Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects.
Topics: Anti-Infective Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Endotoxins; Humans; Imipenem; Lip | 1998 |
Failure of ciprofloxacin prophylaxis for ultrasound guided transrectal prostatic biopsy in the era of multiresistant enterobacteriaceae.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Biopsy; Ciprofloxacin; Drug Resistance, Microbi | 1999 |
[Ciprofloxacin neurotoxicity].
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Epilepsy, Generalized; Humans; Male; Middle A | 1999 |
Pseudomonas osteomyelitis of the symphysis pubis after inguinal hernia repair.
Topics: Adult; Ciprofloxacin; Diagnosis, Differential; Hernia, Inguinal; Humans; Male; Osteitis; Osteomyelit | 1999 |
Community acquired Pseudomonas aeruginosa pneumonia.
Topics: Anti-Infective Agents; Ciprofloxacin; Community-Acquired Infections; Humans; Male; Middle Aged; Pneu | 1999 |
Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azlocillin; Ceftazidime; Cephalosporins; Ciprofloxacin | 1999 |
Ciprofloxacin-resistant Pseudomonas keratitis.
Topics: Adolescent; Adult; Anti-Infective Agents; Child; Ciprofloxacin; Drug Resistance, Microbial; Drug The | 1999 |
Study quantifies impact of resistant Pseudomonas on outcomes.
Topics: Anti-Bacterial Agents; Boston; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Hospitalizati | 1999 |
If you can't stand the rash, get out of the kitchen: an unusual adverse reaction to ciprofloxacin.
Topics: Anti-Infective Agents; Child; Ciprofloxacin; Cystic Fibrosis; Dermatitis, Photoallergic; Female; Hum | 1999 |
Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Drug Resistance, Micr | 2000 |
Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Adult; Anti-Infective Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; Ciprofloxacin; | 2000 |
Evaluation of post-antibiotic effects of antipseudomonal antibiotics using an automated system.
Topics: 4-Quinolones; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Automation; Ceftazidime; Cipro | 2000 |
A rare infection caused by Chryseomonas luteola.
Topics: Adult; Anti-Infective Agents; Anti-Infective Agents, Local; Chlorhexidine; Ciprofloxacin; Diabetes C | 2000 |
Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Chi-Square Distribution; Ciprofloxacin; Colo | 2000 |
Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Female; Humans; Inject | 2000 |
Epithelial infectious crystalline keratopathy.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Corneal Diseases; Corynebacterium Infections; Epitheliu | 2001 |
Case report: severe neurologic reaction to ciprofloxacin.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Coma; Decerebrate State; Female; Humans; Infusions, Intr | 2001 |
Ciprofloxacin-induced acute renal failure in a patient with cystic fibrosis.
Topics: Acute Kidney Injury; Adolescent; Anti-Infective Agents; Ciprofloxacin; Creatinine; Cystic Fibrosis; | 2001 |
Post-antibiotic and synergic effects of fluoroquinolones and ceftazidime in combination against Pseudomonas strains.
Topics: Anti-Infective Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Comamonas testosteroni; Drug Syne | 2001 |
Pseudomonas parotid abscess.
Topics: Abscess; Aged; Anti-Infective Agents; Biopsy, Needle; Ciprofloxacin; Diagnosis, Differential; Draina | 2001 |
Malignant otitis externa in an infant with selective IgA deficiency: a case report.
Topics: Child, Preschool; Ciprofloxacin; Cloxacillin; Combined Modality Therapy; Debridement; Drug Therapy, | 2001 |
In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy.
Topics: Adolescent; Anti-Infective Agents; Bacterial Outer Membrane Proteins; Carrier Proteins; Ciprofloxaci | 2001 |
Incidence, spectrum and antibiotic sensitivity pattern of bacterial infections among patients with acute pancreatitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Cefotaxime; | 2001 |
[Antibiotic therapy. Avoiding resistance].
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Multiple; Germany; Humans; Pseudomonas aeruginosa; | 2001 |
[The activity of four fluoroquinolones against strains of Pseudomonas aeruginosa with a different sensitivity pattern to ceftazidime and imipenem].
Topics: 4-Quinolones; Anti-Infective Agents; Ceftazidime; Ciprofloxacin; Drug Resistance; Fluoroquinolones; | 2001 |
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Urinary; Cipro | 2001 |
Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin | 2001 |
Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Cefozopran; Cephalosporins; Cilastatin; Ciprofloxa | 2001 |
[Current therapeutical management, new antibiotics and treatment of Pseudomonas aeruginosa in bacterial ENT-infections].
Topics: Ceftazidime; Chronic Disease; Ciprofloxacin; Clinical Trials as Topic; Dose-Response Relationship, D | 2002 |
Early Pseudomonas aeruginosa colonisation in cystic fibrosis patients.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Ciprofloxacin; Clinical Trials as Topic; Coli | 2002 |
Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug | 2002 |
[Pseudomonas aeruginosa corneal abscess refractory to fluoroquinolones].
Topics: Abscess; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Ceftazidime; Ciprofloxacin; Contact Le | 2002 |
Long-term oral ciprofloxacin in the treatment of prosthetic valve endocarditis due to Pseudomonas aeruginosa.
Topics: Administration, Oral; Adult; Aortic Valve; Ciprofloxacin; Drug Administration Schedule; Endocarditis | 1992 |
Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients.
Topics: Azlocillin; Bacterial Typing Techniques; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Resistanc | 1992 |
Treatment of malignant otitis externa in a younger diabetes patient.
Topics: Adult; Ciprofloxacin; Diabetes Mellitus, Type 1; Female; Humans; Otitis Externa; Pseudomonas aerugin | 1992 |
Ciprofloxacin levels in a patient undergoing veno-venous haemodiafiltration.
Topics: Acute Kidney Injury; Adult; Chromatography, High Pressure Liquid; Ciprofloxacin; Dialysis Solutions; | 1992 |
Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Ciprofloxacin; Cystic Fibrosis; Dr | 1992 |
[Resistance to antibiotic treatment produced in a model of experimental Pseudomonas aeruginosa peritonitis].
Topics: Amikacin; Animals; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; D | 1992 |
Ciprofloxacin and prednisolone therapy for experimental Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Mo | 1992 |
Pseudomonas exit site infections in continuous ambulatory peritoneal dialysis patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Catheters, Indwelling; Ciprofloxacin; Female; Humans; | 1992 |
Inducible beta-lactamases in clinical isolates of non-aeruginosa Pseudomonas.
Topics: beta-Lactamases; Cefazolin; Chloromercuribenzoates; Ciprofloxacin; Clavulanic Acids; Cloxacillin; Do | 1992 |
Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.
Topics: Bacterial Outer Membrane Proteins; beta-Lactamases; Carbon Radioisotopes; Chloramphenicol O-Acetyltr | 1991 |
[Common pathogens in burn infection and changes in their drug sensitivity].
Topics: Amikacin; Burns; Ciprofloxacin; Female; Humans; Male; Microbial Sensitivity Tests; Piperacillin; Pro | 1991 |
Therapy of established experimental Pseudomonas aeruginosa infections with oral ciprofloxacin and five human monoclonal antibodies against lipopolysaccharide antigens.
Topics: Animals; Antibodies, Monoclonal; Antigens, Bacterial; Burns; Cellulitis; Ciprofloxacin; Immunotherap | 1991 |
Ciprofloxacin pharmacokinetics after administration via a jejunostomy tube.
Topics: Ciprofloxacin; Humans; Intubation; Jejunostomy; Male; Middle Aged; Pseudomonas Infections | 1991 |
[Otitis externa maligna. Report of a case resistant to ciprofloxacin].
Topics: Aged; Aged, 80 and over; Ceftazidime; Ciprofloxacin; Diabetes Mellitus, Type 1; Drug Resistance, Mic | 1991 |
Ciprofloxacin: drug of choice in the treatment of malignant external otitis (MEO).
Topics: Aged; Aged, 80 and over; Chronic Disease; Ciprofloxacin; Female; Follow-Up Studies; Humans; Male; Mi | 1991 |
The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Ciprofloxacin; Colony Count, Microbial; Keratitis; Norfloxacin; Ps | 1991 |
Treatment of Pseudomonas infections in peritoneal dialysis patients.
Topics: Ceftazidime; Ciprofloxacin; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Peritone | 1991 |
Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin.
Topics: Adolescent; Adult; Cartilage, Articular; Child; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Join | 1991 |
[Ciprofloxacin and osteomyelitis caused by Pseudomonas aeruginosa].
Topics: Aged; Ciprofloxacin; Humans; Male; Osteomyelitis; Pseudomonas Infections | 1991 |
[Activity of fluoroquinolones studied on a model of suppurative meningoencephalitis caused by Pseudomonas aeruginosa in mice].
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; E | 1991 |
In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
Topics: Aztreonam; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Microbial | 1990 |
Current therapy of malignant external otitis.
Topics: Aged; Cefoperazone; Ceftazidime; Ciprofloxacin; Diabetes Mellitus, Type 1; Drug Therapy, Combination | 1990 |
Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa.
Topics: Agranulocytosis; Animals; Antibodies, Monoclonal; Ciprofloxacin; Combined Modality Therapy; Disease | 1990 |
Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa.
Topics: Bacterial Outer Membrane Proteins; Ciprofloxacin; DNA Topoisomerases, Type II; DNA, Bacterial; DNA, | 1990 |
Pseudomonas paucimobilis peritonitis in a patient on CAPD successfully treated with ciprofloxacin and netilmicin.
Topics: Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Middle Aged; Netilmicin; Peritoneal Dialys | 1990 |
Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis.
Topics: Aminoglycosides; Animals; Aqueous Humor; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Mi | 1990 |
Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis.
Topics: Attitude to Health; Ciprofloxacin; Cystic Fibrosis; Humans; Pseudomonas Infections; Quality of Life; | 1990 |
Blastomycosis-like pyoderma caused by Pseudomonas aeruginosa: report of a case responsive to ciprofloxacin.
Topics: Aged; Aged, 80 and over; Blastomycosis; Ciprofloxacin; Humans; Male; Pseudomonas Infections; Pyoderm | 1990 |
[Malignant otitis externa and HIV antibodies. A case report].
Topics: Acquired Immunodeficiency Syndrome; Adult; Ciprofloxacin; Drug Therapy, Combination; Gentamicins; HI | 1990 |
Tolerance and safety of ciprofloxacin in paediatric patients.
Topics: Adolescent; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosis; Drug Evaluation; Female; Humans | 1990 |
Hot tub (Pseudomonas) folliculitis.
Topics: Adult; Baths; Ciprofloxacin; Female; Folliculitis; Humans; Male; Pseudomonas Infections; Water Micro | 1990 |
Successful treatment of malignant external otitis with oral ciprofloxacin: report of experience with 23 patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Ciprofloxacin; Combined Modality Therapy; Debridement | 1990 |
Caution indicated in prescribing ciprofloxacin.
Topics: Ciprofloxacin; Humans; Otitis Externa; Pseudomonas Infections | 1990 |
Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Female; Humans; Male; Middle Aged; Osteom | 1990 |
Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin.
Topics: Ciprofloxacin; Humans; Male; Middle Aged; Pneumonia; Pneumonia, Pneumococcal; Pseudomonas Infections | 1990 |
[Treatment with oral ciprofloxacin of pubic osteomyelitis caused by Pseudomonas aeruginosa].
Topics: Ciprofloxacin; Humans; Male; Middle Aged; Osteomyelitis; Pseudomonas Infections; Pubic Bone | 1989 |
Fatal anaphylaxis associated with ciprofloxacin in a patient with AIDS related complex.
Topics: Administration, Oral; Adult; AIDS-Related Complex; Anaphylaxis; Ciprofloxacin; Humans; Male; Otitis | 1989 |
Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations.
Topics: ADP Ribose Transferases; Animals; Bacterial Toxins; Ceftazidime; Ciprofloxacin; Dose-Response Relati | 1989 |
L-658,310, a new injectable cephalosporin. II. In vitro and in vivo interactions between L-658,310 and various aminoglycosides or ciprofloxacin versus clinical isolates of Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Drug Synergism; Female; Gen | 1989 |
Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Blood Sedimentation; Ciprofloxacin; Diabetes Complic | 1989 |
Treating malignant otitis with oral ciprofloxacin.
Topics: Administration, Oral; Aged; Ciprofloxacin; Ear, External; Humans; Male; Middle Aged; Otitis Externa; | 1989 |
Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
Topics: Aged; Chromatography, High Pressure Liquid; Ciprofloxacin; Cross Infection; Drug Resistance, Microbi | 1989 |
Acute epididymo-orchitis caused by Pseudomonas aeruginosa and treated with ciprofloxacin.
Topics: Administration, Oral; Adolescent; Aged; Ciprofloxacin; Epididymitis; Humans; Male; Orchitis; Pseudom | 1989 |
[Local treatment of Pseudomonas infection of the ear. A small clinical study].
Topics: Audiometry, Pure-Tone; Auditory Threshold; Ciprofloxacin; Follow-Up Studies; Humans; Otitis Externa; | 1989 |
Treatment of nail puncture wounds.
Topics: Animals; Child; Ciprofloxacin; Foot Injuries; Humans; Osteomyelitis; Pseudomonas Infections; Shoes; | 1989 |
Ciprofloxacin treatment of malignant external otitis.
Topics: Aged; Aged, 80 and over; Ciprofloxacin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Otitis | 1989 |
Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients.
Topics: Administration, Oral; Adolescent; Adult; Chromatography, High Pressure Liquid; Ciprofloxacin; Cystic | 1989 |
Cystic fibrosis and drug-induced arthropathy.
Topics: Adolescent; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Joint Diseases; Pseudomonas Infections | 1989 |
Treatment of Pseudomonas aeruginosa auricular perichondritis with oral ciprofloxacin.
Topics: Administration, Oral; Aged; Ciprofloxacin; Female; Humans; Male; Middle Aged; Otitis Externa; Pseudo | 1989 |
Oral ciprofloxacin and a monoclonal antibody to lipopolysaccharide protect leukopenic rats from lethal infection with Pseudomonas aeruginosa.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Ciprofloxacin; Combined Modality Therapy; Cyc | 1989 |
Successful treatment of malignant otitis externa with oral ciprofloxacin.
Topics: Administration, Oral; Adult; Ciprofloxacin; Humans; Male; Otitis Externa; Pseudomonas Infections | 1989 |
Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Ciprofloxacin; Cystic Fibrosis; Dr | 1989 |
Clinical resistance to long-term oral ciprofloxacin.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Microbial; Humans; Male; Pseudomonas a | 1985 |
Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary | 1986 |
Ciprofloxacin in cystic fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Male; Pseud | 1986 |
Ciprofloxacin for Pseudomonas aeruginosa meningitis.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Therapy, Combination; Humans; Male; Meningitis; Middle Ag | 1986 |
Ciprofloxacin and antacids.
Topics: Aged; Antacids; Anti-Infective Agents, Urinary; Ciprofloxacin; Drug Interactions; Humans; Pseudomona | 1986 |
Ciprofloxacin resistance.
Topics: Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Humans; Pseudomonas; Pseudomonas Infecti | 1987 |
Ciprofloxacin and tenosynovitis.
Topics: Aged; Ciprofloxacin; Humans; Male; Pseudomonas Infections; Tenosynovitis | 1988 |
Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis.
Topics: Animals; Azlocillin; Ciprofloxacin; Drug Therapy, Combination; Endocarditis, Bacterial; Microbial Se | 1985 |
Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Therapy, Combination; Enterobac | 1985 |
Oral treatment of Pseudomonas-induced urinary tract infections with ciprofloxacin.
Topics: Administration, Oral; Adult; Aged; Bacteriuria; Ciprofloxacin; Female; Humans; Male; Middle Aged; Ps | 1986 |
The importance of pharmacodynamics in determining the dosing interval in therapy for experimental pseudomonas endocarditis in the rat.
Topics: Animals; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Therapy, Combination; Endocardit | 1986 |
[New oral quinolone compounds in chronic bronchitis].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Cipr | 1986 |
New 4-quinolones in the treatment of urinary tract infections.
Topics: Anti-Infective Agents, Urinary; Ciprofloxacin; Drug Combinations; Humans; Male; Norfloxacin; Pefloxa | 1986 |
Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection.
Topics: Animals; Azlocillin; Bacteria; Carbenicillin; Ciprofloxacin; Drug Synergism; Drug Therapy, Combinati | 1986 |
Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; | 1985 |
Successful treatment of Pseudomonas ventriculitis with ciprofloxacin.
Topics: Anti-Infective Agents; Cerebral Ventricles; Cerebrospinal Fluid Shunts; Ciprofloxacin; Encephalitis; | 1986 |
Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Enoxacin; Guinea Pigs; Kinetics; Naphthyridines; Oflo | 1986 |
Experience with ciprofloxacin in the treatment of various infections caused mainly by Pseudomonas aeruginosa.
Topics: Abscess; Administration, Oral; Adolescent; Adult; Aged; Bronchopneumonia; Child; Ciprofloxacin; Fema | 1985 |
Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Ciprofloxacin; Drug | 1986 |
Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.
Topics: Abscess; Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bronchopneumonia; Chi | 1986 |
Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Azlocillin; C | 1986 |
Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria.
Topics: Anti-Bacterial Agents; Bacterial Infections; Bone Diseases; Catheters, Indwelling; Ciprofloxacin; Dr | 1986 |
Ciprofloxacin in the treatment of urinary tract infection in patients with multiple sclerosis.
Topics: Anti-Infective Agents; Catheters, Indwelling; Ciprofloxacin; Cystitis; Enterobacteriaceae Infections | 1986 |
Ciprofloxacin in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.
Topics: Abscess; Animals; Anti-Infective Agents; Aortic Valve; Azlocillin; Ciprofloxacin; Drug Therapy, Comb | 1986 |
In vivo efficacy of azlocillin and amikacin versus ciprofloxacin with and without amikacin in experimental right-sided endocarditis due to Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Azlocillin; Ciprofloxacin; Drug Therapy, Combination; Endocarditis, Bacterial; Fe | 1986 |
[Gyrase inhibitor in the local treatment of the chronically infected middle ear following surgery].
Topics: Administration, Topical; Adult; Aged; Bacterial Infections; Ciprofloxacin; Drug Resistance; Escheric | 1986 |
Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients.
Topics: Adolescent; Adult; Azlocillin; Ciprofloxacin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Ps | 1986 |
Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits.
Topics: Animals; Ceftazidime; Ciprofloxacin; Disease Models, Animal; Meningitis; Pseudomonas aeruginosa; Pse | 1986 |
Dose response of experimental Pseudomonas endophthalmitis to ciprofloxacin, gentamicin, and imipenem: evidence for resistance to "late" treatment of infections.
Topics: Animals; Ciprofloxacin; Dose-Response Relationship, Drug; Endophthalmitis; Gentamicins; Imipenem; Ps | 1987 |
Emergence of ciprofloxacin-resistant Pseudomonas aeruginosa after combined therapy with ciprofloxacin and amikacin.
Topics: Adult; Amikacin; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Human | 1986 |
Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis.
Topics: Animals; Azlocillin; Ciprofloxacin; Drug Synergism; Drug Therapy, Combination; Female; Pseudomonas a | 1987 |
Efficacy of ciprofloxacin in stationary-phase bacteria in vivo.
Topics: Animals; Cell Cycle; Ciprofloxacin; Escherichia coli; Escherichia coli Infections; Mice; Pseudomonas | 1987 |
[Prevention of gram-negative and gram-positive infections with 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection with intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].
Topics: Animals; Bacterial Infections; Burns; Ciprofloxacin; Combined Modality Therapy; Female; Immunoglobul | 1987 |
Two neutropenic patients with multiple resistant Pseudomonas aeruginosa septicaemia treated with ciprofloxacin.
Topics: Adolescent; Aged; Agranulocytosis; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Microbial; | 1987 |
Arthropathy in a patient with cystic fibrosis taking ciprofloxacin.
Topics: Adolescent; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Joint Diseases; Knee Joint; Pseudomonas | 1987 |
Therapy of experimental Pseudomonas burn wound sepsis with ciprofloxacin and Pseudomonas immune globulin.
Topics: ADP Ribose Transferases; Animals; Antibodies, Bacterial; Bacterial Toxins; Burns; Ciprofloxacin; Com | 1987 |
Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis.
Topics: Animals; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Mice; Mice, I | 1987 |
The activity of ciprofloxacin against Pseudomonas aeruginosa in normal and granulocytopenic mice.
Topics: Agranulocytosis; Animals; Ciprofloxacin; Male; Mice; Microbial Sensitivity Tests; Pseudomonas aerugi | 1987 |
Enterococcal superinfection in patients treated with ciprofloxacin.
Topics: Adult; Aged; Ciprofloxacin; Enterococcus faecalis; Humans; Kidney Failure, Chronic; Male; Pseudomona | 1988 |
The relative efficacies of tobramycin and ciprofloxacin against Pseudomonas aeruginosa in vitro and in normal and granulocytopenic mice.
Topics: Agranulocytosis; Animals; Ciprofloxacin; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Tobra | 1988 |
Tolerance of Pseudomonas aeruginosa to killing by ciprofloxacin, gentamicin and imipenem in vitro and in vivo.
Topics: Animals; Ciprofloxacin; Gentamicins; Imipenem; In Vitro Techniques; Male; Pseudomonas aeruginosa; Ps | 1988 |
Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacteria; Chemical Phenomena; Chemis | 1988 |
Long-term oral ciprofloxacin: experience in the treatment of incurable infective endocarditis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Drug Administration Schedule; E | 1988 |
Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits.
Topics: Administration, Topical; Animals; Aqueous Humor; Ciprofloxacin; Cornea; Keratitis; Ophthalmic Soluti | 1988 |
Osteomyelitis of the maxilla with associated vertical root fracture and Pseudomonas infection.
Topics: Adult; Chronic Disease; Ciprofloxacin; Humans; Incisor; Male; Maxillary Diseases; Osteomyelitis; Pse | 1988 |
Ciprofloxacin therapy of respiratory tract infection with Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Cross Infection; Humans; Middle Aged; Pse | 1988 |
Treatment of Pseudomonas aeruginosa peritonitis in a CAPD patient with ciprofloxacin.
Topics: Ciprofloxacin; Female; Humans; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; | 1988 |
Activity of ciprofloxacin and colistin against Pseudomonas aeruginosa isolates from neutropenic patients: a possible approach to prophylaxis.
Topics: Agranulocytosis; Ciprofloxacin; Colistin; Drug Resistance, Microbial; Humans; Microbial Sensitivity | 1988 |
Ciprofloxacin treatment of periapical Pseudomonas aeruginosa infection.
Topics: Ciprofloxacin; Female; Humans; Middle Aged; Periapical Diseases; Pseudomonas aeruginosa; Pseudomonas | 1988 |
Ciprofloxacin (BAY 09867): clinical evaluation in urinary tract infections due to Pseudomonas aeruginosa.
Topics: Adult; Ciprofloxacin; Female; Humans; Male; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infecti | 1987 |
Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Bone and Bones; Chronic Disease; Ciprofloxacin; Drug Resistance, Mic | 1985 |
Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs.
Topics: Agranulocytosis; Animals; Anti-Bacterial Agents; Ciprofloxacin; Guinea Pigs; Half-Life; Microbial Se | 1985 |
Relapsing malignant otitis externa successfully treated with ciprofloxacin.
Topics: Aged; Ciprofloxacin; Humans; Male; Otitis Externa; Pseudomonas Infections; Radionuclide Imaging; Rec | 1988 |
Malignant external otitis: the use of oral ciprofloxacin.
Topics: Administration, Oral; Aged; Ciprofloxacin; Female; Humans; Otitis Externa; Pseudomonas Infections | 1988 |
A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria.
Topics: Abscess; Animals; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacteroides Infecti | 1988 |
The possible role of ciprofloxacin in the treatment of endocarditis caused by Pseudomonas aeruginosa.
Topics: Aged; Ciprofloxacin; Drug Combinations; Endocarditis, Bacterial; Female; Gentamicins; Humans; Penici | 1988 |
Long-term oral ciprofloxacin therapy in a cystic fibrosis patient.
Topics: Administration, Oral; Adult; Ciprofloxacin; Cystic Fibrosis; Humans; Male; Pseudomonas Infections; T | 1988 |
Efficacy of ciprofloxacin in treatment of CAPD peritonitis.
Topics: Ciprofloxacin; Humans; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Pseudomonas Infectio | 1987 |
The use of ciprofloxacin in the treatment of patients with cystic fibrosis.
Topics: Adult; Bacterial Infections; Ciprofloxacin; Cystic Fibrosis; Drug Resistance, Microbial; Haemophilus | 1987 |
Treatment of chronic osteomyelitis with ciprofloxacin.
Topics: Adult; Aged; Bacterial Infections; Chronic Disease; Ciprofloxacin; Female; Humans; Male; Middle Aged | 1987 |
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enterobacteriaceae In | 1986 |
Efficacy of ciprofloxacin in experimental aortic valve endocarditis caused by a multiply beta-lactam-resistant variant of Pseudomonas aeruginosa stably derepressed for beta-lactamase production.
Topics: Animals; Aortic Valve; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Endocarditis, Bacteri | 1986 |
[Autologous spongiosa as an antibiotic carrier in the treatment of osteitis].
Topics: Administration, Topical; Bone Transplantation; Ciprofloxacin; Combined Modality Therapy; Female; Fra | 1986 |
Ciprofloxacin therapy in complicated urinary tract infections caused by Pseudomonas aeruginosa and other resistant bacteria.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Ciprofloxacin; Escherichia coli Infections; Female; | 1986 |
Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model.
Topics: Bacterial Infections; Ciprofloxacin; Escherichia coli Infections; Humans; In Vitro Techniques; Infus | 1987 |
Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Cellulitis; Ciprofloxacin; Enterob | 1987 |
Efficacy of ciprofloxacin in animal models of infection: endocarditis, meningitis, and pneumonia.
Topics: Animals; Ciprofloxacin; Disease Models, Animal; Drug Evaluation, Preclinical; Endocarditis, Bacteria | 1987 |
Ciprofloxacin therapy in cystic fibrosis.
Topics: Adolescent; Adult; C-Reactive Protein; Child; Ciprofloxacin; Cystic Fibrosis; Humans; Pseudomonas In | 1987 |
Dosage of intravenous ciprofloxacin.
Topics: Acute Kidney Injury; Adult; Ciprofloxacin; Humans; Injections, Intravenous; Male; Pseudomonas Infect | 1987 |
Therapeutic efficacy of cefpiramide-ciprofloxacin combination in experimental Pseudomonas infections in neutropenic mice.
Topics: Agranulocytosis; Animals; Cephalosporins; Ciprofloxacin; Cyclophosphamide; Drug Therapy, Combination | 1987 |
Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis.
Topics: Adolescent; Adult; Ciprofloxacin; Cystic Fibrosis; Female; Humans; Kinetics; Male; Pseudomonas Infec | 1986 |
The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection.
Topics: Adult; Aged; Chronic Disease; Ciprofloxacin; Female; Humans; Male; Middle Aged; Pseudomonas Infectio | 1986 |